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TOWARDS THE RATIONAL DESIGN AND APPLICATION OF POLYMERS FOR 
GENE THERAPY: INTERNALIZATION AND INTRACELLULAR FATE 
 
 
Gene therapy is an approach for the treatment of acquired cancers, infectious 
disease, degenerative disease, and inherited genetic indications. Developments in the fields 
of immunotherapies and CRISPR/Cas9 genome editing are revitalizing the efforts to move 
gene therapy to the forefront of modern medicine. However, slow progress and poor 
clinical outcomes have plagued the field due to regulatory and safety concerns associated 
with the flagship delivery vector, the recombinant virus. Immunogenicity and poor 
transduction in certain cell types severely limits the utility of viruses as a delivery agent of 
nucleic acids. As a result, significant efforts are being made to develop non-viral delivery 
systems that perform mechanistically similarly to viral delivery but lack immunogenic 
factors. Though safer, existing agents lack the efficacy inherent in the natural design of 
viral vectors. Clinical relevance of non-viral vectors will therefore depend on the ability to 
engineer optimized systems for cellular delivery in physiological environments. 
Progress in non-viral vector design for gene delivery requires a deep understanding 
of the various barriers associated with nucleic acid delivery, including cell surface 
interaction, internalization, endosomal escape, cytosolic transport, nuclear localization, 
unpackaging, etc. Further, it requires a knowledge of vector design properties (surface 
chemistry, charge, size, shape, etc.) and how these physical parameters affect interactions 
with the cellular environment. Of these interactions, charge is shown to govern how 
particles are internalized and subsequently processed, thereby affecting the intracellular 
fate and efficacy of delivery. Charge also affects the in-serum stability where negative zeta 
potential improves stability and circulation time. Therefore, it is important to understand 
the effects of polyplex charge and other parameters on the internalization and intracellular 
fate of polyplexes for gene therapy. 
In chapter 2, studies are performed to delineate the effects of polyplex charge on 
the cellular internalization and intracellular processing of polymer-mediated gene delivery. 
Charge is shown to affect the endocytic pathway involved in internalization, and the 
caveolin-dependent and macropinocytosis pathways lead to higher gene delivery efficacy, 
likely due to avoidance of acidified compartments such as late endosomes and lysosomes. 
In chapters 3-4, novel nanoparticles carrying DNA, RNA, and antioxidants are assessed 
for therapeutic effect with an emphasis on studying the internalization mechanisms and 
resulting effect on efficacy. Novel RNA delivery agents are shown to benefit from EGFR-
targeting aptamer and nanoceria/PEI hybrids are demonstrated to provide simultaneous 
antioxidant and gene therapy. Finally, chapter 5 demonstrates the use of silencing RNA 
and CRISPR/Cas9 genome editing to study the prevalence of gene targets in vivo. 
The overall goal of this work is to contribute to the design and application of novel 
nanoparticles for gene delivery and offer insight into the engineering of novel polyplexes. 
It remains clear that route of internalization is key to successful gene delivery, and 
designing polyplexes to enter through non-acidified endocytic pathways is highly 
beneficial to transgene expression. This can be achieved through incorporation of surface 
chemistries that trigger internalization through targeted pathways and is the source of 
further work in the lab. 
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CHAPTER 1. INTRACELLULAR AND LIMITING STEPS TO GENE THERAPY 
1.1 Introduction 
This chapter will focus on the fundamental concepts of gene therapy and the 
current strategies for gene delivery. Non-viral vectors that do not stimulate immunogenic 
response are discussed that offer alternative options to viruses. Next, the characteristic 
barriers to delivery are presented to establish the process by which non-viral agents must 
chaperone their cargo into the cell. These steps and their implications on efficacy are 
demonstrated through years of research by the lab and other groups. Finally, the 
importance of rational design is discussed for the engineering of new polymeric vectors 
for gene delivery. Various properties are outlined and their effects on delivery delineated. 
The understanding of how these design properties affect vector-cell interactions is 
extremely important to the development of polymer vectors for gene delivery and is the 
subject of this dissertation. 
1.1.1 A Brief History 
Over three decades ago, scientist begun exploring the hypothesis that inherited 
genetic indications could be cured through genetic modification using delivered exogenous 
DNA. The underlying hope was that the manipulation of the genome offered a robust, one-
time treatment capable of permanent curative effects. Inspired by nature, viral delivery 
vectors became the choice delivery agents as their natural evolution promotes highly 
efficient delivery and expression. In 1985, proof of concept was established when 
collaborative efforts of national agencies showed that ADA, an immunodeficiency disease, 
could be corrected through integration of a compensatory gene into patient cells in tissue 
culture. In the early 90’s reports began to demonstrate that ex vivo T-cell therapies were 
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capable of safe and efficient administration in human patients, but clinical trials in the late 
90’s demonstrated the primary weakness of the golden viral vector, immunogenicity. The 
field experienced a slow-down at the turn of the century as a patient experienced extreme 
immunogenic shock from a viral therapy and died shortly thereafter. This elucidated a need 
for alternative vectors for gene delivery that do not produce immune system response in 
the patient. 
Despite the safety concerns associated with the virus, successful clinical trials 
resulted in the first approved gene therapy in 2012. The EMA approved Glybera in Europe 
for treatment of rare forms of pancreatic cancer. However, the target population was so 
small that the drug was forced to sell for unrealistic prices, resulting in discontinuation. 
Several more overly expensive orphan drugs were approved in Europe over the years but 
all have faced the tribulation of unaffordability and small patient bases. In 2017, the United 
States approved two CAR-T therapies (Kymriah and Yescarta) for ex vivo treatment of 
ALL and B-cell lymphoma. Shortly thereafter, Luxturna was approved as the first in vivo 
gene therapy in the US for the treatment of retinal dystrophy. While still expensive, these 
drugs are at the pioneers of modern gene therapy. While only a few approved therapies 
exist, dozens of gene therapies continue to enter the developmental pipeline as over 250 
companies pursue the field. This is a prime indication that gene therapy is on the brink of 
a golden era that will disrupt modern medicine. 
1.1.2 The Ethical Dilemma 
Because many of the uses of gene therapy involve the permanent alteration to the 
body’s basic set of instructions, several scientific, economic, and social concerns arise. 
These questions are primarily centric on the poor understanding of the human genome and 
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the effects of anthropogenic modification on healthy function. These concerns are 
particularly focused on the technology of heritable modifications of germ cells (sperm and 
egg cells). Germline modifications involve the permanent genetic manipulation of 
reproductive cells, affecting individuals who have not yet been born and have no 
governance in the treatment. Due to our poor understanding of genetics in development, 
these alterations have the potential to cause detrimental effects to normal development and 
lifelong handicap. For these reasons, the US government and many governments of the 
world do not allow federal funding of these controversial germline therapies in humans. 
Despite these restraints, a Chinese scientist secretly genetically modified an egg to resist 
HIV and implanted it in a woman, producing healthy twins. Though no disfigurement 
resulted, the scientist’s actions were ruled illegal and unethical and he was fired from his 
institution. This is an indication that, while the world condemns this unethical behavior, it 
is incapable of restraining unscrupulous individuals with the technical capacity for 
controversial gene therapies. 
The concept of gene therapy is somewhat foreign to healthcare in that it produces 
curative effects instead of symptom relief. This means that, similar to an organ transplant, 
a single treatment is required to permanently correct for the indication. Since most modern 
medicines offer treatments and not cures, modern healthcare doesn’t have much experience 
in establishing the economic value of a cure. Due to unregulated drug economics, the price 
tag associated with gene therapies ranges from $425k (per eye) for Luxturna (ocular 
dystrophy) to >$1M for Glybera (pancreatitis) with new gene therapies expected to exceed 
$4M. Clearly, this introduces the dilemma of access. People with potentially life 
threatening disease untreatable by alternatives are faced with a price tag that the average 
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consumer cannot afford. Whether these astronomical costs will be covered by healthcare 
is yet to be determined. 
1.2 Gene Delivery Strategies 
In order to effectively provide therapeutic utility to a cell, nucleic acid (DNA or 
RNA) must be delivered to its target in a manner that retains its functionality and integrity. 
DNA delivered directly into the bloodstream or ingested through enteral routes is easily 
digested by the stomach or degraded by circulating nuclease enzymes. While certain 
modifications to the structure can provide resistance to degradation or immune activation, 
efficient circulation and uptake in most tissue must be facilitated by a delivery vector. This 
vector is responsible for the protection of the nucleic acid from serum factors (nucleases 
and protein) and transfer across the cell membrane. Further, mammalian immune response 
can be incited by recombinant plasmid DNA produced by prokaryotic sources. The 
immune system can recognize specific methylation patterns in CpG islands characteristic 
of prokaryotic-synthesized DNA [1, 2]. Therefore, a delivery vector simultaneously shields 
the DNA from the body and the body from the DNA. Currently there are three delivery 
options available: naked nucleic acid, viral vectors, and non-viral vectors. 
1.2.1 Naked DNA 
Naked nucleic acid refers to DNA or RNA that is not associated with any protective 
agent (delivery agent). While DNA tends to be localized to the intracellular environment, 
its presence in the bloodstream is not uncommon due to cell lysis and invading pathogens. 
To combat the presence of genetic information in circulation, blood is rich in serum 
nucleases (DNase and RNase). These factors make it difficult for extended circulation of 
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nucleic acids and help minimize infection. As a result, unprotected DNA circulation is 
severely limited. Furthermore, cellular permeability of naked DNA is inhibited by size, 
shape, and anionic charge. Despite these challenges, naked DNA delivery has become quite 
common in the arena of DNA vaccines. 
DNA vaccines are injections of naked DNA that codes for the production of a 
specific antigen that triggers immune response [3]. Upon tissue internalization, the antigen 
is expressed and stimulates immunogenic response. This approach is safer and more stable 
than conventional vaccines since DNA is non-live and non-replicating. Further, the risk of 
genome integration of a simple plasmid is lower than that associated with naturally 
occurring mutations [4]. Interestingly, the type of cell that most readily uptakes naked 
plasmid DNA is muscle cells that do not typically contribute to immune signaling [5]. This 
technique has moved rapidly into its second generation where secondary and/or adjuvant 
molecules are delivered co-currently with DNA in order to increase uptake or direct 
immunogenic response. Mixed modality treatments of traditional vaccines with naked 
DNA encoding equivalent immune responses are even being used to produce synergistic 
effects on vaccine efficacy [6-8]. Though simplistic and fragile, these advancements in 
DNA vaccines make naked DNA delivery an exciting prospect for gene therapy. 
1.2.2 Viral Gene Therapy 
As previously mentioned, the traditional modality for gene delivery is the virus. A 
virus is an intracellular parasite evolved as an efficient vehicle for nucleic acid to cells. As 
there is a broad spectrum of viral vectors capable of gene delivery, they are categorized 
according to several phenotypic characteristics such as transient vs. stable expression, type 
of nucleic acid carried (DNA vs. RNA), and the single- vs. double-stranded nature of that 
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nucleic acid [9]. Each virus possesses certain advantages or disadvantages associated with 
its subset. However, all viruses contain two components 1) a nucleic acid genome and 2) a 
protective protein capsid that contains the genome. Some subsets of viruses also contain a 
lipid envelope that envelopes the capsid, aids in binding the host cell, and facilitates entry 
[10]. Due to the presence of the protein capsid or lipid envelope, all natural-occurring 
viruses produce immune stimulation. The most common viral subsets used for gene 
therapy, as will be discussed here, are retroviruses, lentiviruses, adenoviruses, and adeno-
associated viruses. 
1.2.2.1 Retrovirus 
Retroviruses are RNA viruses that deposit their RNA payload into the cell to be 
reverse-transcribed into double stranded DNA, which is subsequently integrated at random 
into the host genome [11]. This permanent incorporation is highly advantageous as it 
provides permanent therapeutic effect. However, these viruses require cell division for 
infection and are primarily used ex vivo due to powerful immune response. Though initially 
the most preferred viral subset for gene delivery, safety concerns have shifted focus away 
from the retroviral system for several reasons. First, the random incorporation of the viral 
genome into the host presents the possibility of insertional mutagenesis. Disruption of vital 
genes in the host can result in deleterious expression profiles, which manifest themselves 
in phenotypic changes or cellular functional losses. For example, a retrovirus was used to 
treat severe combined immunodeficiency-X1 (SCID)-X1 in children with success [12]. 
However, after a one-year checkup, a patient had developed lymphoblastic leukemia 
attributed to retroviral insertional mutagenesis [13]. Second, and more severe, retroviruses 
carry the possibility to generate replication competent retroviruses (RCR). These RCRs 
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essentially recover their ability to self-replicate and produce viral side effects like standard 
viruses [14]. Despite these safety concerns, retroviruses remain strong contenders for 
clinical trials due to advances in directed insertion and reduction in RCR generation [15]. 
However, safer categories of retroviruses (such as the lentivirus) have been engineered to 
avoid many safety concerns associated with retroviruses and may one day render them 
obsolete. 
1.2.2.2 HIV-1 Lentivirus 
The lentivirus is a special group within retroviruses with the capacity to infect 
dividing and non-dividing cells. Unlike the retrovirus, lentiviruses do not possess viral 
proteins or contain replication competent genomes [16]. Like their counterparts, however, 
they retain the ability to stably integrate their genome into the host. Unfortunately, this 
integration remains random, which retains the possibility of insertional mutagenesis. 
Lentiviruses were developed to solve some of the safety concerns with retroviruses and 
have largely replaced them. In fact, one of the US-approved CAR-T therapies employs the 
lentivirus for ex vivo T-cell transduction [17]. While the lentivirus is by no means perfect, 
it does demonstrate the advancements in virology to solve safety and immunogenic 
concerns. 
1.2.2.3 Adenovirus 
The adenovirus is a DNA virus that does not integrate into the host genome but 
localizes to the nucleus as an episomal element. Therefore, it is limited by transient 
expression of days to weeks and usually requires multiple administrations [11]. With the 
capacity to infect dividing and quiescent cells, the adenovirus is an attractive candidate for 
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in vivo studies and is the most used virus in gene therapy. However, 90% of humans have 
been exposed to the common adenovirus through natural means and have thus already 
acquired antibodies against the virus [11]. Due to the extreme immunogenic nature of the 
virus, repeat administration becomes less effective, even after a single exposure. Further, 
the efficient uptake of the virus make it non-specific in vivo, which is a problem when 
targeting specific cells, such as cancer [18]. The virus can be engineered to be replication-
defective for treatments involving foreign gene expression or replication-competent to seek 
out and destroy cancer cells through the natural lytic nature of viral infection [19]. As such, 
the replication-defective adenovirus is commonly used in gene therapy vaccines while 
replication-competent vectors are being used heavily for cancer treatment. 
1.2.2.4 Adeno-Associated Virus (AAV) 
The adeno-associated virus (AAV) is one of the most investigated vehicles for gene 
delivery. It was initially thought to be a contaminant of adenovirus preparation but was 
discovered to be a separate, single-stranded DNA virus [20]. A primary advantage of this 
virus is that its evolution mediates cellular entry through very specific receptors or surface 
biomarker, which can be tuned by the engineer. This allows selective targeting with the 
virus and certain variants might even be able to traverse the blood-brain barrier to infect 
neurons in the central nervous system [21, 22]. Another advantage is that genome 
integration always occurs at a defined location in chromosome 19, thereby minimizing 
insertional mutagenesis because no vital genes are disrupted [23]. Further, the immune 
response associated with AAV is less severe than previously discussed viruses, which make 
it safer in terms of immunogenicity. However, like the adenovirus, many people have pre-
existing antibodies to AAV from natural exposure to the virus. This diminishes the effects 
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of treatment, potentially even the first time. A viable solution to this problem is to apply 
different AAV serotypes to each re-administration to avoid immune clearance. 
1.2.2.5 Other Viruses 
Though the retrovirus, lentivirus, adenovirus, and AAV make up a large portion of 
viruses in clinical trials, there is a host of exotic viruses being studied for their unique 
properties. Herpes simplex virus (HSV) is an efficient neuronal-infecting virus with 
excellent packaging capacity and ease of production of replication-defective titre. Genome 
integration and broad tropism make HSV an extremely advantageous, especially for 
neurological disease [24]. A similar large-capacity virus is the poxvirus, the same virus 
used to eradicate smallpox. This vector has been studied for decades due to its non-
integrating and low immunogenicity and is used extensively in veterinarian medicine. 
Attenuated sub-strains Ankara and Copenhagen NYVAC are of human clinical interest and 
are promising gene delivery vectors [25]. Further, self-amplifying ssRNA alphaviruses 
offer a rich arena of low-packaging capacity viruses that produce transient, high-expression 
profiles. These vectors are highly promising for their oncolytic capacity [26]. For example, 
the Newcastle disease virus (NDV) has been shown to replicate only in cancer cells, 
making it a focus for cancer gene therapy [27]. These lesser-studied viruses often offer 
advantages to the more-popular standard vectors but often possess a fatal flaw that makes 
them difficult to tame. However, as they become better understood by the scientific body, 
they may one day be engineered to be among the most efficient and safe gene delivery viral 
vectors. 
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1.2.3 Non-viral Gene Therapy 
Safety and production concerns associated with the recombinant virus stunted 
funding and momentum of the gene therapy field around the turn of the millennium due to 
adverse clinical trials. This caused a split in the direction of gene delivery as scientists 
begun to delve into potential alternative vectors for delivery of nucleic acids. These 
alternative vectors include biomaterials such as liposomal assemblies of lipids, cationic 
polymers, and cell penetrating peptides [28]. Though synthetic vectors are generally 
considered less efficient, they do not possess the inherent immunogenic nature or 
complexity of the virus. Despite this simplicity, they retain the problematic issues of 
formulation and storage inherent in most biological drugs. These vectors work by 
condensation and encapsulation of plasmid DNA such that they sterically hinder DNA 
access to serum nucleases, preventing degradation. Though efficient at carrying DNA and 
entering cells in vitro, synthetic vectors do tend to have poor toxicological profiles and 
circulatory clearance problems [29]. These issues are being addressed through rational 
design of next-generation synthetic vectors that overcome these issues while retaining the 
ability to transport nucleic acids. 
1.2.3.1 Lipid Assemblies 
Cationic lipids are attractive biomaterials for gene delivery due to their ease of 
preparation, ability to modify individual structural elements, and ease of characterization. 
All lipid delivery systems are comprised of three components 1) polar head group 2) 
hydrophobic moiety and 3) linker [30]. The polar head group is a positive charged, 
hydrophilic structure usually produced from protonation of amine groups [31]. Multivalent 
head groups have been shown to be more effective than more simple univalent head groups, 
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making lipids with multivalent head groups used more often [32]. The hydrophobic section 
is comprised of saturated or unsaturated steroid or alkyl chains [30]. Finally, the linker is 
the bond between groups and determines chemical stability and biodegradability of the 
lipid [33]. These three components form individual lipids that make up the greater 
liposomal structure for gene encapsulation. However, formations of ionizable lipids are 
coming of interest. These advanced lipids increase gene delivery efficacy through 
modulated pKa. At mild basic formulation pH, nucleic acid loading is maximized due to 
the positive charge of the lipids. At circulatory physiological pH, the particles take on 
neutral charge that helps to avoid clearance. However, once in the cellular endolysosomal 
environment, where pH is continuously lowered, the amines of the lipid head group become 
protonated and associate with the endosome lipid bilayer. This “charge pairing” causes 
DNA release and membrane disruption, resulting in leaky endosomal compartments 
susceptible to DNA escape [34]. 
Lipid nanoparticles are efficient at electrostatically condensing nucleic acid 
(lipoplexes) on the scale of just a few base pairs (therapeutic RNA) to millions of base 
pairs (chromosomes). Further, these structures are easily functionalized with stealth and 
targeting ligands that allow cellular specificity and circulatory longevity [34]. However, 
lipids are not without their shortcoming. Physiochemical properties such as charge and size 
are shown to be limiting factors in uptake of lipoplexes into cells and transfection 
efficiency [35, 36]. These properties further induce severe cytotoxicity which limits clinical 
application of lipids [37]. 
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1.2.3.2 Cationic Polymers 
Cationic polymers were discovered to have the ability to electrostatically condense 
nucleic acid (polyplex) and traverse the cell membrane [38]. As a result, these biomaterials 
have established a prominence in the non-viral gene delivery arena. The primary 
differences in cationic polymers and lipids is that polymers lack a hydrophobic moiety and 
are soluble in water [39]. Multiple properties such as molecular weight, surface charge, 
charge density, hydrophilicity, and structure effect the delivery and transfection efficiency 
of polyplexes, making their optimization a focus of the scientific field [40]. Like lipids, 
polymers offer the ability to be chemically modified, allowing engineering of structural 
motifs and conjugation of molecules that enhance functionality [41]. Common polymers 
for gene delivery include PEI, PAMAM, PLL, and Chitosan [42], each with their own 
advantages (Figure 1.1). Though promising advances have been made in polyplex design, 
the mechanisms of cellular interaction, internalization, and intracellular trafficking are not 
well understood. Since these processes are believed to pose limitations on gene delivery 
efficiency, there is a push to better understand these mechanisms for the improved rational 
design of polyplexes. This is a necessary step if polymer-based gene delivery is to rival the 
efficacy of the virus. 
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Figure 1.1: Common polymer vectors for gene delivery. 
Polyethylene imine (PEI) is the gold standard of polymers for gene delivery due to 
high transfection capability resulting from the ability to buffer endosomal influx of protons 
[43]. This causes chlorine influx that results in osmotic swelling and subsequent escape of 
polyplexes into the cytoplasm. PEI is available in branched or linear format at various 
molecular weights. Increasing molecular weight was found to improve transfection but 
increase cytotoxicity, limiting the in vivo applications [44]. To offset this toxicity, 
modifications are commonly made to the PEI structure to chemically modify or shield the 
structure from the biological environment to mitigate toxicity while preserving transfection 
quality [45-48]. Despite these improvements, clinical application of PEI is limited to lower 
molecular weights to avoid toxicity. 
Dendrimers are highly branched spherical polymers of controlled surface charge 
and diameter. As a popular dendrimer, PAMAM has been used to mediate efficient, albeit 
nonspecific gene transfer in vitro [49]. Abundance of amine surface groups allows facile 
chemistries and endosomal escape via similar mechanisms as PEI. Toxicity of PAMAM is 
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a prevalent problem though less severe to that of PEI. The characteristics of the dendrimer 
(size, surface charge, surface density) are controlled by the number of synthetic steps [50]. 
While primarily generations 3-6 are used for efficient gene delivery, strides must be made 
to reduce the cytotoxicity of these vectors. Attempts to shield the surface amine groups 
using hyaluronic acid, PEG chains, arginine, cyclodextrin, and Tat peptide have been 
successful in mitigating this toxicity [51]. 
Polylysine (PLL) was one of the earliest polymers discovered for non-viral gene 
delivery. This polymer is biodegradable and, upon modification with dextran or PEG, 
exhibits essentially no cytotoxicity as a condensed polyplex [52]. However, PLL is often 
associated with poor transfection quality due to the lack of endosomal buffering capacity. 
Therefore, the polymer is often delivered accompanied by endosomal buffering agents to 
facilitate escape and efficient gene expression. Though improvements have been made, 
PLL is primarily used as a reference for other vector’s transfection quality. 
Chitosan is an attractive, natural polymer for gene delivery due to its low toxicity, 
biocompatibility, and biodegradability [53]. The cationic polysaccharide contains ample 
amines for DNA condensation and chemical modification to enhance delivery. However, 
use of chitosan can be challenging due to poor solubility, poor cellular specificity, and low 
transfection efficiency [42]. However, manipulation of surface amine groups is beginning 
to rectify these shortcomings. Interestingly, chitosan is a mucoadhesive polymer, making 
it a powerful transfecting agent of gastrointestinal epithelia in gut-associated lymphoid 
tissue [54]. 
 
15 
 
1.2.3.3 Cell Penetrating Peptides 
Cell penetrating peptides (CPP) are small amino acid sequences (10-30 residues) 
that have the ability to cross the cell membrane independent of endocytosis [55]. CPPs 
were discovered in the 1980s when it was demonstrated that the tat gene encoded by the 
HIV-1 virus could be taken up by cells in vitro and translocate to the nucleus [56]. Further 
studies showed that its biological conjugation with impermeable compounds resulted in 
cellular uptake of these compounds without loss of therapeutic activity [57]. Furthermore, 
immunogenicity associated with CPP is minimal [58] and there remains astonishingly low 
cytotoxicity since CPPs do not cause cellular membrane disruptions [59]. Early studies 
showed high competency of CPP for the delivery of siRNA into cancer cells, representing 
promising potential for gene therapy vectors. While there seems to be no disadvantage of 
CPP-based delivery, cell specificity seems lacking. However, reports indicate that specific 
cancer targeting are possible [60]. Though poorly understood and early in development, 
CPPs offer exciting potential for delivery not just of nucleic acids but many 
macromolecules. 
1.3 Barriers to Non-Viral Gene Delivery 
Successful gene delivery is contingent on vector ability to effectively navigate 
through various physiological environments while protecting its cargo and avoiding 
clearance. The simplest environment for gene delivery is the controlled in vitro setting 
where cellular delivery is achieved with minimal extracellular resistance. In the body, 
however, polyplexes and lipoplexes are subject to lytic enzymes and electrostatic exposure 
to serum elements that destabilize and degrade the vector and cargo [61]. Delivery in vivo, 
therefore, is subject to a number of environmental interactions that act as barriers to 
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delivery. Further, vectors that localize to the target tissue are faced with the additional 
barriers of internalization and intracellular processing. These extra- and intra- cellular 
barriers are inherently detrimental to efficacy and involve extracellular transport, serum 
stability, cellular membrane interaction, internalization, endosomal escape, intracellular 
trafficking, cytosolic transport, and nuclear localization (Figure 1.2). 
Figure 1.2: Barriers to non-viral gene delivery. A) Extracellular transport/stability. B) 
Extravasation from vasculature endothelium or diffusion by enhanced permeation and 
retention effect. C) Surface interaction and internalization by endocytosis. D) Early 
endosome maturation into late endosome. E) Transport and fusion of late endosome with 
lysosome. F) Endosomal escape through osmotic selling. G) Transport through cytosol to 
nuclear envelope. H) Nuclear localization. I) Vector dissociation into DNA and cation. 
1.3.1 Serum Stability and Extracellular Transport 
Condensation of DNA is often performed by electrostatic binding with excess 
cation, resulting in a vector of positive charge. Naked DNA alone is capable of stimulating 
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inflammatory response by toll-like receptors [62]. Therefore, this electrostatic 
incorporation into a nanoparticle results in shielded DNA that avoids immune activation 
and protects the cargo from enzymatic degradation. The positive charge mediates cell 
uptake but causes non-specific interactions in circulation. Interaction with serum 
components in the blood results in electrostatic disruptions between the nucleic acid and 
vector, which can lead to premature dissociation or deteriorated shielding [63]. Since the 
presence of nucleic acids in the blood stream is discouraged by high concentration of 
nucleases, lack of shielding directly corresponds to nuclease degradation and poor delivery. 
Binding serum proteins also expedites aggregation of vectors, leading to condensation and 
renal clearance. Further still, electrostatic interaction with non-target cells and extracellular 
matrix diminish delivery efficiency. Binding plasma proteins leads to recognition by the 
reticuloendothelial system (RES) which localizes delivery to RES organs such as the liver, 
spleen, and bone marrow [64]. These interactions within the blood stream are major 
barriers to successful gene delivery and their mitigation or avoidance are a subject of 
critical study. 
Perhaps the first barrier to gene delivery is introduction to the blood stream 
followed by effective shielding of non-specific interactions in circulation. However, to 
reach non-vascular targets, non-viral vectors must extravasate through the vasculature wall 
to gain access to the desired tissue. Of the common vesicular wall structures, the 
discontinuous structure contains gaps of 30-500 nm capable of mediating random diffusion 
of vectors through the wall [65]. Nanoparticles or aggregates of particles beyond this size 
will remain in circulation until encountering vascular beds in the liver where they 
accumulate and become cleared [66]. Non-viral vectors must be capable of condensing 
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their cargo into nanoparticles within this size range for non-vascular delivery. Diffusion 
through these gaps, therefore, is a tremendous barrier to intravascular delivery in the 
absence of vasodilators that temporarily increase the size of fenestrations in the vessel 
lumen. However, gene delivery to cancer tumors is much more trivial due to the enhanced 
permeation and retention effect (EPR) associated with the tumor endothelium. Tumors 
undergoing angiogenesis tend to possess a leaky, discontinuous structure that allows 
permeation of macromolecules and most nanoparticles [67]. This in conjunction with poor 
lymphatic drainage results in accumulation of nanoparticles within the tumor vasculature, 
making the EPR effect an effective means for passively targeting established tumors [68-
70]. 
1.3.2 Cellular Membrane Interactions 
Once the administered non-viral vector has navigated its way through the biological 
extracellular barriers, it must interact with the target cell membrane such that 
internalization occurs through endocytosis. This process of internalization is energy 
dependent and in most cases requires activation through interaction with intermembrane 
protein domains [71]. Though cationic amphiphile-DNA complexes were originally 
believed to undergo fusion with the cell membrane, studies have proven that most all non-
viral vectors internalize through endocytosis, even the vectors considered non-specific 
[72]. These vectors bind to the cell through either receptor interactions or non-receptor 
binding. Receptor binding is mediated by cognate recognition of a ligand by a surface 
biomarker. Multiple ligands such as transferrin, insulin, EGFR, and folate [73-76] have 
been conjugated to non-viral vectors in order to provide specificity in targeting. Non-
receptor binding, on the other hand, is primarily driven by electrophilic interactions of 
19 
 
vectors with charged intermembrane proteins. For example, the cell surface comprises a 
large concentration of proteoglycans, one of the most negatively charged components of 
the cell [77]. Cationic vectors likely bind these protein complexes through electrostatic 
interactions and trigger subsequent internalization as shown by inhibited transfection upon 
proteoglycan inhibition [78]. Negative zeta potential vectors are repulsed by these 
proteoglycans and are forced to localize to regimes of positive cell surface charge to 
interact with protein groups of positive charge. It is highly likely that the internalization 
mechanism associated with these positive and negative particles are different [79], leading 
to disparities in intracellular processing and gene expression as discussed in chapter 2. 
1.3.3 Internalization and Endosomal Escape 
As previously discussed, internalization of non-viral vectors is preceded by 
interaction with the cell membrane, which governs the endocytic mechanism of uptake. 
Internalization through receptor-mediated endocytosis involves concentration of receptors 
in special membrane regimes of clathrin-coated pits followed by invagination of the cell 
membrane around the vector-receptor complex and transport through the membrane [80]. 
At the inner side of the cell membrane, the particle becomes encased by structural actins 
and coated with clathrin to form clathrin-coated vesicles (CCV). These vesicles are 
acidified as they are trafficked to late endosomes and then to lysosomes [81]. This clathrin-
dependent endocytic pathway is well characterized and by far the most studied endocytic 
mechanism. However, alternate mechanisms involving membrane transport independent 
of clathrin are known to be involved in the intermembrane transport of many 
macromolecules. Perhaps the most studied clathrin-independent mechanism involves 
flask-like membrane invaginations that bud off the membrane in caveolin-structured 
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vesicles called caveolae [82]. Unlike clathrin-dependent internalization mechanisms that 
are solely purposed for endocytosis, caveolae are implicated in a host of cellular functions 
such as calcium signaling, homeostasis, and cholesterol transport [83, 84]. A further 
differentiation from clathrin-dependent uptake is that caveosomes are suspected to avoid 
harsh acidification and trafficking to lysosomes [85, 86]. Interestingly, cells also possess 
non-specific internalization pathways for the fluid phase uptake of solutes and extracellular 
constituents from the immediate surroundings. Phagocytosis is one such pathway uniquely 
utilized by macrophages and other immune cells to engulf large components even on the 
cellular level. However, this is a pathway used only by specialized cells. The common cell 
approach to non-specific fluid phase internalization occurs through macropinocytosis, a 
process that involves the formation of membrane ruffles that eventually engulf large 
portions of extracellular fluid. The resulting vesicle is called a macropinosome and can 
measure up to 5 microns in size [87]. Though this mechanism is non-specific, it is generally 
activated through stimulation of growth factor receptors on the cell membrane [88]. Cancer 
cells overexpressing growth factors, therefore, are particularly active in terms of uptake 
through macropinocytosis. Though other unique, clathrin-independent pathways do exist 
[89-92], clathrin-dependent endocytosis, caveolin-dependent endocytosis, and 
macropinocytosis are believed to be responsible for the internalization of most 
macromolecules. 
Following internalization and the formation of an early endosomal vesicle (CCV, 
caveosomes, macropinosome, etc.) the cell must sort the endosomal contents for secretion, 
digestion, or recycle to the cell surface. Though this sorting process is poorly understood 
[80], the current model involves the procession from early endosomes to acidified 
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endosomes to lysosomes [93]. This endosomal classification defines the compartments 
based on pulse or pulse-chase protocols and presence of unique marker proteins. Generally, 
the early endosome is sorted into a maturing endosome that is acidified from physiological 
conditions to a pH of 5-6 when fully matured as a late endosome. This late endosome is 
characterized by the presence of degradative enzymes and the highest concentration of the 
cation-independent mannose 6-phosphate receptor (M6PR) which is localized to the 
internal wall of the vesicle [94]. This late endosome undergoes fusion with lysosomal 
cellular compartments to form a hybrid vesicle containing high concentrations of 
degradative enzymes and a pH of ~4.5 [81]. Any nucleic acid that survives sorting to the 
lysosome will surely be degraded by the compartment acidity and host of nucleases. 
Therefore, efficient gene delivery requires vector escape from the endosome before 
conditions destroy its cargo. 
The process, or lack thereof, of endosomal escape is a major limiting step to 
efficient gene delivery [95]. As such, early vectors showed high levels of uptake but low 
subsequent gene expression due to lack of ability to escape the endosome [96]. Therefore, 
three main mechanisms have been developed to promote endosomal escape of non-viral 
vectors for gene delivery. First, the pore formation model involves conjugation of pH-
activated peptides that undergo conformational changes at the pH of the maturing 
endosome. These changes result in peptide insertion into the endosomal membrane, 
creating ion channels allowing vector escape [97]. Since this mechanism is common in 
viruses, fusogenic peptides were isolated and conjugated to vectors and showed increases 
in delivery [98]. The second model is termed flip-flop and involves endosomal escape by 
the fusion of the vector with the endosomal membrane. This is a popular technique for 
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lipoplexes since they require a phospholipid for lipid bilayer stabilization. 
Dioleoylphosphatidylethanolamine (DOPE) is particularly successful at providing 
fusogenic activity of the lipoplex with the endosomal wall [97]. The final model, the proton 
sponge, is a system inherent in several cationic polymers such as PEI and PAMAM. These 
vectors possess high densities of amine groups capable of protonation at endosomal pH. 
Influx of protons during endosomal acidification are buffered by the amine groups, 
resulting in excessive accumulation. This invokes chloride ion influx, causing the 
endosome to swell and become increasingly permeable, allowing escape [99]. Since many 
cationic lipids and polymers do not possess this buffering ability, conjugation of 
endosomolytic agents such as glycerol or chloroquine can provide this endosomal buffering 
capacity for improved efficacy. 
The process of internalization is known to affect the resulting endosomal sorting 
[100-106]. While clathrin-mediated endocytosis leads to rapid internalization, the pathway 
is known to sort its contents to late endosomes and lysosomes [81]. While this may seem 
to be of benefit since most endosomal escape mechanisms require acidification, efficient 
internalization of cationic polymer PEI shows higher efficacy upon internalization through 
caveolin-dependent endocytosis, a route hypothesized to avoid endosomal acidification 
and lysosomal trafficking [100]. Therefore, avoidance of the endolysosomal pathway by 
caveolin-mediated uptake may be more efficient than endosomal escape by the 
hypothesized proton sponge effect mediating escape after clathrin-mediated uptake. This 
is indicative that internalization pathway is closely linked to subsequent intracellular 
trafficking and transfection efficiency of non-viral vectors. 
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1.3.4 Cytosolic Transport and Nuclear Localization 
Upon micro-injection into the cytosol, naked DNA becomes rapidly degraded by 
cytosolic nucleases, producing little gene expression [107]. Therefore, it is highly likely 
that at least a portion of the vector-DNA complexes escape the endosome intact such that 
nucleic acid shielding continues to occur in the cytosol. However, smaller segments of 21 
bp DNA were shown to be more successful at traversing the cytosol and entering the 
nucleus where double stranded DNA sequences up to 500 base pairs were shown to localize 
to the nuclear envelope and 6 kb DNA was immobilized, likely due to cytosolic crowding 
[108, 109]. Cationic lipid lipoplexes directly injected into the cytosol showed decreases in 
expression compared to naked DNA, indicating their dissociation in the endosome is 
critical [110], whereas PEI or PLL polyplex microinjection resulted in boosted expression 
[111]. Therefore, efficiency in polycation-based vectors is most likely dependent on 
continued condensation and shielding of DNA after endosomal escape. As an alternative 
hypothesis to cytosolic diffusion, models of active transport have been suggested that 
involve the transport of complexes or naked DNA along cytoplasmic spanning structures 
such as actin filaments or microtubules [112]. Interestingly, the inhibition of tubulin 
transport using nocodazole was shown to improve gene expression in lipoplexes [113]. 
Though this was expected to be from the avoidance of trafficking along microtubules to 
lysosomes, it indicated that microtubule transport was indeed a mode of cytosolic transport 
for lipoplexes. For PEI-DNA polyplexes, depolymerization of microtubules or inhibition 
of dynein motors decreased expression while microtubule stabilization increased 
expression 20-fold [114]. This indicates that lipoplexes and polyplexes are dissimilar not 
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only in their mechanism of dissociation, but also in their mechanism of active or passive 
cytosolic transport. 
Nuclear accession is achieved either by transport through nuclear pore complexes 
or by entrainment during nuclear formation. Nuclear pores are the exclusive method of 
chaperoned entry to the nucleus, excluding compounds of >45 kDa without explicit nuclear 
localization signals [115, 116]. This would seem to indicate that dissociation of DNA from 
the vector would be a prerequisite of nuclear internalization. However, PEI-DNA 
complexes were shown in the nucleus after delivery, indicating that dissociation is not 
required for nuclear localization [111, 117]. A proposed mechanism for entrance is that 
exposed DNA is bound by transcription factors in the cytosol. Since these transcription 
factors localize to the nucleus, they possess the import signals needed to enter through 
nuclear pore complexes, thereby ushering the bound vector-DNA complex into the nucleus 
[118]. Alternative theories of nuclear localization of dividing cells involves the breakdown 
and formation of the nucleus during mitosis. The formation of the newly formed nucleus 
simply entrains the vector-DNA or naked DNA, which is then trapped in the new nuclear 
environment. A third, less-likely hypothesis is that the membrane disruptive nature of the 
cationic vector facilitates membrane disruption of the nuclear wall in a similar fashion to 
endosomal membrane disruption. This forms a temporary avenue by which the vector-
DNA and other compounds can pass through the membrane [95, 119]. 
1.3.5 Intracellular Dissociation 
Though it is unclear as to when the vector-DNA complex dissociates within the 
cell, intact polyplexes were observed within the nucleus after transfection, indicating that 
dissociation is not required for nuclear delivery [111]. However, it is likely that exposure 
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to acidifying factors in the endosome as well as cytosolic proteins caused decreased 
electrostatic interaction between the vector and DNA, allowing access of the genetic cargo 
to transcriptional factors required for expression. Further, it is possible that dissociation 
does not occur universally. Dissociation location might vary depending on a variety of 
factors and interactions within the cell, resulting in polyplexes and lipoplexes of varying 
stability in all cellular compartments. 
1.4 Rational Design of Non-Viral Vectors 
Many structural, chemical, and physical properties of non-viral vectors influence 
the stability of the vector-DNA complex and ability to overcome the many barriers to 
delivery. Though advancements have been made in vitro leading to increased gene 
delivery, the efficacy of in vivo vectors is wanting. Therefore, a deep understanding is 
required for the manipulation of particle properties to optimize the stability and robustness 
of non-viral vectors. These properties as they apply to nanoparticles are well studied [41, 
120-122]. However, much less attention has been devoted to their effects on non-viral gene 
delivery vectors. Here, a brief review of several of these properties will be explored in the 
context of polymer-mediated gene delivery. 
1.4.1 Size and Shape 
The effect of particle size on internalization is somewhat confounding. Intuitively, 
larger particles should internalize slower and to lesser extent than smaller particles due to 
the extra energy required for their internalization. However, this is not the case for PEI-
DNA polyplexes where polyplexes of hundreds of nm exhibited more transfection than 
particles <100 nm [123, 124]. A proposed explanation for this in vitro phenomenon 
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suggested that smaller polyplexes remain in suspension while larger polyplexes sediment 
onto the surface of the adherent cells, forcing more cellular interaction than the suspended 
smaller polyplexes. This was supported by an increase in transfection upon centrifugation 
of smaller particles to promote sedimentation [125]. However, this was not a generalized 
statement for all polymers since PLL and pDMAEMA exhibited differing results. An 
alternative explanation is that the size of the polyplex governs the endocytic pathway of 
internalization [126]. Large polyplexes might therefore internalize through pathways 
alternate to their smaller counterparts. Since clathrin-mediated endocytosis is the suspected 
uptake mechanism of the smaller PEI-DNA polyplexes [73], larger ones might avoid the 
endolysosomal demise of the smaller. This phenomenon is not surprising since endocytic 
uptake mechanisms possess upper size limits that cause a shift in uptake pathway from 
smaller to larger particle, as demonstrated by polystyrene internalization [127]. Large 
polyplex design is also though to benefit endosomal escape by the proton sponge effect as 
higher weights of polymer capable of protonation allows higher endosomal buffering 
capacity. This was supported by increased transfection of smaller PEI-DNA polyplexes but 
not larger polyplexes when transfected in the presence of lysosomotropic agent chloroquine 
[128]. Though this is true for protonable polymers, the same might not be said for those 
unable to buffer the endosome. A further advantage of large polyplexes is the direct 
relationship between DNA protection from degradation by nucleases, where large 
polyplexes were shown to be more effective at DNase shielding than smaller, exposed 
polyplexes [129]. Though it may seem that larger polyplexes are advantageous in many 
concepts, they are not without their shortcomings. Polymeric vectors are shown to pose 
significant and sometimes excessive cytotoxity [29]. However, this toxicity is heavily 
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dependent on the molecular weight and chemical makeup of the cationic polymer [130]. 
Further, large polyplex mobility was shown to be greatly impeded in the cytosol, as 
previously discussed. Therefore, design of polyplex size should optimize the transfection 
capacity while maintaining cytosolic mobility and low cytotoxicity. 
Shape of nanoparticles is an important property since larger surface area mediates 
maximum membrane interaction. Polyplexes, however, lack the ability to control the 
electrostatically bound complex form. Condensation of DNA with cationic polymer results 
in a globular shape or a rod shape when functionalized with PEG [131]. However, toroidal 
polyplexes micelles were formed by PEG-DNA-polymer condensation in the presence of 
600 mM NaCl and exhibited superior transfection over standard rod shaped polyplexes 
[132]. This process involved the spooling of DNA into a polymer micelle, a process similar 
to viral packaging [133]. Though of interest in forming artificial viruses, this technique 
requires highly controlled complexation and is likely too complicated to consider for most 
applications. Therefore, the rational design of polyplex shape is limited. 
1.4.2 Surface Chemistry 
Though great strides have been made in the field of biomaterials, the need exists 
for a deeper understanding of their interactivity at the cellular interface. This is true for 
non-viral vectors where these interactions govern the physiochemical response of the cell 
and subsequent vector efficacy. Therefore, extensive work has been performed to 
characterize the chemical and structural properties of polymer vectors as they relate to 
biological interactions [134]. Modification of these surface properties is key to optimizing 
desirable biological interactions (DNA condensation, cellular internalization, protection 
against nucleases, cell targeting, etc.) while minimizing the undesirable (non-specific 
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binding, aggregation, toxicity, etc.). Though the term “surface chemistry” encompasses 
many different aspects of the vector surface design such a hydrophobicity, elemental 
composition, morphology, charge, and end-functionalization, only design strategies 
involving moiety substitutions and molecular conjugations are discussed here with surface 
charge/density addressed in the following section. 
Oftentimes, surface moiety modifications that disrupt the homogeneity or 
hydrophobicity of the vector surface are beneficial to vector functionality [135]. These 
modifications help to reduce the original properties while promoting new interactions 
through replacement of chemical functional groups. For example, acetylation of up to 57% 
of the primary amines of PEI was shown to enhance gene expression up to 58-fold in 
HEK293 cells [48, 136]. The source of this enhancement was determined to be the decrease 
in interaction with DNA, allowing easier dissociation within the cell. Further, succinylation 
of PEI was shown to produce a similar effect, improving gene expression through reduced 
serum interaction and intracellular dissociation [137]. Substitution of amines on 2-kDa PEI 
with various aliphatic lipids also exhibited positive effects on gene delivery by boosting 
the inferior expression associated with low molecular weight PEI to rival that of 25-kDa 
PEI without increasing toxicity [138]. A particularly interesting modification for the 
generation of degradable PEI was the appending of low molecular weight PEI with linear 
biodegradable polyesters with carbon-carbon double bonds [139]. The resulting, cross-
linked polymers retained the ability to effectively condense DNA while providing 
transfection similar to 25-kDa with little toxicity. These modifications are used to alter the 
surface chemistry in a way that enhances or shields the effects of functional groups by 
substitution. 
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One of the advantages of polymer and lipid vectors is the ease of functionalization 
due to accessible surface groups. Therefore, conjugation of ligands, small molecules, 
proteins/peptides, stealth agents, and antibodies has become mainstream. Perhaps the most 
common conjugation is that of the stealth agent polyethylene glycol (PEG). This 
modification results in a PEGylated particle with a hydroxyl-rich shell that reduces surface 
charge, resulting in decreased non-specific serum interactions and clearance by phagocytic 
systems, thereby extending circulation in vivo [140]. While this hydrophilic shell helps to 
shield undesirable interaction, it hampers desirable interactions such as cellular uptake, 
controlled intracellular trafficking, and endosomal escape too, reducing gene delivery 
efficiency [141, 142]. Other beneficial conjugation techniques involve the installation of 
ligands that compliment specific biomarkers on a targeted cell population. This is a 
particularly effective method to specifically targeting cancer cells with known 
overexpressed surface receptors. Ligand selection often involves the selection of a pre-
existing endogenous molecule that couples to well-studied receptors [143]. Perhaps the 
most widely studied ligand is transferrin, whose receptor is expressed on the surface of 
many proliferating cells and overexpressed on many cancers [144]. Transferrin has been 
extensively used in polymer delivery systems for the purpose of targeting cancer [100, 
123]. Another effective targeting ligand is folic acid, a vitamin heavily sought out by ovary, 
kidney, uterus, testis, brain, colon, lung, and myelocytic blood cancers [145]. It has also 
been used extensively in the therapeutics arena, including cancer-targeted polymer gene 
delivery [100, 146-148]. Another type of receptor common to cancers are growth factors. 
In particular, the epidermal growth factor (EGFR) has shown promise as a cancer-targeting 
agent, being overexpressed in approximately 30% of solid tumors [149, 150]. This growth 
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factor has been used in polymer systems to increase specific transfection in lung cancers 
[75], colon cancers [151], liver cancers [152], and several others. Other ligands being 
utilized for cancer targeting of polymer vectors include but are not limited to the RGD 
peptide [153, 154], hyaluronic acid [155, 156], and DNA/RNA aptamers. These aptamers 
are an exciting new field that involves the sequencing of DNA or RNA to fold into complex 
tertiary structures that compliment cell receptors, offering targeting capacity for many 
therapeutic systems [157]. Though these aptamers have been used in polymer systems for 
drug delivery [158, 159], their use for polymer gene delivery is essentially unexplored 
[160]. 
1.4.3 Charge Density and Zeta Potential 
A particularly impactful trait of the non-viral vector surface is charge group density 
and the subsequent effect on DNA condensation and cell cytotoxicity. The DNA-binding 
mechanism (electrostatics) is the same for all cationic polymers. Therefore, the defining 
differences from vector to vector are the functionality and length of the polymer backbone 
[161]. Even the same cationic polymer can exhibit significantly different toxicity and 
delivery efficiency at varying lengths as exemplified by higher molecular weights of PEI 
producing higher transfection efficiency and toxicity while lower weights are less toxic but 
also less efficient [130]. However, when comparing different vectors of equivalent 
molecular weight, the density of positive charge groups becomes the source of performance 
disparities. In general, higher charge group density results in higher localized charge and 
greater local electrostatic interaction with opposite-charged surfaces. This greatly aids in 
the condensation of DNA into smaller polyplexes as increased charge pairing neutralizes 
the DNA backbone repulsion of itself to allow higher angles of folding [162]. This charge 
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group density also affects the polyplex surface interactions after complexation through 
strong interactions with negative surface groups on the cell membrane as discussed 
previously. This leads to higher binding and internalization potential, but tighter DNA 
compaction requires more dissociative effort in order to expose the DNA for transcription. 
Stronger binding of the cell membrane is beneficial for internalization but can also results 
in irreparable membrane disruptions that induce cytotoxic effects on the cell [163]. Further, 
high cationic surface density can also lead to increased in vivo interaction with non-specific 
blood factors, resulting in aggregate formation, clearance, and off-site targeting. Therefore, 
polymers of high cationic charge group density tend to have strong performance in vitro 
but are rapidly cleared when administered in vivo. As such, several strategies are in place 
to prevent the undesirable interactivity of the polyplex surface with the in vivo environment 
while preserving the transfection potency of these polymers. As discussed in the previous 
section, substitution of a portion of the charge groups is an effective means to reduce the 
number of cationic functional groups at the polyplex surface, decreasing interactivity. This 
method is successful at improving serum stability and reducing cytotoxicity, but it fails to 
vastly mitigate non-specific interactions as required by in vivo application, which requires 
polyplexes of neutral or negative charge for extended circulation through prevention of 
non-specific interactions with negative serum proteins. An alternative strategy is to involve 
a further layer of electrostatic interactions to coat the polyplex surface in a layer of anionic 
polymer to form a ternary system. This coating serves to partially or fully neutralize the 
cationic groups of the polycation, resulting in reduced surface charge and lessened DNA 
interaction [164]. Several different polyanion coatings such as hyaluronic acid [165] and 
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poly (glutamic acid) [166, 167] have been used to produce ternary polyplexes for gene 
delivery. 
The major benefit to ternary polyplexes is the ability to control zeta potential 
through varying the weight ratio of polycation, polyanion, and DNA. Excess weights of 
polyanion can even result in negative surface charge. This surface charge plays a pivotal 
role in non-specific in vivo interactions, cellular internalization, and intracellular fate of 
polyplexes [164]. Therefore, investigation of the effects of charge on each of these 
mechanisms is important for the rational design of polyplexes for in vivo application. 
Though physiological implications are somewhat explored [164], there is little 
investigation of the effect of negative polyplex charge on the cellular barriers to gene 
delivery. Cell surface interactions, internalization, and intracellular processing are all areas 
that lack characterization in terms of negative charged polyplexes and are therefore a focus 
of chapter 2. Here, it was demonstrated that charge is an important factor in the process of 
internalization where positive ternary polyplexes emphasized different endocytic pathways 
than negative polyplexes. Therefore, there is much work to be done in the development 
and understanding of ternary polyplex systems before clinical relevance can be established. 
1.5 Concluding Remarks 
The onset of the Human Genome Project has brought gene therapy into great 
relevance in modern medicine. The juxtaposition of healthy genetics against disease states 
allows for the identification of genetic etiology and subsequent curative therapies. The 
applications have therefore become endless, including but not limited to acquired cancers, 
infectious disease, cardiovascular disease, degenerative disease, and heritable genetic 
indications. Though viral vectors exhibit exceptional gene delivery capacity, their poor 
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safety profiles, while ever improving, remain largely restrictive of their in vivo application 
as exemplified by poor clinical success. Therefore, considerable efforts are being made to 
develop non-viral alternatives that lack the immunogenic hallmark of viral counterparts. 
These vectors, while safer and easier to functionalize, fall short of the efficacy achieved by 
the virus and are therefore the center of intense design efforts. While some non-viral 
vectors have been established as high performers, it is critical that a deep understanding of 
vector interactions with the physiological and cellular environments be characterized. This 
knowledge will help to improve the efficiency of non-viral gene delivery through the 
rational design of new systems or modification to current ones. 
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CHAPTER 2. EFFECT OF SURFACE CHARGE ON POLYPLEX INTERNALIZATION AND 
INTRACELLULAR TRAFFICKING 
2.1 Introduction 
Transport of biomolecules across the plasma membrane is required for cell-to-cell 
communication, immune surveillance, uptake of nutrients, and recycling of surface 
markers that interface with the surroundings. Such transport often occurs by endocytosis, 
which encompasses several distinct energy-dependent processes. Various nanoparticle 
drug and gene delivery vehicles, including polymer-DNA complexes (polyplexes), also 
utilize endocytosis to enter cells. As understanding of endocytic processes has advanced, 
it has become apparent that the endocytic pathway involved in polyplex internalization 
plays a prominent role in the intracellular fate of the genetic cargo and efficiency of 
transgene expression.  
The primary mechanisms for nanoparticle internalization are clathrin-dependent 
endocytosis, caveolin-dependent endocytosis, and macropinocytosis. Clathrin-dependent 
endocytosis results from invaginations of the plasma membrane known as clathrin-coated 
pits (CCPs), which form clathrin-coated vesicles (CCVs) following dynamin-mediated 
scission [168]. During the subsequent endocytic trafficking, the vesicles are acidified by 
the influx of protons and counter ions to pH 5-6 before being trafficked to lysosomes for 
further acidification to pH ~4.5 [81, 169]. Caveolin-dependent endocytosis begins in cup-
like invaginations in the cell membrane called caveolae, which are released from the 
membrane by dynamin, similar to CCVs, but have a very slow turnover at steady state. 
Unlike CCVs, caveosomes are believed to avoid extreme acidification and trafficking to 
lysosomes [86, 170]. Finally, macropinocytosis is a fluid-phase mechanism for rapid, non-
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specific uptake of solutes and large components near the plasma membrane. Stimulation 
of surface growth factors triggers Arf6-induced ruffle formations, which propagate into 
macropinosomes. These vesicles range in size up to 5 µm, encapsulate large volumes of 
extracellular fluid and any other species in solution adjacent to the cell membrane, and are 
inherently leaky [87, 168]. Though macropinosomes are mildly acidified, trafficking to 
lysosomes is only apparent in macrophages, while in most other cell types macropinosomes 
are believed to avoid fusion with lysosomal compartments [171, 172]. Multiple 
nanoparticle properties (size, shape, charge, surface chemistry, etc.) influence the cellular 
mechanisms through which nanoparticles are internalized and their subsequent 
intracellular processing [41]. Therefore, understanding the effect of such design properties 
on cellular processing is critical for rational design of nanoparticle drug and gene delivery 
systems. 
Polyethylenimine (PEI) is a cationic polymer composed of repeating amine groups 
and an ethylene spacer, and studies using PEI as a gene delivery vector are abundant [173-
175]. The high density of ionizable amines allows the polymer to effectively condense 
DNA and, in polyplexes with excess PEI, provides electrostatic binding to the cellular 
membrane and internalization through endocytosis [176]. It has been hypothesized that, 
within acidified endocytic vesicles, protonation of the amine groups results in influx of 
counter ions, osmotic swelling, and vesicle rupture, releasing the polyplexes into the 
cytosol [99, 177]. However, the highly cationic nature of the polymer also results in 
cytotoxicity due to disruption of cell and mitochondrial membranes in many cell types 
[163]. Furthermore, high cationic charge density leads to agglomeration with negatively 
charged serum proteins, which promotes rapid clearance and inhibits cellular 
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internalization of PEI/DNA polyplexes [178, 179]. These disadvantages may be alleviated 
by inclusion in the polyplexes of an anionic material that decreases the overall surface 
charge and the severity of the electrostatic disruption of the cell membrane. Inclusion of an 
anion also results in competition with DNA for binding of PEI, which facilitates 
dissociation of the polyplexes within the cell and reduces aggregation with serum proteins 
en route to the cell through charge shielding [164]. 
Here we show that poly(α-glutamic acid) (PGA) is a suitable anionic polymer for 
the formation of ternary polyplexes (PGA/PEI/DNA). By addition of varying amounts of 
PGA to PEI/DNA polyplexes, the zeta potential could be controlled to investigate the 
effects of polyplex charge on cellular internalization in HeLa (cervical adenocarcinoma), 
U-87 MG (glioblastoma), and HEK 293 (embryonic kidney) cell lines. We and others have 
shown that the endocytic pathway through which polyplexes are internalized governs 
intracellular processing and efficiency of gene delivery [100-106]. That some endocytic 
pathways result in transport to acidified endosomes while others do not offers a partial 
explanation for the differences in effectiveness of various gene delivery polymers [170]. 
Therefore, it is important to understand the mechanisms of internalization for rational 
design of polymeric gene delivery vectors. Transfection with PGA/PEI/DNA polyplexes 
exhibiting varying zeta potential, in the absence and presence of pharmacological inhibitors 
of specific endocytic pathways, were employed to investigate the effect of polyplex charge 
on uptake pathway, the resulting intracellular trafficking, and subsequent reporter gene 
expression. 
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2.2 Materials and Methods 
2.2.1 Cell Culture 
HeLa (CCL-2), U-87 MG (HTB-14), and HEK 293 (CRL-1573) cell lines and 
EMEM cell culture media were purchased from ATCC. Cell culture was performed 
according to the ATCC protocols in EMEM supplemented with 10% fetal bovine serum 
(FBS) at 37ºC and 5% CO2. Phosphate buffered saline (GE Life Sciences,10 mM Na2HPO4, 
1.8 mM KH2PO4, 137 mM NaCl, pH 7.2) was used to wash cells while Trypsin comprising 
0.53 mM EDTA (Corning) was used to dissociate cells. Cells were lysed with cell culture 
lysis reagent at pH 7.8 composed of 25 mM Tris-Phosphate buffer, 0.7 g/L 1,2-
diaminocyclohexane, 10% glycerol, 1% Triton X-100, and 1% protease inhibitor cocktail 
(Millipore).  
2.2.2 Materials 
pGL3-control vector, encoding a modified firefly luciferase optimized for 
transcription in mammalian cells under control of the SV40 promoter-enhancer, was 
purchased from Elim BioPharm. Polymers (branched, 25-kDa polyethylenimine and 15-
kDa poly-L-α-glutamic acid sodium salt)  and pharmacological endocytosis inhibitors 
(genistein, methyl-β-cyclodextrin, chlorpromazine hydrochloride, amantadine 
hydrochloride, and amiloride hydrochloride) were all purchased from Sigma-Aldrich. 
2.2.3 Polyplex Formation  
PGA, PEI, and pGL3 stocks were produced by dissolution in PBS at 0.1 mg/mL. 
Subsequently, desired weight of pGL3 was further diluted 1:5 v:v in PBS. Differing 
amounts of PEI or PGA were diluted in PBS to the same volume to produce solutions of 
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varying PEI or PGA concentrations. The diluted PEI solution was added to the pGL3 
solution, gently mixed, and incubated for 10 min at room temperature in order to form 
binary polyplexes. Ternary polyplexes were then formed by adding the dilution of PGA to 
the binary polyplex solution and incubating at the same conditions for 10 min. These 
polyplexes were then diluted to the desired well volume by addition of EMEM and 
supplementation to 5% FBS. All transfections were performed in 5% FBS unless stated 
otherwise. 
2.2.4 Size and Zeta Potential 
Particle size analysis was performed on a Brookhaven 90Plus Particle Size 
Analyzer. Polyplexes were formed according to the protocol described above at various 
PEI/DNA and PGA/PEI/DNA ratios containing 2 µg pGL3 plasmid and then diluted to 1 
mL in 0.1X PBS. Particles were transferred to a disposable cuvette and analyzed over three 
reads at 5 min per read. Zeta potential was determined using a Malvern Zetasizer. 
Polyplexes containing 800 ng pGL3 were formed at various PEI/DNA and PGA/PEI/DNA 
ratios by the standard protocol and then diluted to 750 µL in 0.1X PBS. The polyplex 
suspension was transferred to a Malvern Nano Series disposable folded capillary cell and 
analyzed for three reads, each consisting of 20 measurements. All samples were run in 
triplicate and averaged. 
2.2.5 Agarose Gel Electrophoresis 
Ternary polyplexes of varying weight ratios were prepared in 10uL 1X TAE buffer 
by adding desired weights of 0.1 mg/mL PEI to 200 ng DNA tagged with YOYO-1 at 1 
dye molecule per 50 bp, incubation for 10 min, and then the addition of desired weight 
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ratio of 0.1 mg/mL PGA. After a further 10 min incubation, polyplexes were diluted in 1X 
TAE buffer to a total volume of 20 µL and then 4 µL 6X loading buffer added (Enzo Life 
Sciences). A 250 - 10,000 bp DNA ladder (Ampigene) and polyplexes were loaded in a 
0.8% agarose gel and electrophoresed at 100 V for 2 h before washing and visualizing by 
a BioRad ChemiDoc MP Imaging System. 
2.2.6 Measurement of Non-Specific Protein Binding 
Polyplexes at 0:3:1, 1.5:3:1, 4:3:1, 5.2:3:1, and 5.6:3:1 (w:w:w) PGA:PEI:DNA 
were formed according to the protocol above, producing zeta potentials of 16, 11, 0, -11, 
and -16 mV, respecitively (w:w:w). An equal volume of 2 mg/mL bovine serum albumin 
(BSA) was added to polyplex suspensions containing 800 ng DNA or free PEI at equivalent 
weights and incubated at 37ºC for 1 h. The samples were centrifuged at 10,000 rpm for 10 
min to precipitate aggregates of polyplex/protein. The supernatant was then assayed for 
total protein using a BCA assay and protein concentration was determined by comparison 
to a standard curve of known BSA concentrations. The fraction of BSA aggregated with 
polyplexes or free PEI was calculated by the equation below where CS is the protein 
concentration in the supernatant, VS is the total sample volume, C0 is the initial BSA 
concentration (2 mg/mL), and V0 is the initial BSA volume (0.5VS).  
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝐵𝐵𝐵𝐵𝐵𝐵 𝐵𝐵𝐴𝐴𝐴𝐴𝐹𝐹𝐴𝐴𝐴𝐴𝐹𝐹𝐹𝐹𝐴𝐴𝐴𝐴 = 1 −
𝐶𝐶𝑆𝑆𝑉𝑉𝑆𝑆
𝐶𝐶0𝑉𝑉0
 
2.2.7 In Vitro Transfection 
Cells were cultured in standard growth media and seeded at 2x104 cells per well in 
96-well tissue-culture plates 24 h prior to transfection. Polyplexes at various 
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PGA/PEI/DNA weight ratios were formed by the standard protocol with 200 ng DNA at 
100 µL well volume. Wells were aspirated and polyplex solution added for 3 h. For 
transfections in the presence of endocytosis inhibitors, growth media was removed and 
replaced with 50 µL EMEM with 5% FBS and concentrations of either genistein, methyl-
β-cyclodextrin, chlorpromazine HCl, amantadine HCl, or amiloride HCl producing 80% 
cell viability (Error! Reference source not found. in appendix). After 1 h, 50 µL of 
polyplex suspension containing 200 ng DNA was added to each well to a final well volume 
of 100 µL and incubated for 3 h. Subsequently, the transfection medium was replaced with 
100 µL fresh growth media. Luciferase expression was assessed on cell lysate 24 h after 
transfection using a luciferase assay system (Promega) according to manufacturer’s 
protocol. Luciferase activity was measured in RLU using Synergy 2 microplate reader. 
Luminescence results were normalized to total lysate protein using a BCA protein assay 
system (G-Biosciences). 
2.2.8 Flow Cytometry 
Cells were seeded into 24-well plates at 2x105 cells per well with growth media and 
allowed to grow for 24 h before transfection. pGL3 plasmid was fluorescently labeled with 
YOYO-1 iodide (Invitrogen) at 1 YOYO/50 bp, and polyplexes were prepared following 
the protocol described above. Transfections were performed in the absence or presence of 
endocytosis inhibitors as described above. After 3 h, the polyplexes were removed, and the 
cells were washed once with 0.001% SDS in PBS, twice with 300 µL PBS, and dissociated 
with 200 µL trypsin. After approximately 10 min, the trypsin was neutralized by addition 
of 50 µL FBS, and 750 µL PBS was added to bring the total volume in each well to 1 mL. 
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Collected cell samples were analyzed on an Attune Acoustic Focusing Cytometer 
(ThermoFisher). Cytometry data was analyzed with FlowJo data analysis software 
(FlowJo). Standard gating techniques were used to remove cell debris and calculate mean 
fluorescence. 
2.2.9 Cytotoxicity 
Cytotoxicity of polyplexes and endocytosis inhibitors was assessed using the 
CellTiter Blue cell viability assay (Promega). Cells were seeded in a 96-well plate at 2x104 
cells per well and incubated for 24 h in growth media. Growth media was replaced with 50 
µL of each inhibitor diluted to desired concentrations (Error! Reference source not 
found. in appendix) using EMEM supplemented with 5% FBS. Cells were incubated with 
the inhibitors for 1 h and then 50 µL growth media added to the well to simulate addition 
of polyplex. After 3 h, wells were aspirated, washed with 50 µL PBS, and 100 µL growth 
media added. Approximately 20 h later, growth media was removed and replaced with 120 
µL of 1:5 (v:v) CellTiter Blue in growth media and incubated for 2 h at 37ºC and 5% CO2. 
One hundred µL was transferred from each well to an opaque 96-well plate and the 
fluorescence (530/25 ex, 590/35 em) was quantified using a Synergy 2 microplate reader 
(BioTek). Fluorescence was converted to cell count using a standard curve of non-treated 
cells. 
2.2.10 Confocal Fluorescence Microscopy 
Cells were seeded at 2x104 cells/well of an eight-chamber Lab-Tek 2 Chamber 
Slide (ThermoFisher) and incubated for 24 h. Ternary polyplexes were prepared according 
to the standard protocol, and polyplexes containing 200 ng DNA were added to each well 
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of the chamber slide for 30 min. During this time, 0.5 mg/mL 70 kDa dextran Texas red 
(Invitrogen) was added to some of the wells as a macropinosome marker. Following 
transfection, the transfection media was aspirated, and the cells were washed with 0.001% 
SDS in PBS to remove any surface bound particles and washed twice with PBS. Cells were 
then fixed with 4% formaldehyde for 10 min, washed three times with PBS, permeabilized 
with 0.1% Triton X100 in PBS for 15 min, and again washed three times with PBS. After 
permeabilization, cells were blocked with 1% BSA in PBS for 45 min, then exposed to 
primary antibodies for caveolin-1 (CAV-1) or clathrin heavy chain (CLTC, Invitrogen) 
diluted to 1:125 and 1:200, respectively, in blocking solution for 2 h at room temperature 
or overnight at 4°C. The wells were aspirated and cells washed four times with PBS before 
incubating 1 h with Alexa Fluor 405 Phalloidin (Invitrogen) at 165 nM and Alexa Fluor 
594 goat anti-mouse IgG secondary antibody (Invitrogen) diluted in PBS to 2 µg/mL. 
Finally, cells were washed four times with PBS before adding Prolong Diamond Antifade 
mountant (Invitrogen) and mounting with a No.1.5H precision coverslip (Thor Labs). 
Slides were imaged using the 60X objective in a Leica SP8 confocal fluorescence 
microscope. 
2.2.11 Scanning Transmission Electron Microscopy 
Polyplexes were formed at varying stoichiometries according to the standard 
protocol with the exception that all polymers and DNA were dissolved in water to avoid 
the presence of salt. Once polyplexes were formed, Lacey Carbon 300 mesh copper grids 
(Ted Pella Inc.) were dipped into polyplex solution for 10 seconds and allowed to dry 
overnight. Scanning transmission microscopy was performed on a Talos F200X 
microscope. 
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2.2.12 Intracellular Trafficking 
To assess whether particles of positive and negative charge are trafficked to the 
lysosome, LysoTracker Deep Red (Thermo Fisher) was used to fluorescently label the 
lysosome. Cells were seeded at 2x104 cells per well of an 8-chamber slide. After 24 h, cells 
were transfected as described above. After 30 min, Lysotracker was added to each well to 
a concentration of 1.6 µM. After an additional 30 min, cells were washed and mounted as 
described above and imaged for co-localization of polyplexes with Lysotracker dye. 
To study the effect of acidification on endosomal processing of polyplexes, cells 
were seeded in 96-well plate at 2x104 cells per well and incubated 24 h. Cells were then 
exposed to 10 nM Bafilomycin A1, 20 µM Chloroquine, or both for 1 h. Polyplexes were 
then prepared according to the standard protocol, and 50 µL of polyplex suspension 
containing 200 ng DNA was added to each well. After 3 h, the transfection media was 
replaced with growth media, and the cells were incubated for an additional 21 h before 
assessing reporter gene expression and total protein, as described above. 
2.3 Results and Discussion 
2.3.1 Polyplex Characterization 
PGA/PEI/DNA polyplexes were prepared in two steps (Figure 2.1). First, PEI was 
added to a DNA solution to form binary polyplexes. To these binary polyplexes, PGA was 
added to form ternary polyplexes. By varying the PEI and PGA weight ratios at fixed 
amount of DNA, the polyplex zeta potential could be controlled (Figure 2.2A). At 
PEI/DNA ratios from 0.5:1 to 5:1 (w:w), the zeta potential of the binary polyplexes was 
+10-16 mV and tended to increase with increasing PEI/DNA ratio. The zeta potential of 
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the polyplexes decreased with addition of PGA. The zeta potentials of the ternary 
polyplexes with PEI/DNA ratios of 0.5:1, 1:1, and 1.5:1 (w:w) reached a minimum of -32 
to -35 mV, and the amount of PGA present at the minimum increased with increasing 
PEI/DNA ratio. With further addition of PGA, the zeta potential increased. This increase 
may be due to competition between PGA and DNA for PEI binding resulting in the 
formation of PGA/PEI “ghost particles” and disruption of the polyplexes. In fact, gel 
electrophoresis of ternary polyplexes revealed DNA dissociation from the polyplex at 
PGA/PEI/DNA ratios corresponding to the minimum zeta potential (Figure 2.2B). These 
ghost particles are suspected to be smaller than the polyplex and form up to 97.5% of the 
overall particle composition at PGA/PEI/DNA ratios of 1.2:1.8:1 [180]. Their presence 
may aid endosomal disruption, similar to the effect of free PEI [181], though to a lesser 
degree.  
 
Figure 2.1: Polyplex complexation process according to bulk mixing protocol. PEI is added 
in excess to DNA to form binary polyplexes. PGA is then added to binary polyplexes to 
form ternary polyplexes. Some free PEI binds PGA to form polyelectrolyte ghost particles. 
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Figure 2.2: (A) Polyplex zeta potential at various PGA/PEI/DNA weight ratios. (B) Gel 
electrophoresis of polyplexes at PEI:DNA weight ratios 0.5:1, 1:1, 2:1, and 3:1. Ladder 
indicates standard DNA ladder. (C) Polyplex sizes at various PGA/PEI/DNA weight ratios. 
(D) Scanning transmission electron micrographs of polyplexes at PGA/PEI/DNA weight 
ratios of 0:3:1 (zeta potential +16 mV), 1.5:3:1 (+11 mV), 4:3:1 (0 mV), and 5.2:3:1 (-11 
mV). (E) BSA aggregation with free PEI and polyplexes at 3:1 PEI/DNA of varying PGA 
weight. (n=4, error bars represent standard deviation; *p=0.0008, **p=0.004) 
 
46 
 
The size of binary PEI/DNA polyplexes decreased with increasing PEI/DNA ratios. 
Weight ratios of 1:1, 2:1, 3:1, and 5:1 exhibited sizes of 232, 162, 143, and 111 nm, 
respectively, suggesting that the higher PEI/DNA ratios result in more condensed 
polyplexes. The size of the ternary polyplexes increased with addition of PGA (Figure 
2.2C) to a maximum and then decreased to a plateu around 150 nm. The increase in size 
with addition of PGA may be due to competition between PGA and DNA for binding the 
PEI, loosening the polyplexes and allowing them to swell. Alternatively, the increase in 
size may be due to aggregation of polyplexes, as the PGA/PEI/DNA ratios exhibiting the 
maximum size corresponds closely to the ratios leading to zeta potential near zero. TEM 
revealed individual polyplexes with sizes that are consistent with the hydrodynamic 
diameters determined by DLS (Figure 2.2D), which is consistent with an increase in size 
due to swelling. Binary polyplexes at the PEI/DNA weight ratio 3:1, as measeured by TEM, 
were ~168 nm. Ternary polyplex weight ratios at 3:1 PEI/DNA resulting in +11 mV 
(1.5:3:1) and -11 mV (5.2:3:1) were 231 nm and 205 nm respectively as opposed to neutral 
polyplexes at 358 nm (4:3:1). As PGA is added beyond the weights resulting in neutral 
charge, polyplex size decreases. It is possible that, at this point, all free PEI is bound up in 
ghost particles and additional PGA is forced to interact with PEI from the polyplex. This 
decrease in size following neutral zeta potential might therefore be accounted to the loss of 
PEI from the polyplex upon disruption by excess PGA.  
Polyplexes exhibiting a negative zeta potential may be expected to aggregate to a 
lesser extent with negatively charged serum proteins compared to polyplexes exhibiting a 
positive zeta potential. Thus, aggregation of BSA with polyplexes of varying zeta potential 
was quantified (Figure 2.2E). At concentrations similar to those present during 
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transfections, free PEI and polyplexes with PGA/PEI/DNA weight ratios of 0:3:1 (binary 
polyplexes, ζ = +16 mV), 1.5:3:1 (+11 mV), 4:3:1 (0 mV), 5.2:3:1 (-11 mV) and 5.6:3:1 (-
16 mV) were incubated with 2 mg/mL BSA, which is comparable to the total anionic 
protein concentration in cell growth media containing 10% serum. The isoelectric point of 
BSA is 4.9, making the protein negatively charged at physiological pH. After 1 h, the 
mixture was centrifuged to pellet any aggregated protein and polyplexes. Increasing 
amounts of PGA in the polyplexes, corresponding to decreasing zeta potential, decreased 
the aggregation of BSA. 
2.3.2 Transfection and Cellular Internalization of Ternary Polyplexes 
The reduced aggregation of PGA/PEI/DNA with serum proteins may be expected 
to enhance transfection in the presence of serum. In addition, competitive binding of PGA 
and DNA may be expected to facilitate polyplex dissociation within the cell, which is 
necessary for DNA transcription. The presence of sufficiently high amounts of PGA, 
however, may result in exposure of the DNA to nucleases, premature decomplexation, or 
loss of DNA from the polyplexes, as observed in gel electrophoresis (Figure 2.2B). 
Therefore, the effect of PGA/PEI/DNA ratios on transfection efficiency in three model cell 
lines was investigated.  
Transfections were performed with ternary polyplexes containing a fixed amount 
of DNA and varying ratios of PGA and PEI (Figure 2.3A, D, and G). At all PEI:DNA 
ratios, transgene expression increased with addition of PGA to a maximum and then 
decreased, and the ratio of PGA in polyplexes at the maximum increased with increasing 
PEI/DNA ratios. This may be expected since greater amounts of PEI should require greater 
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amounts of PGA to coat the surface and loosen the PEI interaction with DNA. In addition, 
transgene expression increased with increasing PEI/DNA ratios up to 3:1 (w:w), but 
decreased for ternary polyplexes with PEI:DNA 5:1 (w:w). In all three cell lines, the 
maximum gene delivery efficiency was observed at PGA/PEI/DNA ratio of 1.5:3:1 
(w:w:w), which exhibited a zeta potential of +11 mV. These trends are consistent with the 
competing effects of PGA in facilitating polyplex dissociation described above.  
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Figure 2.3: Transfection (A,D,G), cellular uptake (B,E,H), and cytotoxicity (C,F,I) of 
PGA/PEI/DNA polyplexes at various PGA:PEI:DNA weight ratios in HeLa (A-C), U-87 
MG (D-F), and HEK 293 (G-I) cell lines. PGA/PEI ghost particles (GHOST) were formed 
at ratios corresponding to the PGA:PEI weight ratios that provided maximum transfection 
efficiency (0.5:1:1, 1.5:3:1, and 2:5:1). 
To determine if the differences in gene delivery efficiency were due to the amount 
of DNA entering the cells, cellular internalization of fluorescently labeled PGA/PEI/DNA 
polyplexes was quantified by flow cytometry (Figure 2.3B, E, and H). Addition of small 
amounts of PGA to PEI/DNA at 1:1 (w:w) resulted in an increase in internalization, but 
uptake decreased to levels similar to binary PEI/DNA polyplexes at higher amounts of 
PGA. The effect of PGA on PEI/DNA at 2:1 (w:w) in U-87 MG cells was similar. In 
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contrast, addition of PGA to PEI/DNA at 2:1 (w:w) in HeLa and HEK 293 cells and 
PEI/DNA 3:1 (w:w) in all three cell lines resulted in ~2- to 3-fold decrease in 
internalization with PGA/DNA ratio of 1:1 (w:w), followed by an increase and subsequent 
decrease in internalization as the amount of PGA further increased. Interestingly, the 
polyplex stoichiometries resulting in the maximum internalization did not correlate with 
the ratios leading to the maximum transgene expression. In fact, the maximum uptake was 
observed for polyplexes exhibiting nearly neutral zeta potential. This is somewhat 
surprising since neutral polyplexes lack the potential for electrostatic interaction with the 
cell membrane. That the ideal PGA/PEI/DNA ratio for internalization is not necessarily 
ideal for gene delivery suggests that polyplex charge may govern the pathway of 
internalization, which is known to affect delivery efficiency.  
PEI is known to be cytotoxic in many cell lines, primarily due to the disruption of 
the cell membrane by the high density of protonated amines [163]. Addition of a polyanion 
to the polyplex may reduce cytotoxicity by shielding the positively charged PEI from the 
cell membrane. Thus, the cytotoxicity of polyplexes with various compositions was 
investigated (Figure 2.3C, F, and I). Binary and ternary polyplexes with PEI/DNA ratio of 
1:1 (w:w), as well as free PEI at an equivalent concentration, exhibited minimal 
cytotoxicity, regardless of the presence of PGA. Free PEI at concentrations equivalent to 
that present in the polyplexes with PEI/DNA 3:1 and 5:1 (w:w), however, decreased 
viability by 20-30% and ~40-60%, respectively. Addition of PGA to PEI/DNA 3:1 (w:w) 
polyplexes had little effect on cytotoxicity in HeLa and U-87 MG cells but decreased 
cytotoxicity in HEK 293 cells. In contrast, increasing amounts of PGA in the ternary 
polyplexes at PEI/DNA weights ratio of 5:1 significantly decreased cytotoxicity in all three 
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cell lines and at 3:1 PEI/DNA in HEK 293. In the presence of PGA/PEI/DNA polyplexes 
at the optimal stoichiometry for gene delivery, 1.5:3:1 (w:w:w), viability of all three cell 
lines was estimated to decrease by less than 20%.  
Suspensions of PEI/DNA polyplexes are known to contain a significant amount of 
free PEI (up to 85% of total PEI), which is thought be beneficial for transfection by 
participating in endosome escape but may also play a significant role in the cytotoxicity of 
PEI/DNA polyplexes [181]. In the preparation of PGA/PEI/DNA polyplexes, free PEI 
likely interacts with the PGA to form ghost particles. Ghost particles prepared at PGA/PEI 
weight ratios of 0.5:1, 1.5:3, and 2:5, corresponding to the ratios in ternary polyplexes 
providing optimal transfection efficiency, were significantly less cytotoxic than free PEI at 
an equivalent concentration. Furthermore, transfection efficiency of binary PEI/DNA 
polyplexes at 1:1 (w:w) increased 15-fold in the presence of ghost particles prepared at 
equivalent weights of 200 ng PGA/PEI while only a factor of 2 in the presence of 600 ng 
free PEI (Figure 2.4). Thus, it appears that the presence of PGA in ternary polyplexes may 
enhance transfection by facilitating polyplex dissociation and reducing aggregation, as 
described above, as well as by binding free PEI, decreasing cytotoxicity.  
2.3.3 Ghost Particle Effect on Transfection and Viability 
To determine the effects of ghost particles and free PEI on transfection efficiency 
and resulting cell viability, binary polyplexes of PEI/DNA at 1:1 (w:w) were transfected 
in HeLa cells in the presence of ghost particles at PGA/PEI 1:1 (w:w) or equivalent weights 
of free PEI. The presence of ghost particles had a clear positive effect on the transfection 
efficiency where transgene expression was increased by a factor of 15 with the addition of 
200 ng of PGA and PEI whereas free PEI increased transgene expression by a factor of 2 
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in the presence of 600 ng free PEI (Figure 2.4A). Both ghost particles and free PEI induced 
toxicity in the cells. Ghost particles, however, were less toxic than equivalent weights of 
free PEI (Figure 2.4B). At the ghost particle weight producing maximum transgene 
expression, toxicity was 13% whereas free PEI toxicity at equivalent weights was 40%. 
Free PEI toxicity at its weight producing maximum transgene expression was 67% whereas 
the equivalent weight of ghost particles produced 55% toxicity. Therefore, the presence of 
PGA reduces the toxicity associated with free PEI. This likely occurs due to PEI amine 
group electrostatic interactions with PGA carboxylic groups, reducing the potential for cell 
membrane disruption. However, the reduction of membrane interactions also reduces the 
capacity for endosomal buffering and escape. Therefore, the dramatic increase of transgene 
expression in the presence of ghost particles compared to free PEI is surprising. It is 
possible that excessive free PEI taken into endosomes with the polyplex dominates the 
buffering process, preventing the polyplex from buffering its amine groups and 
dissociating. The addition of PGA to form ghost particles prevents this buffering 
misbalance and allows polyplex dissociation. However, at excessive weights of ghost 
particles, buffering dominance is again detrimental to dissociation as indicated by 
decreased gene expression after the optimum ghost particle weight. 
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Figure 2.4: (A) Transfection of HeLa cells with binary PEI/DNA polyplexes at 1:1 (w:w) 
in the presence of PGA/PEI ghost particles of 1:1 (w:w) or free PEI. All samples were 
normalized to binary polyplex controls transfected in the absence of ghost particles or free 
PEI. (B) HeLa cell viability after transfection with binary polyplexes in the presence of 
ghost particles or free PEI as in A. (n=4, error bars represent standard deviation). 
2.3.4 Inhibitor Toxicity and Specificity 
To provide a more quantitative analysis of internalization mechanisms associated 
with polyplex charge, pharmacological inhibitors were used to selectively inhibit clathrin-
dependent endocytosis, caveolin-dependent endocytosis, or macropinocytosis. Genistein 
(GST) is a potent inhibitor of tyrosine phosphorylation on caveolin and microtubule 
polymerization, which makes it suitable for inhibiting the caveolin-dependent pathway 
[182]. Another caveolin-dependent endocytosis inhibitor is methyl-β-cyclodextrin 
(mBCD), which sequesters membrane cholesterol and disrupts lipid-rich domains that form 
caveolae [183]. Chlorpromazine HCl (CPZ) is a cationic, amphipathic drug responsible for 
sequestering clathrin on endosomal membranes, preventing recycle to the plasma 
membrane for pit formation [184]. Amantadine HCl (AMN) is a similar drug shown to 
inhibit clathrin heavy chain recycling to the cell membrane [185]. Amiloride (AML) blocks 
membrane Na+/H+ channels, which serves to lower sub-membranous pH and prevent Rac1 
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and Cdc42 signaling involved in macropinocytosis [186]. These inhibitors are known to 
have non-specific effects, making it necessary to include appropriate controls [187, 188]. 
Therefore, the cytotoxicity of each inhibitor and inhibition of internalization of pathway-
specific markers was investigated in each cell line.  
To determine allowable inhibitor concentrations, the cytotoxicity of the inhibitors 
was evaluated in each cell line (Figure 2.5A). Inhibitors performed as expected with 
decreases in viability with increasing dose. CPZ was the least cytotoxic in all three cell 
lines followed by GST, AML, AMN, and mBCD. The U-87 MG cell line was the most 
resilient to the inhibitors, tolerating the highest concentrations of all inhibitors. HeLa and 
HEK 293 each possessed similar tolerance, though less than that of U-87 MG. For further 
experiments involving transfections in the presence of inhibitors, concentrations were 
selected at which >80% viability was achieved in order to maintain healthy cell function 
after exposure to inhibitors (Figure 2.5A-C). To verify the inhibitory quality of the selected 
concentrations, fluorescently tagged endosome markers were delivered 1 h after pathway 
inhibition and compared to non-inhibited controls (Figure 2.5D-F). Transferrin is an iron-
binding glycoprotein that has been shown to bind the transferrin receptor and internalize 
through invaginations of clathrin-coated pits [189, 190]. Cholera toxin subunit B (CTxB) 
is a pentamer that binds specifically to surface ganglioside GM1, which is distributed on 
the plasma membrane and is concentrated in caveolae. Though many internalization 
mechanisms are implicated in its uptake, CTxB tends to become trapped in caveosomes. 
When used in low concentration for short periods, trapped CTxB can be used to identify 
caveosomes [191-193]. Finally, dextran is known to internalize through macropinocytosis 
[194, 195], making it a good marker of the macropinosome. Caveolin-dependent 
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endocytosis inhibitors GST and mBCD both reduced uptake of CTxB by 50% or more 
(p<0.03) in all three cell lines while not statistically significantly affecting uptake of 
clathrin and macropinocytosis markers. CPZ and AMN reduced the uptake of Tf by 
approximately 50% in HeLa and HEK 293, while uptake of Tf by U-87 MG cells in the 
presence of AMN was not statistically significant (p>0.07). Unfortunately, clathrin 
inhibitors exhibited some non-specificity in HeLa and HEK 293 cells as demonstrated by 
the mild effect of CPZ and AMN on CTxB uptake, though the decrease was not statistically 
significant. Finally, macropinocytosis inhibition by AML produced at least 50% reduction 
in uptake of DEX in all three cell lines without non-specific effects on uptake of caveolin 
or clathrin markers (p<0.01).  
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Figure 2.5: (A-C) Cytotoxicity of GST, mBCD, CPZ, AMN, and AML in (A,D) HeLa, 
(B,E) U-87 MG, and (C,F) HEK 293 cell lines. Metabolic activity was normalized to cells 
in the absence of inhibitors. (D-F) GST, mBCD, CPZ, AMN, and AML effect on uptake 
of markers of caveosomes (CTxB), clathrin-coated vesicles (Tf), and macropinosome 
(DEX). (n=3, error bars represent standard deviation; *p<0.05, †p<0.01, ‡p<0.001 
compared to control groups). 
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Table 1: Endocytic inhibitors, their mechanisms of action, and concentrations producing 
80% viability in HeLa, U-87 MG, and HEK 293 cell lines. 
  HeLa U-87 MG HEK 293 
Genistein 
Caveolin Inhibitor: Inhibits 
tyrosine kinase necessary for 
caveolar vesicle trafficking 100 mg/L 200 mg/L 70 mg/L 
mBCD 
Caveolin Inhibitor:  Sequesters 
plasma membrane cholesterol, 
inhibiting lipid raft formation 10 g/L 27 g/L 20 g/L 
Chlorpromazine 
Clathrin Inhibitor:  Stabilizes 
intracellular clathrin and prevents 
recycling to plasma membrane 15 mg/L 20 mg/L 18 mg/L 
Amantadine 
Clathrin Inhibitor:  Stabilizes 
intracellular clathrin and prevents 
recycling to plasma membrane 750 mg/L 800 mg/L 650 mg/L 
Amiloride 
Macro-pinocytosis Inhibitor: 
Blocks membrane Na+/H+ 
channels 500 mg/L 665 mg/L 300 mg/L 
2.3.5 Effect of Polyplex Charge on Endocytic Pathway 
To investigate the effect of polyplex charge on internalization pathways and 
subsequent intracellular trafficking, co-localization of PGA/PEI/DNA polyplexes with 
specific endosomal vesicle markers, clathrin heavy chain, caveolin-1, and dextran (which 
is internalized primarily by micropinocytosis), was visualized by confocal fluorescence 
microscopy. PGA/PEI/DNA 1.5:3:1 (w:w:w) with a zeta potential of +11 mV were chosen 
as representative positively charged polyplexes, while 5.2:3:1 (w:w:w) exhibiting an 
estimated zeta potential of -11 mV represented negatively charged polyplexes. Co-
localization of PGA/PEI/DNA polyplexes of positive or negative charge was observed with 
the markers of all three pathways (Figure 2.6). Mander’s coefficient represents the fraction 
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of a specific fluorophore that co-localizes to another fluorophore where 0 indicates no 
overlap and 1 indicates complete co-localization. Positively charged polyplexes showed 
strong co-localization to caveosomes (Mander’s coefficient > 0.7) in all three cell lines. 
However, there was a much less co-localization to clathrin-coated vesicles (Mander’s 
coefficient < 0.35) and an even lower overlap with dextran in macropinosomes (Mander’s 
coefficient < 0.1), with the exception of U-87 MG where the Mander’s coefficient was 
0.33. These data suggest that positively charged polyplexes are internalized through a 
combination of all three pathways with the largest portion of uptake through caveolin-
dependent endocytosis. Negatively charged polyplexes were less dependent on caveolin-
dependent endocytosis where Mander’s coefficients ranged from 0.42 to 0.55 in the three 
cell lines. However, negatively charged polyplex co-localization to clathrin-coated vesicles 
exhibited Mander’s coefficients of 0.65 to 0.71, Negatively charged polyplex co-
localization to macropinosomes, similar to that of positively charged polyplexes, gave a 
Mander’s coefficient of <0.15, which may be expected as macropinocytosis is a non-
specific endocytic pathway.  Thus, it appears that positively and negatively charged 
polyplexes were internalized by different mechanisms, with positively charged polyplexes 
preferentially internalized via caveolin-dependent endocytosis and negative polyplexes via 
clathrin-dependent endocytosis (Figure 2.7).  
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Figure 2.6: (Top) Fluorescence confocal micrographs of HeLa, U-87 MG, and HEK 293 
cells transfected with positive (1.5:3:1 w:w:w:, +11 mV) and negative (5.2:3:1 w:w:w:, -
11 mV) polyplexes and immuno-stained for caveolin-1 or clathrin heavy chain, or exposed 
to dextran Texas Red to label caveosomes, clathrin-coated vesicles, or macropinosomes. 
Mander’s coefficients are listed for green overlap with red under each image (M2). Blue 
indicates cell cytoskeleton, green indicates polyplexes, and red indicates endosomes. 
(Bottom) Co-localization maps highlighting only overlap regions. 
 
Figure 2.7: Co-localization of positively and negatively charged polyplexes to caveosomes, 
clathrin-coated vesicles (CCV), and macropinosomes. Mander’s coefficients were 
normalized for co-localization to each of the three pathways. 
The effect of polyplex charge and internalization pathway on gene delivery was 
investigated by quantifying the transfection efficiency and cellular internalization of 
PGA/PEI/DNA 1.5:3:1 (+11 mV) and 5.2:3:1 (-11 mV) in the absence and presence of the 
pathway-specific endocytosis inhibitors (Figure 2.8). The caveolin-dependent endocytosis 
inhibitors (GST and mBCD) essentially eliminated transgene expression mediated by both 
positively and negatively charged polyplexes in all three cell lines with the exception of 
GST in the HEK 293 cells, in which the inhibitor had no significant effect. The presence 
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of GST also produced greater than 50% inhibition of uptake of positively charged 
polyplexes in all three cell lines, ~50% inhibition of uptake of negatively charged 
polyplexes in U-87 MG and HEK 293 cells, and no effect on uptake of negatively charged 
polyplexes in HeLa cells. Uptake of positively charged polyplexes in the presence of 
mBCD increased to 250% in HeLa and HEK 293 cells and 130% in U-87 MG cells. 
Negatively charged polyplex uptake in the presence of mBCD was unaffected in HeLa and 
HEK 293 but increased to 160% in U-87 MG cells. The decreases in transgene expression 
in the presence of both GST and mBCD indicate that caveolin-dependent endocytosis is an 
effective route for transfection mediated by both positively and negatively charged 
PGA/PEI/DNA polyplexes.  
 
 
 
 
62 
 
 
Figure 2.8: Luciferase gene expression (A-C) and polyplex uptake (D-F) of positive 
(1.5:3:1 w:w:w, +11 mV) and negative (5.2:3:1 w:w:w, -11 mV) polyplexes in the presence 
of endocytic inhibitors of caveolin-dependent endocytosis (GST and mBCD), clathrin-
dependent endocytosis (CPZ and AMN), or macropinocytosis (AML) in HeLa (A,D), U-
87 MG (B,E), and HEK 293 (C,F). All inhibited samples were normalized to a non-
inhibited control of equivalent polyplex charge to determine effect on gene expression or 
uptake. (n=6 for gene expression, n=3 for uptake, error bars represent standard deviation; 
*p<0.05, †p<0.01, ‡p<0.001 compared to control groups). 
In HeLa and U-87 MG cells, inhibition of macropinocytosis by AML had similar 
effects to GST in that transgene expression following transfection with both positively and 
negatively charged polyplexes was severely reduced to less than 10%, while uptake was 
only mildly decreased. In HEK 293 cells, however, AML had no effect on transfection 
efficiency of positively charged polyplexes, but decreased transfection of negatively 
charged polyplexes to approximately 45%. This suggests that macropinocytosis is 
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important in transfection by positively and negatively charged PGA/PEI/DNA polyplexes, 
especially in HeLa and U-87 MG. This is not unexpected as macropinocytosis is a non-
specific endocytic pathway. Furthermore, the pathway is upregulated in cancer cells as a 
rapid means to internalize nutrients, which is demonstrated by the more prominent effect 
of AML on the cancer cell lines (HeLa and U-87 MG). 
Transfection efficiency of negatively charged polyplexes in all cell lines was 
reduced to approximately half in the presence of clathrin inhibitors CPZ and AMN. 
However, transfection with positively charged polyplexes nearly doubled in the presence 
of CPZ in HeLa and U-87 MG while increasing to 130% in the presence of AMN in U-87 
MG. Interestingly, the opposite effect on transfection with positively charged polyplexes 
was observed in HEK 293 cells as both CPZ and AMN decreased transgene expression to 
~50%. Thus, it appears that clathrin-dependent endocytosis is an inefficient pathway for 
positively charged polyplexes in HeLa and U-87 MG cells, but leads to transfection in HEK 
293 cells. However, this was not the case for negatively charged polyplexes where 
decreased transgene expression suggest clathrin-dependent endocytosis is an effective 
pathway for gene delivery. Clearly, efficiency of clathrin-dependent internalization and 
resulting transgene expression is not only cell line dependent, but also dependent on 
polyplex charge. This may be explained by differing amounts of clathrin-dependent 
endocytosis or sorting of the resulting endocytic vesicles from cell line to cell line.  
2.3.6 Intracellular Trafficking 
To investigate the effect of polyplex charge on endocytic trafficking, including 
potential trafficking to lysosomes, and the role of acidification of endocytic vesicles on 
gene delivery efficiency, transfections were performed in the presence of 10 nM 
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bafilomycin, 20 µM chloroquine, or a combination of both [100]. Bafilomycin A1 (BAF) 
is a V-type ATPase inhibitor that inhibits endosomal acidification [196]. Chloroquine (CQ) 
is an endosomal buffering agent commonly used to enhance gene delivery mediated by 
vectors lacking ionization potential through promoting endosomal escape by membrane 
disruption [197]. For example, CQ has been shown to improve transgene expression 
mediated by polymers such as polylysine [198], starches [199], and beta-cyclodextrin-
containing polymers [200], as well as lipids such as PCEP [201] and DORIE [32]. In 
addition to endosomal buffering, the aromatic rings of CQ are capable of intercalating 
DNA and causing conformational changes, which inhibit enzymatic digestion of DNA 
[202, 203]. CQ is known to accumulate in acidic endosomal compartments, primarily 
lysosomes. Therefore, CQ is expected to affect the transfection efficiency of polyplexes 
that pass through acidic late endosomes or lysosomes.  
The presence of BAF and/or CQ had no effect on transfection mediated by 
positively charged polyplexes in any of the three cell lines (Figure 2.9A), suggesting that 
these polyplexes are do not enter acidified endosomes or lysosomes, or do not depend on 
an acidic environment for endosome escape or polyplex dissociation. . These results agree 
with co-localization of positively charged polyplexes with caveosomes (Figure 2.6) and 
loss of transfection efficiency in the presence of caveolin-dependent endocytosis or 
macropinocytosis inhibitors (Figure 2.8). Upon transfection with negatively charged 
polyplexes, however, 80% and 50% decreases in transgene expression were observed in 
the presence of BAF and CQ, respectively, suggesting that negative polyplexes are 
trafficked through acidified vesicles and the exposure to lower pH plays a role in effective 
gene delivery. In addition, negatively charged, but not positively charged, polyplexes co-
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localized with Lysotracker, a fluorescent, acidotropic probe with high selectivity for acidic 
organelles (Figure 2.9B). However, the decrease in transgene expression in the presence of 
GST and mBCD (Figure 2.8A-C) suggests that internalization of negatively charged 
polyplexes is dependent to some degree on caveolin-dependent endocytosis. Therefore, it 
is likely that negatively charged polyplex internalization involves a combination of all three 
endocytic mechanisms. Though caveolin-dependent endocytosis is likely the more efficient 
pathway for gene delivery (as indicated by the effects of GST and mBCD), acidification of 
clathrin-dependent endocytosis and macropinocytosis or lysosomal degradation of 
clathrin-dependent endocytosis is not preventing transfection mediated by negatively 
charged polyplexes. 
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Figure 2.9: (A) HeLa, U-87 MG, and HEK 293 transfections of positive (1.5:3:1 w:w:w, 
+11 mV) and negative (5.2:3:1 w:w:w, -11 mV) polyplexes in presence of ATPase inhibitor 
bafilomycin A1 (BAF) and/or endosomal buffering agent chloroquine (CQ). All samples 
treated with BAF and/or CQ were normalized to untreated controls. (B) Co-localization of 
negative (top) and positive (bottom) polyplexes with acidified endosomes marked by 
Lysotracker in HeLa cells. Green indicates polyplexes, red indicates endosomes, and blue 
indicates cell cytoskeleton. (n=4, error bars represent standard deviation; *p<0.02, 
**p<0.004). 
These results suggest that polyplexes undergo internalization through multiple 
endocytic pathways (Figure 2.10). While the conventional model of endosomal escape is 
dependent on the acidification of endosomes, the present results suggest that exposure to 
an acidified environment is not necessary for efficient gene delivery. Caveolin-dependent 
internalization and macropinocytosis, not clathrin-dependent endocytosis, appear to lead 
to successful transfection with both positively and negatively charged polyplexes. While 
polyplex charge does not cause exclusive uptake through a singular pathway, it does affect 
the dominant pathway involved. Positively charged particles were found predominately in 
caveolin-containing endosomal compartments, while at least half of the negatively charged 
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polyplexes were trafficked to acidified late endosomes or lysosomes, which result from 
clathrin-dependent endocytosis. Negatively charged polyplexes were shown to have 
similar amounts of uptake to positive polyplexes. However, gene expression associated 
with negatively charged polyplexes was inferior to that of positively charged polyplexes 
(Figure 2.3B, E, and H). Therefore, the limiting step in transfection efficiency lies not in 
the process of internalization, but in the intracellular trafficking differences of the 
polyplexes. Since negatively charged polyplexes were shown to traffic to acidic late 
endosomes and lysosomes while positively charged polyplexes were not, this 
endolysosomal pathway is likely a source of inefficiency. Therefore, negatively charged 
polyplexes may benefit from surface chemistries that trigger internalization through 
alternative pathways. This may be achieved by addition of targeting moieties that bind 
receptors or surface markers that are known to internalize through desirable endocytic 
pathways. Herein, we have shown caveolin-dependent endocytosis to be an effective means 
of internalization of polyplexes due to the avoidance of acidified endosomes and 
lysosomes. Therefore, design of negatively charged polyplexes to target entry through non-
acidified pathways may result in higher efficacy of delivery vectors capable of in vivo gene 
therapies. This has been achieved in various nanoparticles systems through the use of 
mimetic peptides [204], folate [100], integrin [205], and insulin [206], all targeting 
caveolin-dependent uptake. Conjugation of these factors to the surface of negatively 
charged polyplexes, therefore, may improve internalization and subsequent gene 
expression through controlled intracellular trafficking. 
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Figure 2.10: Summary of internalization pathways associated with positive and negative 
charged polyplexes. CME designates clathrin-dependent endocytosis, CAV designates 
caveolin-dependent endocytosis, and MP designates macropinocytosis. 
2.4 Conclusions 
The rational design of polymer vectors for gene delivery requires an understanding 
of the effects of various design parameters on particle function. Here, we showed that 
polyplex charge plays an important role in cellular internalization and intracellular 
processing. While negatively charged polyplexes internalize through clathrin-dependent 
endocytosis and are trafficked to lysosomes, positively charged polyplexes tend to avoid 
acidified endolysosomal compartments by internalization through caveolin-dependent 
endocytosis. The avoidance of the acidified, degradative environment of lysosomes results 
in increased transfection efficiency. Therefore, design of negatively charged polyplexes to 
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internalize through caveolin-dependent endocytosis is expected to help compensate for 
poor transfection efficiency through targeted intracellular trafficking. 
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CHAPTER 3. DELIVERY AND INTRACELLULAR PROCESSING OF POLYMER AND 
NANOCERIA HYBRID POLYPLEXES FOR GENE AND ANTIOXIDANT THERAPY 
3.1 Introduction 
Gene therapy is a promising approach to treat genetic and acquired indications [207, 
208], in which nucleic acids are delivered to cells by either viral [10, 209] or non-viral 
[210-212] vectors. Recombinant viral vectors remain unrivaled in delivery efficiency, but 
safety concerns have prevented the progression of many clinical trials. As a result, non-
viral systems comprising non-toxic, non-immunogenic materials, such as cell penetrating 
peptides, lipids, polymers, and inorganic materials, are of interest, but the efficiency of 
these vectors is comparatively poor. Rational design of more efficient non-viral vectors 
and their components, therefore, is necessary to improve their potency while ensuring 
safety.  
The vast majority of cancer cells exhibit an imbalance of pro-oxidants and 
antioxidants, resulting in higher levels of oxidative stress in tumors compared to healthy 
tissue [213, 214]. In healthy cells, highly regulated production of reactive oxygen species 
(ROS) is involved in signaling pathways involving cell division, immune regulation, 
inflammation, autophagy, and stress-related response [215]. However, dysregulation of 
homeostasis by an elevated redox state produces DNA damage and overall poor genomic 
integrity [216]. This oxidative stress results in rapid tumorigenesis and tumor progression, 
causing further ROS generation and activation of pro-oncogenic signaling and survival 
[215]. Mature cancer cells may even develop feedback loops to maintain the elevated ROS 
levels that promote survival and high metabolic function while avoiding extreme ROS 
levels that trigger apoptosis [217]. Therefore, two strategies involving ROS modulation 
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have been developed for cancer treatment [218]. First, delivery of natural oxidants and 
chemotherapeutics inducing ROS generation to apoptotic levels has shown success at 
inducing tumor and cell death [219-221]. However, off-site targeting of healthy cells can 
result in tumorigenesis and cytotoxicity. Further, advanced-stage cancers often have the 
capacity to confer drug resistance in response to modulated ROS levels through 
upregulated antioxidant response, rendering this technique ineffective [222]. As a second 
approach, antioxidants that scavenge and neutralize ROS have long been suspected to have 
anticancer properties [223, 224], though evidence of this has never been established [225]. 
Reduced oxidative stress is thought to minimize the chance of cancer development in 
healthy cells while ROS scavenging potentially downregulates tumor growth and invasion 
[226]. Therefore, treatment of early-stage cancers with antioxidants might be a successful 
method to help reduce or prevent tumor progression, mobility, and aggressive growth 
associated with high oxidation environments without adversely affecting healthy tissue. 
This strategy has implications for stand-alone therapies or adjunct treatments that synergize 
with other cancer treatments [227, 228]. Several gene therapies targeting ROS-generating 
sources have been shown to be effective in reducing oxidative stress in cells [229, 230]. 
However, such treatments act by preventing pro-oxidant generation and are unable to 
remove radicals already present. On the other hand, many radical scavengers have short-
term effects since they lose potency after radical absorption. Therefore, there exists an 
opportunity to provide a combined gene and antioxidant therapy for the immediate 
reduction and extended downregulation of ROS in cancers. 
Cerium is a rare-earth element of the lanthanide series that, when combined with 
oxygen, can be found in one of two oxidation states, Ce3+ or Ce4+. The resulting fluorite 
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crystalline structure possesses a large, catalytic surface area capable of interacting with free 
radicals. A characteristic property of cerium oxide nanoparticles (nanoceria) is the unique 
ability to shift between oxidation states based on environmental conditions. This trait 
endows nanoceria with oxygen radical scavenging capability similar to catalase or 
superoxide dismutase (SOD), which maintains low levels of oxidative stress in the cellular 
environment [231]. Therefore, nanoceria is a potent antioxidant that works to reduce 
oxidative stress in cells through free radical scavenging [232, 233]. Though most 
endogenous antioxidants are targeted for specific radicals, the catalytic activity associated 
with nanoceria allows neutralization of all kinds of radical species, making it an 
outstanding option for antioxidant therapies [234]. However, the oxidation state of 
nanoceria is pH dependent. It acts as an antioxidant at physiological pH and shifts to a pro-
oxidant state at more acidic pH [235, 236]. Since many cancer cells promote more acidic 
extracellular environments than healthy cells [237], it has been hypothesized that nanoceria 
might act as an antioxidant in the healthy cellular environment at physiological pH while 
acting as a pro-oxidant in more acidic cancer cell environments, triggering cancer apoptosis 
from induced oxidative insults [238]. However, this mechanism is highly controversial as 
reports using the same core elements produce radically different results [239, 240]. It has 
been further hypothesized that the disparities in the literature may be due to differences in 
physiochemical parameters of the nanoceria such as the method of synthesis, particle size, 
and stabilizer (coating) [239, 240]. Functionality and oxidative state are therefore not only 
dependent on environmental factors but also on physiochemical and structural properties, 
making the therapeutic effect of nanoceria (antioxidant vs. pro-oxidant) vary on a case-by-
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case basis [241]. As such, this report and others show promising results for cancer 
treatment using nanoceria [235, 238, 242-246]. 
Here, we show that citrate-coated nanoceria (NC), DNA, and 25-kDa 
polyethylenimine (PEI) can form a ternary electrostatic complex providing co-delivery of 
nucleic acid and antioxidant to HeLa cells. PEI is a common benchmark for polymeric gene 
delivery due to its relatively high in vitro gene delivery efficiency and has been used to 
deliver NC previously [247]. To our knowledge, however, a polymer system for 
simultaneous delivery of DNA and NC to cancer cells has not been previously reported. 
The resulting NC/PEI/DNA polyplexes were characterized and gene delivery efficiency 
quantified and compared to ternary polyplexes comprising 15-kDa poly-L-α-glutamic acid 
(PGA)/PEI/DNA. The Trolox equivalent antioxidant capacity of the NC/PEI/DNA 
polyplexes was evaluated as a measure of antioxidant activity, and the effect of NC on the 
mechanism of cellular internalization and intracellular processing of NC/PEI/DNA 
polyplexes was investigated.  
3.2 Materials and Methods 
3.2.1 Materials 
Polymer (25-kDa polyethylenimine and 15-kDa poly-L-α-glutamic acid sodium 
salt) and pharmacological endocytic inhibitors (genistein, methyl-β-cyclodextrin, 
chlorpromazine hydrochloride, amantadine hydrochloride, and amiloride hydrochloride) 
were purchased from Sigma-Aldrich. The luciferase reporter plasmid (pGL3) encoding 
firefly luciferase was purchased from Elim BioPharm. 
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3.2.2 Cell Culture 
HeLa cells used in this project were purchased from ATCC along with EMEM cell 
culture media. Cells were cultured according to the ATCC recommended protocol using 
EMEM supplemented with 10% fetal bovine serum (FBS) at 37ºC and 5% CO2. Cells were 
washed with phosphate buffered saline (GE Life Sciences, 6.7 mM PO4, 137 mM NaCl, 
pH 7.2) and dissociated with Trypsin (Corning, 0.53 mM EDTA). Cell culture lysis reagent 
(CCLR) was used to lyse cells at pH 7.8 composed of 25 mM Tris-Phosphate buffer, 0.7 
g/L 1,2 diaminocyclohexane, 10% glycerol, 1% Triton X-100, and 1% protease inhibitor 
cocktail (Millipore). 
3.2.3 Standard Transfection Protocol 
Solutions of DNA, PEI, PGA, or NC at 0.1 mg/mL were diluted in 5X volume PBS. 
The polycation (PEI) is then rapidly mixed into the DNA dilution while vortexing to 
electrostatically form a binary polyplex. After 10 min incubation at room temperature, the 
anion (PGA or NC) is added to the binary solution and incubated 10 min at room 
temperature. Cation and anion may be varied at a constant DNA dose of 1 µg per 1x105 
cells. 96 well plates and 24 well plates are prepared at 2x104 cells and 2x105 cells per well 
respectively. The resulting ternary polyplex is then added to EMEM and FBS added to 5%. 
This solution was added to a 96 well plate at 50 µL or a 24 well plate at 500 µL. Wells 
were aspirated and washed with PBS before addition of polyplexes. For experiments 
involving endocytic inhibitors, cells were incubated with concentrations of inhibitor 
producing less than 20% cell death for 1 h to disable selected endocytic pathways. 
Polyplexes were then added on top of inhibitors for 3 h before aspirating and adding growth 
media. Cells were then incubated until 24 h after transfection before lysing and collecting 
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lysate. A BCA assay (G Biosciences) was used to determine sample total protein and a 
bioluminescence Luciferase protein assay (Promega) used to evaluate reporter gene 
expression on a BioTek Synergy 2 microplate reader. Relative luminescence units (RLU) 
were normalized to total protein for each well. All transfections were performed in the 
presence of 5% serum unless stated otherwise. 
Charge ratios were calculated based on the molar quantity of carboxylic groups (O) 
in 15 kDa PGA or citrate coating of NC, the molar quantity of primary amine groups (N) 
in 25 kDa branched PEI, and the molar quantity of phosphodiester backbone units (P) in 
DNA. P charge was calculated assuming DNA monomer weight of 330 g/mol (3.03 mol 
P/mg DNA) and N charge calculated assuming PEI monomer weight of 43 g/mol (23.26 
mol N/mg PEI). For PGA, O charge was calculated assuming PGA monomer weight of 
129 g/mol with two CO bonds per monomer (15.5 mol O/mg PGA). For NC coated with 
citrate at 75 citrate molecules (2 available CO charge centers) per NC particle, O charge 
was calculated assuming each particle weight of 14,581 g/mol (10.3 mol O/mg NC). 
3.2.4 Size and Zeta Potential 
Nanoparticle zeta potential was determined using a Malvern zetasizer and particle 
size was determined by dynamic light scattering using a Brookhaven 90Plus Particle Size 
Analyzer. For size analysis, polyplexes of NC:PEI:DNA or PGA:PEI:DNA were formed 
according to the standard protocol at various O/N/P ratios based on 800 ng pGL3 plasmid. 
These particles were diluted to 1 mL in 0.1X PBS and added to a disposable cuvette before 
analyzing size over three reads of 5 min each. For zeta potential measurements, polyplexes 
were formed according to the standard protocol at various O/N/P ratios based on 2 µg pGL3 
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plasmid, diluted to 750 µL in 0.1X PBS, and added to a Malvern Nano Series disposable 
folded capillary cell. Zeta potential was analyzed over three reads, each consisting of 20 
measurements. All samples were run in triplicate. 
3.2.5 Scanning Transmission Electron Microscopy 
PEI:DNA (23:1, N/P), NC:PEI:DNA (1.7:23:1 and 20:23:1 O/N/P), and 
PGA:PEI:DNA (10:23:1 O/N/P) were formed by the standard protocol with the exception 
that all polymer, DNA, and NC were buffered in water to avoid salt presence. All samples 
were prepared on lacey carbon, 300 mesh, copper grids by dipping the grids in the polyplex 
dilution for 60 sec and then drying overnight. Super-resolution scanning transmission 
electron microscopy was performed on a Talos F200X. EDS mapping was performed on 
selected samples to confirm the co-localization of nitrogen (from PEI amine groups), 
phosphor (from DNA backbone), and cerium as a polyplex. 
3.2.6 Generation of Nanoceria 
Nanoceria crystallites were generated via a single step hydrothermal method [248]. 
The ceria nanoparticles were coated with citric acid during synthesis. Citric acid adsorbs 
onto the nanoceria surface to stabilize the aqueous dispersion. The product was dialyzed 
for 120 h in total, changing the dialysate every 24 h, against pH 7.4, 110 mM, iso-osmotic 
citric acid to further coat the nanoceria and remove unreacted cerium salts. The product 
was further dialyzed against DI water for an additional 72 h, again changing the dialysate 
every 24 h, to remove free citric acid. The nanoceria dispersion was then stored in the dark 
at 4°C. Dynamic light scattering and zeta potential were obtained with nanoceria dispersed 
in DI water at a concentration of 0.5 mg/mL. 
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3.2.7 Antioxidant Potential 
Cerium oxide is a known cellular anti-oxidant. It’s ability to scavenge reactive 
oxidative species (ROS) make it a promising therapeutic agent for reducing the high 
oxidative state of cancer cells. This anti-oxidant potential was measured using a CellROX 
Deep Red anti-oxidant kit (Thermo Fisher). HeLa cells at 2x104 cells per well were cultured 
in a 96 well plate or in a multi-chambered Lab-Tek 2 Chamber Slide (ThermoFisher) and 
incubated for 24 h. NC:PEI:DNA or free NC were prepared according to the standard 
protocol and 100 µL added to each well. After a 3 h incubation, wells were aspirated and 
washed with PBS. 24 h after transfection, cells were damaged using 200 µM menadione 
(Sigma Aldrich) for 1 h in growth media. Cell exposure to this reagent results in production 
of high levels of ROS within the cell. CellROX Deep Red Reagent was then added at 10 
µM in each well and incubated 1 h. The reagent is not fluorescent unless reduced by ROS 
into fluorescent state. Cells in microscope slides were then prepared for confocal 
microscopy (see Co-Localization methods) while cells in 96 well plates were lysed. Lysate 
fluorescence was then assessed on a BioTek Synergy 2 micro-plate reader equipped with 
filters at 620/40 ex and 680/30 em. Auto-fluorescence of untreated/undamaged cells was 
subtracted from each sample before normalizing to damaged controls. A Trolox standard 
was also used as a ROS scavenger positive control at concentrations of 0, 12.5, 50, and 200 
nM. Cells were exposed to Trolox standards 1 h before damaging with menadione. 
3.2.8 Polyplex and Inhibitor Toxicity 
Polyplex, NC, and endocytic inhibitor cytotoxicity towards HeLa cells were 
determined using a Cell Titer Blue viability assay (Promega). NC:PEI:DNA, 
PGA:PEI:DNA, or free NC particles were prepared in 96 well plate at varying O/N/P ratios 
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according to the standard protocol. For endocytic inhibitor trials, cells were exposed to 
each of the inhibitors at varying doses for 1 h and then 50 µL EMEM added for the 
remaining 3 h before changing media. 24 h after transfection, well media was replaced with 
100 µL growth media and supplemented with 20 µL of Cell Titer Blue reagent. Cells were 
incubated for 2 h at 37ºC and 5% CO2 before 100 µL of well media was transferred to an 
opaque plate and analyzed for fluorescence on a BioTek Synergy 2 micro-plate reader 
equipped with filters at 530/25 ex and 590/35 em. Fluorescence was converted to cell count 
using a standard curve of non-treated cells. Endocytic inhibitor concentrations were 
selected that produced 80% cell viability. 
3.2.9 Polyplex Transfections Optimizations 
HeLa cells were seeded and incubated for 24 h in 96 well plates at 2x104 cells per 
well for gene expression studies and 2x105 cells per well in 24 well plate for uptake studies. 
For endocytic inhibition studies, 50 µL of each inhibitor (Genistein, Methyl-β-
cyclodextrin, Chlorpromazine hydrochloride, Amantadine hydrochloride, Amiloride 
hydrochloride) at the desired concentration was incubated with cells for 1 h. NC:PEI:DNA 
or PGA:PEI:DNA polyplexes were complexed according to the standard protocol at 
various O/N/P ratios (at constant P) and incubated with cells for 3 h, either in or out of the 
presence of inhibitors. After incubation, 24 well plates were prepared for uptake analysis 
by flow cytometry (see Flow Cytometry methods) and 96 well plates incubate until 24 h 
after transfection, at which time cells were lysed and assayed for total protein and reporter 
gene expression. 
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3.2.10 Flow Cytometry 
Uptake of polyplexes was assessed by flow cytometry. HeLa cells were seeded in 
a 24 well plate 24 h before transfection at 2x105 cells per well. Cells were transfected with 
polyplexes of varying O/N/P ratios according to the standard protocol with the exception 
that pGL3 plasmid was pre-incubated for 30 min with YOYO-1 iodide (Invitrogen) at a 
ratio of 15 μL of 1 mM stock per 1 μg pGL3. For experiments involving endocytic 
inhibition, cells were exposed to inhibitors at desired concentrations in 200 μL growth 
media for 1 h before polyplex addition. After 3 h polyplex incubation, wells were aspirated 
and cells washed twice with PBS then once with 0.001% sodium dodecyl sulfate in PBS to 
remove surface bound particles. Cells were dissociated with 200 μL Trypsin and diluted to 
a total volume of 1 mL in PBS. Cell samples were analyzed by an Attune Acoustic 
Focusing Cytometer (Thermo Fisher) reading forward scatter, side scatter, and 
fluorescence intensity in the YOYO-1 appropriate channel. Data was analyzed using 
FlowJo analysis software by selecting viable cells through standard gating techniques and 
calculating mean fluorescence. 
3.2.11 Co-Localization Imaging 
In order to visualize NC:PEI:DNA or PGA:PEI:DNA polyplexes within the cell, 
PEI was tagged with AlexaFluor 488 fluorescent tag (Thermo Fisher) at a ratio of one dye 
molecule per 50 PEI monomer units. Cells were plated at 1.5x104 cells per chamber in a 
multi-chamber Lab-Tek 2 Chamber Slide (Thermo Fisher) and incubated 24 h. Polyplexes 
were formed according to the standard protocol (using tagged PEI) at 100 μL and added to 
the chamber well. To visualize endocytic vesicles resulting from caveolin-mediated uptake, 
tagged cholera toxin subunit B (Biotium) was added at 2 μg/L 20 min after polyplex 
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addition. To visualize endocytic vesicles resulting from clathrin-mediated uptake, tagged 
transferrin protein (Biotium) was added to the well at 25 μg/L immediately following 
polyplexes. For investigation of co-localization to the macropinosome, 70 kDa dextran 
Texas Red (Invitrogen) at 0.5 mg/mL was added to the well immediately. Polyplex and 
marker solutions were incubated with cells for 30 min to ensure internalized polyplexes 
were localized to early-late endosomes. Cells were aspirated and washed with 0.001% 
sodium dodecyl sulfate in PBS to remove surface bound particles and then washed twice 
with PBS. Cells were fixed with 4% formaldehyde for 10 min, permeabilized with 0.1% 
Triton X100 in PBS for 15 min, and then blocked with 1% bovine serum albumin in PBS 
for 45 min. Wells were aspirated, washed thoroughly and stained for 1 h with Alexa Fluor 
405 Phalloidin (Invitrogen) at 165 nM diluted in PBS. Cells were washed four times in 
PBS before mounting a No.1.5H precision coverslip (Thor Labs) using Prolong Diamond 
Antifade mountant (Invitrogen). Slides were imaged within 24 h using the 60X objective 
of a Leica SP8 confocal microscope. Fiji was used to determine co-localization Mander 
coefficients for overlap of polyplexes with endosomal markers. 
3.2.12 Intracellular Trafficking 
To determine if trafficking to lysosomes is occurring and to assess endosomal 
acidification’s effect on gene delivery, transfections were performed in the presence of 10 
nM bafilomycin A1 and/or 20 µM chloroquine. BafA1 or chloroquine was incubated with 
the cells in 50 µL EMEM for 1 h before NC:PEI:DNA (0.5:5.3:1, w:w:w) or PEI:DNA 
binary (5.3:1, w:w) polyplexes were added to a final volume of 100 µL. 3 h after 
transfection, wells were aspirated and growth media added for 21 h. BCA and Luciferase 
expression assays were performed to quantify total protein and gene expression. NC ternary 
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polyplexes and binary polyplexes were also co-localized on microscope slides with 
acidified andosomal compartments using Lysotracker. Cells were prepared on glass slides 
and transfected with NC:PEI:DNA or PEI:DNA polyplexes for 1 h. After 30 min 
incubation, Lysotracker Deep Red was added to 1.6 µM. After the remaining 30 min of 
incubation, wells were washed, fixed, and permeabilized before staining with Alexa Fluor 
405 Phalloidin for 1 h and mounting for imaging. 
3.3 Results 
3.3.1 Nanoceria Synthesis 
Nanoceria was generated by a hydrothermal method in the presence of citric acid 
to coat the particle surfaces. The zeta potential of the particles was -43.5 ± 1.6 mV at a 
measured pH of 6.5. The nanoceria mean primary particle size was 4.1 ± 0.5 nm as 
determined by TEM. The particles were determined to be hexagonal in shape, consisting 
of closely packed nanoceria crystallites with sharp, distinct edges. As indicated by DLS, 
the hydrodynamic size distribution is bimodal, with the first peak at a diameter of 12 nm 
and the second, 29 nm (Figure 3.1A). However, greater than 90% of the nanoceria is 
present in the first peak and likely represents individual particles or aggregates of a few 
particles. Nanoceria has the tendency to self-associate, resulting in small agglomerates 
when dispersed indicated by the small secondary peak [249]. Fourier-transform infrared 
spectroscopy (FTIR) confirmed the presence of citric acid on the surface of the nanoceria 
(Figure 3.1C). A broad peak ranging from 2800 to 3600 cm-1 is characteristic of a hydroxyl 
group, typically present on metal oxide surfaces. The two peaks at 1375 and 1540 cm-1 are 
attributed to the stretching bands of the carboxyl groups in citric acid.  
82 
 
 
Figure 3.1: (A) Surface-area-weighted distribution of hydrodynamic diameters of 
nanoceria suspended in water. (B) TEM image of polyhedral, crystalline nanoceria. (C) 
FTIR spectrum of citrate-coated nanoceria. Peak at 3300 cm-1 represents a hydroxyl group. 
Peaks at 1375 and 1540 cm-1 represents a carboxylic group. 
3.3.2 Formation and Characterization Ternary Polyplexes 
Ternary polyplexes of NC/PEI/DNA and PGA/PEI/DNA were produced 
sequentially by adding a solution of PEI to a DNA solution to form binary polyplexes and 
subsequently adding a suspension of NC or PGA solution (Figure 3.2A). By varying the 
ratios of PEI and anion (PGA or NC) at a fixed amount of DNA, particles of various charges 
and sizes were formed. TEM imaging showed polyplex diameter of 160 nm, 244 nm, and 
166 nm for PEI/DNA (23:1 N/P), PGA/PEI/DNA (10:23:1 O/N/P), and NC/PEI/DNA 
(1.7:23:1 O/N/P), respectively (Figure 3.2B-E). EDS mapping of NC/PEI/DNA showed 
co-localization of N (from PEI amine groups and DNA), P (from DNA backbone), and Ce 
(from nanoceria), indicating that imaged particles were in fact NC/PEI/DNA polyplexes 
(Figure 3.2F). The binary PEI/DNA polyplexes exhibited a zeta potential of +8.87, 8.90, 
and 9.51 mV at N/P 7.7, 23, and 38, respectively. Addition of NC or PGA to binary 
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polyplexes resulted in decreasing surface charge (Figure 3A-B). For polyplexes at N/P 7.7, 
the zeta potential plateaued at approximately -20 mV at O/N/P 200:7.7:1, whereas the zeta 
potential of polyplexes at N/P 23:1 and 38:1 decreased to -18.8 mV and -22.3 mV at O/N/P 
of 200:23:1 and 272:38:1, respectively. Interestingly, addition of PGA decreased the zeta 
potential until a plateau around -28 mV followed by an increase in zeta potential, with the 
exception of polyplexes at N/P 38:1. The binary PEI/DNA polyplexes exhibited diameters 
of 232, 142, and 111 nm at N/P 7.7, 23, and 38, respectively. Regardless of N/P ratio, 
addition of increasing amounts of PGA increased the particle diameter until the 
PGA/PEI/DNA ratio corresponding to near neutral zeta potential was reached, beyond 
which the size decreased (Figure 3.3C). Addition of NC had a smaller effect on both 
polyplex size and zeta potential as much higher O/N/P ratios were required to observe 
property changes. Addition of NC caused quite small particle growth (<50 nm) initially 
and higher charge ratios resulted in polyplex aggregates (>1 μm) (Figure 3.2B). 
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Figure 3.2: (A) Complexation of NC with PEI and DNA to form a polyplex. (B-D) 
Transmission electron microscope imaging of binary (B) PEI/DNA (23:1 N/P), (C) 
PGA/PEI/DNA (10:23:1 O/N/P), and (D) NC/PEI/DNA (1.7:23:1 O/N/P) polyplexes. (E) 
EDS spectrum of imaged NC/PEI/DNA polyplex. N peak indicates the presence of PEI 
and DNA, P peak indicates presence of DNA, and Ce peak indicates presence of nanoceria. 
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Figure 3.3: (A) NC/PEI/DNA zeta potential curves at various O/N/P ratios. (B) 
PGA/PEI/DNA zeta potential curves at various O/N/P ratios. (C) NC/PEI/DNA and (D) 
PGA/PEI/DNA size curves at various O/N/P ratios determined by DLS. (n=3, error bars 
represent standard deviation). 
3.3.3 Transfection with NC/PEI/DNA and PGA/PEI/DNA Polyplexes 
HeLa cells were transfected with NC/PEI/DNA and PGA/PEI/DNA polyplexes at 
various O/N/P ratios. The ratios of cation (PEI) and anion (NC or PGA) were varied while 
the amount of DNA was held constant in order to determine the optimal O/N/P ratios. The 
NC/PEI/DNA polyplexes exhibited maximum transgene expression at 1.7:23:1 O/N/P, 
which was 80% of the maximum PGA/PEI/DNA polyplex gene delivery activity at 10:23:1 
O/N/P (Figure 3.4A). However, this difference was not statistically significant (p=0.34). 
Cellular internalization of PGA/PEI/DNA polyplexes was generally 10-40% higher than 
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NC/PEI/DNA polyplexes (Figure 3.4B). For all PEI/DNA weights, the NC expression 
optimum remained constant at an O ratio of 1.7 whereas the PGA/PEI/DNA optimums 
required increasing O ratios with increasing PEI amounts. Further, the optimum transgene 
expression of NC/PEI/DNA polyplexes correlated with the maximum uptake whereas the 
PGA/PEI/DNA polyplexes did not. 
NC was not cytotoxic at all concentrations equivalent to the amount of NC present 
in polyplexes during transfection (Figure 3.4C). Binary PEI/DNA polyplexes at N/P 7.7:1 
exhibited no cytotoxicity, but cell viability decreased by ~20% and 40% in the presence of 
PEI/DNA polyplexes at N/P 23:1 and 38:1, respectively, due to disruption of the cell 
membrane and mitochondrial wall by PEI [163]. Addition of NC had no significant effect 
on cytotoxicity of NC/PEI/DNA polyplexes up to 7:23:1 and 68:38:1. Further addition of 
NC decreased cytotoxicity, but at much higher amounts than in polyplexes exhibiting 
optimal transfection efficiency.  
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Figure 3.4: (A) Expression of luciferase reporter gene delivered by NC/PEI/DNA or 
PGA/PEI/DNA polyplexes (dashed lines). (B) Uptake of NC/PEI/DNA and 
PGA/PEI/DNA polyplexes at various O/N/P ratios. (C) NC/PEI/DNA polyplex toxicity 
profiles for varying O/N/P ratios of NC/PEI/DNA. White bars indicate samples treated 
with only NC. (n=4, error bars represent standard deviation). 
3.3.4 Antioxidant Activity of NC/PEI/DNA Polyplexes 
To investigate the potential antioxidant activity of NC/PEI/DNA polyplexes, HeLa 
cells were exposed to menadione to generate free radicals prior to addition of NC or 
polyplexes, and the antioxidant activity was determined 24 h after transfection by the 
addition of CellROX Deep Red, which becomes fluorescent upon oxidation in the presence 
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of ROS. The antioxidant activity was quantified by comparison to the antioxidant activity 
of Trolox standards at 0-200 nM [250, 251]. NC/PEI/DNA polyplexes at the optimum gene 
delivery ratio, 1.7:23:1 O/N/P, produced a 25% reduction in ROS, which corresponded to 
a Trolox equivalence of 12.5 nM (Figure 3.5A). At a charge ratio of 27:23:1 O/N/P, ROS 
was reduced to levels present in cells not exposed to menadione, corresponding to a 200 
nM Trolox equivalence. Similar results were observed by confocal fluorescence 
microscopy in which increasing ratios of NC reduced the CellROX fluorescence (Figure 
3.5B-G). Free NC at weights equivalent to NC/PEI/DNA at 13:23:1 and 27:3:1 was 
observed to reduce ROS levels to 90% and 83%, respectively. Delivery of NC/PEI/DNA 
at a ratio of 27:23:1, therefore, increase the antioxidant effect by 480% compared to 
delivery of equivalent amounts of free NC. 
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Figure 3.5: (A) Anti-oxidant dose curves for Trolox standard and NC/PEI/DNA polyplexes 
at 23:1 N/P. All samples were damaged with menadione except for “Cells” control. NC 
indicates nanoceria incubated with cells in absence of PEI or DNA. Trolox samples were 
normalized to a 0 nM Trolox control and NC/PEI/PGA were normalized to NC-free 
(binary) control. Free NC samples were normalized to non-treated controls. (B) Non-
damaged control HeLa cells and (C) menadione-damaged control cells. (D-E) Trolox 
antioxidant activity in HeLa cells at 12.5 nM and 200 nM concentrations. (F-G) 
NC/PEI/DNA antioxidant activity in HeLa cells at O/N/P ratios of 1.7:23:1 and 27:23:1. 
Red represents CellRox indicating presence of ROS and blue is phalloidin cell cytoskeleton 
stain. (n=3, error bars represent standard deviation). 
3.3.5 Mechanism of Internalization of NC/PEI/DNA Polyplexes 
To investigate the pathways through which NC/PEI/DNA polyplexes enter HeLa 
cells, transfections were performed in the presence of pharmacological agents that inhibit 
caveolin-mediated endocytosis through inhibition of tyrosine phosphorylation and 
cholesterol scavenging (genistein and methyl-β-cyclodextrin), clathrin-mediated 
endocytosis by prevention of clathrin heavy-chain recycle to cell membrane 
(chlorpromazine HCl and amantadine HCl), and macropinocytosis by inhibition of ruffle 
formation upon blocking Na+/H+ channels (amiloride HCl) [182-188]. Concentrations 
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were selected for each at which 80% viability was achieved in HeLa cells under standard 
transfection protocol (data not shown). These concentrations were determined to be 150 
mg/L, 12 g/L, 14.5 mg/L, 450 mg/L, and 140 mg/L for genistein, methyl-β-cyclodextrin, 
chlorpromazine HCl, amantadine HCl, and amiloride HCl, respectively. Inhibition of 
caveolin-mediated endocytosis with genistein (GST) or methyl-β-cyclodextrin (mBCD) 
decreased transgene expression by ~90% compared to non-inhibited controls, while uptake 
was unaffected by genistein but increased by 112% in the presence of mBCD (Figure 
3.6A). Inhibition of clathrin-mediated endocytosis with chlorpromazine HCl (CPZ) 
resulted in a 50% increase in both uptake and transgene expression, but amantadine HCl 
(AMN) had no effect. Finally, the presence of amiloride (AML) decreased transgene 
expression by 60% while uptake was unaffected. Internalization through these three 
pathways was confirmed through co-localization of fluorescently labeled polyplexes with 
fluorescent markers cholera toxin subunit B (CTxB), transferrin, or 70-kDa dextran (Figure 
3.6B). CTxB is a surface ganglioside GM1 binding pentamer that concentrates in caveolae 
when administered at low concentrations for short amounts of time [193, 252]. Transferrin 
binds the transferrin receptor on the cell surface, triggering internalization through 
invaginations of clathrin-coated pits [189]. Finally, dextran is known to be internalized 
primarily through macropinocytosis [194]. Mander’s coefficients of 0.60, 0.87, and 0.60 
were calculated for co-localization of polyplexes to caveosomes, clathrin-coated vesicles, 
and macropinosomes, respectively. 
 
91 
 
 
Figure 3.6: (A) Endocytic inhibitor (GST, mBCD, CPZ, AMN, and AML) effects on gene 
expression and uptake of NC/PEI/DNA at optimum O/N/P ratio (1.7:23:1) in HeLa cells. 
All inhibited samples were normalized to controls in the absence of inhibitors. (B) Co-
localization of NC/PEI/DNA polyplexes to cholera toxin subunit B (caveosomes, CAV), 
transferrin protein (clathrin-coated vesicles, CCV), and 70-kDa dextran (macropinosomes, 
MP). Particles are in green, endosomal compartments in red, and cell cytoskeleton is in 
blue. Images were captured with a 60x objective. (n=4, error bars represent standard 
deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control groups). 
3.3.6 Intracellular Trafficking 
Bafilomycin A1 (BafA1), chloroquine (CQ), and Lysotracker dye were used to 
investigate the trafficking of NC/PEI/DNA polyplexes to acidified vesicles and determine 
the importance of acidification for efficient gene delivery [100]. BafA1 prevents the 
acidification of endosomes through inhibition of V-type ATPase [196], and a decrease in 
gene delivery in the presence of BafA1 suggests that acidification plays a role in endosomal 
escape. Similarly, chloroquine (CQ) is lysosomotropic agent often delivered with vectors 
lacking ionization potential such as polylysine to enhance transfection efficiency [197]. 
Changes in transfection efficiency in the presence of CQ indicates that at least a portion of 
polyplexes was at some point localized to lysosomes. 
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Both PEI/DNA polyplexes and the optimum NC/PEI/DNA polyplex were used to 
transfect HeLa cells in the presence of BafA1and/or CQ. Transgene expression mediated 
by both binary and ternary polyplexes decreased ~80% in the presence of BafA1or a 
combination of BafA1and CQ and ~45% in the presence of CQ (Figure 3.7A). Localization 
of polyplexes in lysosomes was confirmed by confocal fluorescence microscopy (Figure 
3.7B). Mander’s coefficients for co-localization of polyplexes and Lysotracker were 0.27 
and 0.41 for ternary and binary polyplexes respectively.  
 
Figure 3.7: (A) Effects of bafilomycin A1 (BafA1, 10 nM) and chloroquine (CQ, 20 µM) 
on gene expression of optimum ternary NC/PEI/DNA (1.7:23:1, O/N/P) and binary 
PEI/DNA polyplexes (23:1, N/P). Samples treated with BafA1and/or CQ were normalized 
to controls treated with neither. (B) Co-localization at 1 h of NC/PEI/DNA polyplexes or 
(C) binary PEI/DNA polyplexes to lysosomes using Lysotracker. Polyplexes are in green, 
lysosomes (Lysotracker) in red, and cell cytoskeleton in blue. (n=4, error bars represent 
standard deviation; *p<0.05, †p<0.01 compared to control groups). 
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3.4 Discussion 
Citrate-coated NC particles are small, carry a negative charge, resist aggregation, 
and possess antioxidant capacity. The carboxylate groups of the citrate coating provided 
electrostatic interactions with the amine groups of PEI for the formation of hybrid ternary 
polyplexes. Based on significantly decreased antioxidant effect of NC compared to 
NC/PEI/DNA polyplexes at equivalent weight, the nanoceria alone does not efficiently 
enter HeLa cells, likely due to their negative zeta potential (Figure 3.5). However, the NC 
did avoid toxicity and aggregation at physiological pH. Nanoceria offers the unique ability 
to reversibly bind or release free radicals depending on environmental and physiochemical 
factors, such as pH [235, 236]. For HeLa cells (cytosol pH 7.3) [253, 254] transfected with 
citrate-coated nanoceria electrostatically bound to a PEI/DNA polyplex, this report shows 
strong transgene expression and antioxidant capacity in vitro. After mediating cellular 
entry, the NC either dissociates from the polyplex or remains bound (Figure 3.8). In either 
case, NC was shown to produce antioxidant effects through ROS scavenging (Figure 3.5). 
Loading the polyplex with nanoceria corresponding to the transfection optimum had 
minimal effect on particle size and zeta potential (Figure 3.3), despite TEM showing NC 
throughout the polyplex (Figure 3.2). Addition of PGA at similar charge ratios had a much 
stronger effect on polyplex size and charge, indicating that electrostatic interactions 
between PGA and PEI are stronger than those between NC and PEI. At higher amounts of 
NC, particle size increased drastically (Figure 3.3). These large particles of near-neutral 
zeta potential were likely aggregates resulting from lack of charge repulsion. As such, these 
large polyplexes were well outside the range of optimum transfection efficiency.  
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Figure 3.8: Transfection and cellular processing of NC/PEI/DNA polyplexes for combined 
gene and antioxidant therapy in cancer cells. 
The pathways through which nanoparticles are internalized have been shown to 
influence subsequent intracellular processing [100, 102, 103, 105, 106]. Internalization 
through caveolin-mediated endocytosis involves the formation of caveolae vesicles that are 
released from the membrane in a dynamin-dependent process. The resulting caveosomes 
are thought to avoid extreme acidification and trafficking to lysosomal compartments [86, 
170]. Internalization by clathrin-mediated endocytosis, on the other hand, involves the 
formation of clathrin-coated vesicles (CCV) that bud off the membrane in a dynamin-
dependent manner similar to caveosomes. However, these CCVs are rapidly acidified into 
late endosomes of pH 5-6 and then trafficked to lysosomes for further acidification to pH 
~4.5 [81, 169]. This acidic environment is expected to be detrimental to the fate of nucleic 
acids. Finally, macropinocytosis is a fluid-phase pathway for the internalization of large 
components at the cell surface. Arf6-induced ruffle formations internalize large volumes 
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of extracellular fluid into macropinosomes up to 5 µm in size. These macropinosomes are 
inherently leaky and are the internalization pathway used by several types of viruses due 
to the ease of endosomal escape [255]. Though evidence of acidification exists, 
macropinosomes are not believed to fuse with lysosomes in many cell types other than 
macrophages [171, 172]. Internalization of NC/PEI/DNA hybrid polyplexes occurred 
through a combination of caveolin-dependent endocytosis, clathrin-dependent endocytosis, 
and macropinocytosis (Figure 3.6). Inhibitors of caveolin-dependent endocytosis caused a 
significant decrease in NC/PEI/DNA-mediated gene delivery, suggesting that caveolin is 
an efficient pathway for transfection in HeLa cells. Similar but less severe decreases in 
gene delivery were observed in the presence of macropinocytosis inhibitors. In addition, 
co-localization of polyplexes with macropinosomes and caveosomes was similar. This 
indicates that macropinocytosis, a non-specific pathway, is also an efficient mechanism of 
gene delivery, likely due to its inherently leaky nature. Inhibition of clathrin-mediated 
uptake, on the other hand, increased gene expression indicating that clathrin-mediated 
endocytosis does not lead to effective gene delivery. At least a portion of polyplexes were 
trafficked to lysosomes as shown by the effect of chloroquine on gene delivery and the co-
localization of polyplexes with Lysotracker (Figure 3.7). This was not surprising due to 
high polyplex co-localization to the clathrin-mediated pathway. Bafilomycin A1 indicated 
that the acidification process aids in efficient gene delivery. This acidification is believed 
to be an important step in escape from the endosome through osmotic swelling [99, 177]. 
These results would therefore indicate that acidification, but not lysosomal trafficking, is 
likely beneficial to gene expression through promotion of endosomal escape. However, 
efficient delivery through caveolin-dependent mechanisms shows highly efficient 
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internalization and gene expression (Figure 3.6) despite the belief that this pathway avoids 
endosomal acidification. Therefore, the caveolar pathway is either subject to acidification, 
despite scientific belief, or bafilomycin A1 is capable of interfering with non-acidified 
pathways in currently unknown mechanisms. The latter is more likely since caveolin-1 has 
been shown to co-localize with the V-type proton pumps that bafilomycin A1 inhibits 
[256]. Further, bafilomycin A1 was shown to inhibit cellular organelles such as parts of the 
Golgi complex, a target of the caveolin-mediated pathway [257]. Therefore, bafilomycin 
A1 may affect intracellular trafficking of polyplexes through mechanisms other than 
inhibition of endosomal acidification. That being said, it is still likely that at least a portion 
of the decreased transgene expression can be accounted to inhibition of endosomal 
buffering. 
Gene therapies producing antioxidants or inhibiting the production of pro-oxidants 
have been shown to be successful at producing therapeutic effects in cardiovascular disease 
and amyotrophic lateral sclerosis [229, 230]. Strategies designed to deliver genes encoding 
antioxidant proteins such as extracellular superoxide dismutase (EC-SOD) are effective 
methods to produce and excrete SOD. A benefit to this strategy is that excreted SOD helps 
to reduce oxidative stress in the surrounding extracellular space as well as in the 
intracellular environment [258]. Thus, it is not necessary to deliver the genes directly to 
the tumor since transfected healthy tissue will excrete excess EC-SOD, which can provide 
downstream therapeutic effects to the targeted tumor. Another potential gene therapy 
approach is the modulation of transcription factors that elicit concerted expression or 
repression of multiple genes. This pleotropic strategy is particularly successful by 
upregulating nuclear factor erythroid 2–related factor 2 (Nrf2), a transcription factor that 
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regulates the expression of antioxidant proteins that mitigate oxidative stress induced by 
physical injury or inflammation [259]. The complex network of genes regulated by Nrf2, 
however, is not completely understood, making its therapeutic potential accompanied by 
potential undesired pathological consequences. Regardless, upregulation of these 
downstream genes by amplification of Nrf2 has been shown to be an effective means for 
reducing oxidative stress in muscle cells and neurons [260, 261]. Combination of these 
gene therapies designed to activate cellular defense mechanisms with nanoceria would 
likely produce a rapid decrease in oxidative stress (from NC scavenging) followed by long-
term decrease in ROS levels (from transgene expression). However, combined delivery of 
antioxidant nanoceria and genes reducing oxidative stress is redundant.  
An alternative strategy may be to deliver nanoceria with genes that provide 
synergistic therapeutic effects. While only reporter genes were utilized here, combinations 
of antioxidants with genes such as growth factors, tumor suppressors, or anti-inflammatory 
targets could provide synergistic effects in cancer cells. Oxidative stress results in the 
upregulation of many growth factors and inflammatory cytokines [216]. For instance, 
radiotherapy induces epidermal growth factor activation in carcinoma cells, which triggers 
proliferation. Gene therapies blocking this activation prevent this proliferative response to 
radiation and improve radiosensitization [262]. Regarding inflammation factors, therapies 
preventing nuclear factor kappa B activation are increasingly successful at reducing the 
inflammatory nature of cancer cells [263]. Working together, this co-drug would 
ameliorate nearly all the direct and side effects produced by high oxidative stress on the 
cell. Other options are to use tumor suppressor genes to minimize further damage done to 
the cellular genetics or even use genes disabling angiogenesis, thereby starving tumors of 
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key nutrients. Many tumor suppressors are dependent on the type of target cancer [264]. 
However, there are a few genes implicated in almost all cancers such as regulators of 
transcription factors p53 or PTEN. Gendicine is the first gene therapy product that utilizes 
the p53 tumor suppressor while PTEN is commonly used to suppress tumor growth and 
restore chemotherapeutic sensitivity [265]. Finally, a popular tumor suppressor strategy 
involves the knockdown of VEGF, which regulates signaling of new vasculature around 
expanding tumors. Combination of siRNA targeting VEGF mRNA with antioxidants 
would produce a pacified cell that could not effectively expand or produce invasive 
proteins for invading surrounding tissue. These combinations allow for the alleviation of 
multiple facets of stress on the cell simultaneously, resulting in gene therapies of higher 
efficacy with little additional effort in antioxidant loading.  
3.5 Conclusions 
Here, we showed that nanoceria is a potent antioxidant capable of scavenging free 
radicals produced by cancer-generated pro-oxidants. PEI condensed DNA to form binary 
polyplexes exhibiting positive charge, which were further coated with anionic nanoceria. 
The gene delivery efficiency of the NC/PEI/DNA ternary polyplexes was similar to 
PGA/PEI/DNA ternary systems while simultaneously providing antioxidant activity. 
While nanoceria was visible on the polyplex, its presence did not significantly affect the 
route of internalization or intracellular processing. Internalization occured through a 
combination of pathways with clathrin-mediated endocytosis showing highest levels of co-
localization to polyplexes. Caveolin-dependent endocytosis and macropinocytosis showed 
half the co-localization as clathrin but were more efficient means of entry, presumably due 
to the avoidance of lysosomes. While only reporter genes were delivered here, nanoceria 
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paired with genes such as ROS-scavenging proteins, transcription factors, growth factors, 
anti-inflammatory, tumor suppressors, or even angiogenesis inhibitors are expected to 
provide potent co-therapeutic effects on cancers. 
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CHAPTER 4. EGFR-TARGETED RNA APTAMER POTENTIATES 3WJ 
INTERNALIZATION THROUGH CLATHRIN-MEDIATED ENDOCYTOSIS AND INDUCED 
MACROPINOCYTOSIS 
4.1 Introduction 
RNA nanotechnology is a rapidly advancing field involving the bottom-up self-
assembly of organized architectures from sequences of RNA. These structures are of the 
nanometer scale and offer several advantages over DNA assemblies; base stacking, 
noncanonical base pairing, elasticity, thermostability, and catalytic capacity [266]. While 
useful for the fabrication of advanced materials, RNA nano-assemblies also have 
promising capacity for imaging, detection, and gene therapy in biological systems [267]. 
Guo et al. showed that three-way junction (#WJ) motifs could be derived from the phi29 
bacteriophage and functionalized to harbor siRNA, miRNA, fluorophores, 
chemotherapeutic small molecules, or targeting ligands on each of three functional 
modules [268]. These and other phi29-derived structures were shown to remain stable in 
circulation even at ultra-low concentration while undergoing “ratcheting” into tumor 
vasculature [269, 270]. These structures are well suited for the transport of therapeutic 
siRNA as well as RNA aptamers to promote internalization in targeted cells. Little work 
has been done on studying the process of internalization and subsequent intracellular 
trafficking of RNA nanoparticles, which may hold considerable effects on therapeutic 
efficacy. 
Aptamers are sequences of nucleic acids that form tertiary structures that recognize 
specific biomarkers [271]. The onset of SELEX has rapidly increased the rate at which 
DNA/RNA aptamers are being designed for specific targets [272]. For example, a potential 
biomarker for targeting triple negative breast cancers, for which there is no current 
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targeting strategy, is the epidermal growth factor receptor (EGFR) [273]. SELEX 
technology was used to develop several RNA aptamers for high specificity and high avidity 
targeting of EGFR [274-276]. The capacity to functionalize RNA scaffolds with these RNA 
aptamers gives RNA nanoparticles the ability to target cancer cells overexpressing 
receptors on their surface. Such targeting, combined with the capacity to harbor therapeutic 
RNA, provides the opportunity for targeted gene therapies based on RNA nanotechnology. 
Herein, 3WJ motifs developed by Guo et al. [268] were outfitted with imaging 
fluorophores, reporter gene siRNA, and CL4 aptamer targeting EGFR [275]. siRNA 
delivery was evaluated in a MDA-MB-231 cells, a triple negative breast cancer line known 
to overexpress EGFR [277]. Interactions between the aptamer and EGFR were validated 
using tyrosine kinase inhibitors as well as EGFR knockdown via siRNA to ensure specific 
uptake through receptor-mediated endocytosis. Further, the internalization mechanism 
associated with the aptamer and resulting intracellular trafficking were analyzed using 
pharmacological endocytosis inhibitors and confocal fluorescence microscopy. 
4.2 Materials and Methods 
4.2.1 Materials 
Non-targeted control 3WJ and 3WJ equipped with an EGF-targeting aptamer (3WJ-
EGFapt) were purchased from NanoBio Delivery Pharmaceutical Company, LTD. 
Epidermal growth factor protein (EGF) tagged with Alexa Fluor 647 was purchased from 
Invitrogen and non-tagged human epideral growth factor (hEGF) was purchased from 
Sigma- Aldrich. Pharmacological endocytic inhibitors (Genistein, Methyl-β-cyclodextrin, 
Chlorpromazine hydrochloride, Amantadine hydrochloride, and Amiloride hydrochloride) 
were purchased from Sigma-Aldrich. EGF-targeting siRNA (siEGF) was purchased from 
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Dharmacon and siRNA targeting Luciferase reporter gene (siLUC) and negative control 
(siNEG) were purchased from Bioneer. All transfections were performed in Opti-MEM 
reduced serum media from Thermo Fisher Scientific. 
4.2.2 Cell Culture 
The Renilla Luciferase gene was knocked into a standard MDA-MB-231 cell line 
and provided as a gift from Guo Lab at the Ohio State University. MDA-MB-231-Luc cells 
were cultured using L-15 media (ATCC) supplemented with 10% fetal bovine serum 
(VWR Life Sciences) at 37ºC and 5% CO2. Trypsin comprising 0.53 mM EDTA (Corning) 
was used for dissociating cells and phosphate buffered saline (GE Life Sciences, 6.7 mM 
PO4, 137 mM NaCl, pH 7.2) for washing. Culture lysis buffer at pH 7.8 composed of 25 
mM Tris-Phosphate buffer, 0.7 g/L 1,2 diaminocyclohexane, 10% glycerol, 1% Triton X-
100, and 1% protease inhibitor cocktail (Millipore) was used for lysing cells. 
4.2.3 Cell Transfections 
3WJ and 3WJ-EGFapt were transfected either in or out of the presence of endocytic 
inhibitors into MDA-MB-231-Luc cells. Inhibitors were added to 50 µL Opti-MEM 
reduced serum media to concentrations that produced 80% cell viability while retaining 
inhibitory effect and incubated with 25,000 MDA-MB-231-Luc cells in a 96-well plate for 
1 h at 37ºC and 5% CO2. Either 3WJ, 3WJ-EGFapt, or EGF were then added to each well 
at the desired particle concentration and incubated for a further 3 h. After 3 h incubation, 
well contents were replaced by growth media followed by a 21 h incubation. Cells were 
lysed and total protein determined by a BCA protein quantification kit (G Biosciences) and 
Luciferase protein expression quantified by a Luciferase assay (Promega). In trials 
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involving delivery of siLuc, siEGF, 3WJ, or 3WJ-EGFapt mediated by a delivery agent, 
particles were complexed with Lipofectamine 2000 (Invitrogen) for 20 min before adding 
to cells. 
4.2.4 Inhibitor Toxicity and Validation 
Cell Titer Blue viability assay (Promega) was used to determine toxicity of all 
inhibitors used (genistein, methyl-β-cyclodextrin, chlorpromazine hydrochloride, 
amantadine hydrochloride, and amiloride hydrochloride). MDA-MB-231-Luc cells were 
exposed to each inhibitor for 1 h before addition of 10 µL Opti-MEM media to simulate 
addition of nanoparticles. After 3 h incubation, well contents were replaced with growth 
media and incubated another 21 h. Cell Titer Blue was mixed at a ratio of 1:5 (v:v) in L-
15 growth media and 120 µL added to each well. After 4 h incubation, 100 µL was removed 
from the well and transferred to an opaque assay plate for fluorescence analysis on a 
BioTek Synergy 2 micro-plate reader equipped with filters at 530/25 ex and 590/35 em. 
Fluorescence was converted to cell count using a standard curve of non-treated MDA-MD-
231-Luc cells. Inhibitor concentrations were selected that produced 80% viability. To 
verify that uptake was occurring at the selected doses, uptake of fluorescence tagged 
endocytic markers was performed. Cholera toxin subunit B (5 µg/mL) was used to mark 
caveolin-based endosomes, transferrin (25 µg/mL) was used to mark clathrin-coated 
vesicles, and 70-kDa dextran Texas Red (50 µg/mL) was used as a macropinosome marker. 
Uptake markers were added to the cells 1 h after exposure to endocytic inhibitors. 
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4.2.5 Flow Cytometry 
Uptake of 3WJ, 3WJ-EGFapt, or EGF was monitored using the 647 filter of an 
Attune Acoustic Focusing Cytometer (Thermo Fisher). Cells were plated in a 24-well plate 
at 2x105 cells per well. 24 h later, cells were transfected by procedure outlined above. 4 h 
after transfection, cells were washed twice with PBS and collected using 200 μL Trypsin. 
Samples were diluted to 1 mL in PBS before analyzing by cytometry. FlowJo analysis 
package was used to gate out debris and calculate mean fluorescence of each sample. 
4.2.6 EGFR Inhibition 
EGFR was knocked down by EGFR targeting siRNA. 50 nM Luciferase siRNA 
was transfected into 300,000 cells in a 6-well plate using 4 μL Dharmafect Transfection 
Reagent for 6 h. Media was replaced with growth media and cells incubated for 18 h before 
being split into a new 6-well plate at 30% confluency. A further 48 h incubation was 
followed by plating 25,000 cells in a 96-well plate with a 24 h incubation to allow 
attachment and growth. 3WJ, 3WJ-EGFapt, or EGF were then transfected at desired 
concentrations in Opti-MEM for 4 h before pure fetal bovine serum was added to bring the 
well serum concentration to 10%. Cells were incubated for 20 h and then lysed for analysis 
of uptake and Luciferase expression. 
4.2.7 Confocal Microscopy 
To visualize the presence of 3WJ, 3WJ-EGFapt, or EGF within the cell and to 
determine the degree of co-localization with specific endosomal compartments, confocal 
microscopy was employed. 2.5x104 MDA-MB-231-Luc cells per chamber were plated in 
a multi-chamber Lab-Tek 2 Chamber Slide (Thermo Fisher) and incubated 24 h. Cells were 
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then transfected with 3WJ-EGFapt for 1 h. During this time, wells investigating 
macropinosomes co-localization also contain 0.5 mg/mL 70 kDa Dextran as an endosomal 
marker. Wells were washed twice with PBS before fixing with 4% formaldehyde for 10 
min. Cells were then permeabilized with 0.1% Triton X100 in PBS for 15 min followed by 
blocking with 1% bovine serum albumin in PBS for 45 min. Following blocking, cells were 
exposed to primary antibodies for caveolin-1 (CAV-1) or clathrin heavy chain (CLTC, 
Invitrogen) diluted to 1:125 and 1:200 respectively in blocking solution for 2 h. After 
washing, cells were then stained for 1 h with a mixture of Alexa Fluor 405 Phalloidin 
(Invitrogen) at 165 nM and Alexa Fluor 594 goat anti-mouse IgG secondary antibody 
(Invitrogen) diluted to 2 µg/mL. No.1.5H precision coverslip (Thor Labs) and Prolong 
Diamond Antifade mountant (Invitrogen) were used to prepare the slides. Imaging was 
performed on a Leica SP8 using a 60X objective within 24 h of slide preparation and Fiji 
used to calculate Mander’s coefficients. 
4.2.8 Intracellular Trafficking 
Bafilomycin A1 (BAF) at 10 nM was used to assess the importance of acidified 
endosomal environments on the therapeutic efficacy of 3WJ or 3WJ-EGFapt. Chloroquine 
(CQ) at 20 µM was used to determine whether nanoparticle sorting to lysosomal 
compartments occurred or not. MDA-MB-231-Luc cells were pre-incubated with either 
BAF, CQ, or a combination of both for 30 min before adding 200 nM of either 3WJ or 
3WJ-EGFapt. After 3 h incubation, FBS was added to the wells to 10% to stimulate healthy 
cellular activity. 24 h after transfection, cells were lysed and assessed for total protein and 
Luciferase expression. 
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4.3 Results 
4.3.1 Validation of EGFR Expression 
To validate the EGFR expression levels in the MDA-MB-231-Luc cell line 
compared to standard MDA-MB-231 cells, fluorescently tagged epidermal growth factor 
(EGF-AF647) was incubated with both cell lines, and EGF-AF647 fluorescence in cells 
lysates was quantified to determine EGF internalization. At doses commonly used for 
siRNA studies (0-100 nM), there was no statistical significance between uptake for either 
cell line (Figure 4.1A). At concentrations beyond 500 nM, the MDA-MB-231-Luc line 
demonstrated elevated uptake compared to the standard line.  
4.3.2 Transfection with 3WJ Nanoparticles 
3WJ, 3WJ-EGFapt, and EGF-AF647 were incubated with MDA-MB-231-Luc cells 
at varying concentrations. After 6 h, cell lysates were assayed for the presence of RNA 
nanoparticles or EGF-AF647. At all concentrations, EGF was internalized most efficiently, 
followed by 3WJ-EGFapt and 3WJ (Figure 4.1B). Internalization of EGF was statistically 
higher (p<0.01) than either RNA nanoparticle. Further, 3WJ-EGFapt was statistically higher 
than 3WJ uptake at all concentrations (p<0.05). Visualization after 15 min incubation of 
cells with either 3WJ, 3WJ-EGFapt, or EGF confirmed the findings where EGF showed the 
highest number of internalized particles followed by 3WJ-EGFapt and then 3WJ 
nanoparticles (Figure 4.1).  
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Figure 4.1: (A) Uptake of EGF at various concentrations in MDA-MB-231-Luc and MDA-
MB-231 cell lines. (B) 6 h uptake of 3WJ, 3WJ-EGFapt, and EGF at various concentrations 
in MDA-MB-231-Luc cells. (C) Receptor-bound 3WJ, 3WJ-EGFapt, or EGF (red) 15 min 
after transfection. Red represents nanoparticles or EGF. Blue represents cell cytoskeleton 
stain. (n=3, error bars represent standard deviation). 
MDA-MB-231-Luc cells were transfected with 3WJ and 3WJ-EGFapt to evaluate 
their siRNA delivery efficiency (Figure 4.2). As a positive control, siLUC was also 
transfected at equivalent concentrations mediated by Lipofectamine2000. 3WJ particles 
did not produce any statistically significant knockdown at any concentration. 3WJ-EGFapt 
mediated 18% knockdown at 100 nM and 35% at 500 nM. Equivalent concentrations of 
both 3WJ and 3WJ-EGFapt delivered using Lipofectamine2000 produced ~70-80% 
knockdown. Furthermore, the siLUC positive control produced approximately 80% 
knockdown at all concentrations. 
3WJ-EGFapt 3WJ EGFp
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Figure 4.2: Knockdown of luciferase expression mediated by 3WJ and 3WJ-EGFapt in 
MDA-MB-231-Luc cells. All samples were normalized to non-treated controls. (n=3, error 
bars represent standard deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control 
groups). 
4.3.3 EGFR Dimerization 
Dimerization of multiple tagged EGF receptors is a pre-requisite to internalization. 
Therefore, to determine whether 3WJ-EGFapt was capable of triggering dimerization of 
EGFR on the MDA-MB-231-Luc surface, 3WJ-EGFapt was transfected in MDA-MB-231-
Luc cells in the presence of varying concentrations of free EGF (Figure 4.3). Addition of 
EGF at concentrations up to 10 µM had no effect on the uptake of 3WJ-EGFapt. This result 
was verified both by cytometry and by cell lysate analysis on a plate reader.  
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Figure 4.3: Internalization of 3WJ-EGFapt in MDA-MB-231-Luc cells in the presence of 
varying concentrations of EGF. LIPO represents a positive control of 3WJ or 3WJ-EGFapt 
delivered using Lipofectamine2000 transfection agent. Data by (A) cytometry and (B) plate 
reader yielded the similar results. (n=3, error bars represent standard deviation). 
4.3.4 Investigation of EGFR-Specific Internalization of 3WJ Nanoparticles 
In order to evaluate the importance of EGFR on internalization of 3WJ-EGFapt, 
EGFR expression was knocked down by RNA interference. Upon knockdown of EGFR 
expression using siEGFR, internalization of EGF and 3WJ-EGFapt was reduced to ~55-
60% while internalization of 3WJ was not affected (Figure 4.4A). Luciferase knockdown 
by 3WJ was unaffected by siEGFR knockdown, but knockdown mediated by 3WJ-EGFapt 
decreased 40% (Figure 4.4B). 
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Figure 4.4: (A) Uptake and (B) luciferase expression of 3WJ and 3WJ-EGFapt following 
EGFR inhibition using EGFR-targeting siRNA (siEGFR) compared to non-targeted siRNA 
negative controls (siNEG) transfected with 3WJ or 3WJ-EGFapt. (n=3, error bars represent 
standard deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control groups). 
4.3.5 Investigation of Internalization Pathway of 3WJ Nanoparticles 
To investigate the internalization of 3WJ-EGFapt through caveolin-dependent 
endocytosis, clathrin-dependent endocytosis, endosomal compartments were 
immunofluorescently labeled with antibodies against caveolin-1 and clathrin heavy-chain. 
In addition, macropinosomes were marked by exposing cells to 70-kDa dextran Texas Red, 
which is known to be internalized by fluid-phase macropinocytosis [194, 195]. Co-
localization of 3WJ-EGFapt with each marker was observed by confocal fluorescence 
microscopy (Figure 4.5). Mander’s coefficient characterizes the degree of overlap between 
two fluorophores, where 0 indicates no overlap and 1 indicates complete co-localization. 
3WJ-EGFapt were observed to co-localize least to caveolin-containing vesicles, with a 
Mander’s coefficient of 0.101. Co-localization to clathrin-coated vesicles and 
macropinosomes were similar with Mander’s coefficients of 0.699 and 0.634, respectively. 
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Figure 4.5: Endosomal co-localization of 3WJ-EGFapt to caveosomes (CAV), clathrin-
coated vesicles (CCV), or macropinosomes (MP) in MDA-MB-231-Luc cells. Green 
represents tagged endosomes, red represents 3WJ-EGFapt nanoparticles, and blue 
represents cell cytoskeleton. Images were captured using a 60x objective. 
To further elucidate the pathways associated with the uptake of 3WJ and 3WJ-
EGFapt, pharmacological inhibitors were used to disable major endocytosis pathways. 
Genistein (GST) and methyl-β-cyclodextrin (mBCD) are inhibitors of caveolin-dependent 
endocytosis, chlorpromazine (CPZ) and amantadine (AMN) are inhibitors of clathrin-
mediated endocytosis, and amiloride (AML) is an inhibitor of macropinocytosis [182-186, 
188, 278]. The specificity and cytotoxicity of each inhibitor was determined, and the 
concentration producing 80% or more cell viability while maintaining inhibitory effect on 
Endosome 3WJ-EGFapt Co-Localization Combined
CAV
CCV
MP
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uptake of control compounds was selected for endocytic pathway analysis (Figure 4.6A-
B). Concentrations of 0.01, 3.75, 0.006, 0.075, and 0.08 g/L were selected for GST, mBCD, 
CPZ, AMN, and AML, respectively. At these concentrations, GST and mBCD reduced 
uptake of CTxB to approximately 30% and 50%, respectively, with little effect on 
internalization of Tf or dextran. CPZ and AMN reduced uptake of Tf to approximately 
20% and 25%, respectively, and AML reduced uptake of DEX to 40%. Internalization of 
RNA nanoparticles and EGF was unaffected by caveolin inhibitors GST and mBCD 
(Figure 4.6C). However, internalization of EGF and 3WJ-EGFapt decreased to 
approximately 40% and 75%, respectively, in the presence of clathrin inhibitors. The 
presence of AML caused a statistically insignificant reduction in internalization of 3WJ 
and EGF while decreasing uptake of 3WJ-EGFapt to 40%. GST and mBCD decreased 
luciferase expression upon transfection with 3WJ to 70% and 79%, respectively, but the 
effect was not statistically significant. Knockdown mediated by 3WJ-EGFapt was not 
affected by GST or mBCD (Figure 4.6D). CPZ and AMN had no effect on luciferase 
expression following transfection with 3WJ but luciferase expression following 
transfection with 3WJ-EGFapt decreased to 65% and 42%, respectively. Finally, AML had 
no statistically significant effect on luciferase expression upon transfection with either 3WJ 
or 3WJ-EGFapt. 
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Figure 4.6: (A) Cytotoxicity of GST (10 mg/L), mBCD (3.75 g/L), CPZ (6 mg/L), AMN 
(75 mg/L), and AML (80 mg/L) in MDA-MB-231-Luc cells. Inhibited samples were 
normalized to controls in the absence of inhibitors. (B) Inhibitor effect on uptake of control 
compounds marking caveosomes (CTxB), clathrin-coated vesicles (transferrin, Tf), and 
macropinosomes (dextran, DEX). Uptake of all inhibited samples was normalized to 
controls in the absence of inhibitors. (C) Uptake and (D) Luciferase expression of 3WJ, 
3WJ-EGFapt, or EGF following transfections in the presence of GST, mBCD, CPZ, AMN, 
or AML. All inhibited samples were normalized to controls transfected with 3WJ or 3WJ-
EGFapt in the absence of inhibitors. (n=3, error bars represent standard deviation; *p<0.05, 
†p<0.01, ‡p<0.001 compared to control groups). 
4.3.6 Intracellular Trafficking of 3WJ Nanoparticles 
In order to understand the effects of endosomal acidification and lysosomal 
trafficking on 3WJ-EGFapt delivery, MDA-MB-231 cells were transfected in the presence 
114 
 
of 10 nM bafilomycin A1 (BAF), 20 µM chloroquine (CQ), or both [100]. BAF is a V-type 
ATPase inhibitor that prevents acidification of endosomes [196] while CQ is 
lysosomotropic agent commonly used to buffer lysosomes and enhance endosomal escape 
and gene delivery [203]. When delivered in the absence of DNA, CQ is localized to 
acidified cellular endosomes, especially lysosomes [197]. Therefore, responsiveness to 
BAF indicates the importance of endosomal acidification on gene delivery, while 
responsiveness to CQ indicates particle localization to late endosomes and lysosomes. 
Uptake of nanoparticles was unchanged in the presence of BAF or CQ, demonstrating that 
these drugs only affect intracellular trafficking and not uptake (Figure 4.7A). Upon 
transfection with 3WJ in the presence of BAF and/or CQ, the change in luciferase 
expression was negligible (Figure 4.7B). When transfecting with 3WJ-EGFapt, however, an 
increase in luciferase expression (decrease in knockdown) was observed in the presence of 
CQ but not BAF or BAF and CQ together. 
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Figure 4.7: (A) Relative uptake of 3WJ or 3WJ-EGFapt in MDA-MB-231-Luc when 
transfected in the presence of bafilomycin A1 (BAF) and/or chloroquine (CQ). 
(B)Transfections of 3WJ or 3WJ-EGFapt in the presence of BAF and/or CQ. All inhibited 
samples were normalized to controls transfected with 3WJ or 3WJ-EGFapt in the absence 
of inhibitors. Further, all inhibited samples were corrected for metabolic shift associated 
with BAF or CQ by normalization to BAF- or CQ-only controls. (n=3, error bars represent 
standard deviation; *p<0.05, compared to control groups). 
4.4 Discussion 
The MDA-MB-231-Luc cell line exhibited equivalent EGFR expression levels 
compared to standard MDA-MB-231 cells (Figure 4.1A). In this cell line, EGF 
internalization was significantly greater than that of 3WJ or 3WJ-EGFapt. However, the 
presence of the EGF aptamer did increase uptake of 3WJ-EGFapt compared to the non-
targeted 3WJ nanoparticles (Figure 4.1B). This improved uptake correlated with 
knockdown mediated by 3WJ-EGFapt where 500 nM 3WJ-EGFapt produced 36% 
knockdown compared to no knockdown with 3WJ nanoparticles at the same concentration 
(Figure 4.2). This knockdown was extremely poor compared to Lipofectamine-mediated 
transfection of siLUC at concentrations of only 50 nM, which resulted in 80% knockdown. 
However, when 3WJ and 3WJ-EGFapt were delivered using Lipofectamine, knockdown 
was comparable to that of siLUC controls, demonstrating that 3WJ and 3WJ-EGFapt are 
capable of delivering the siLUC oligonucleotide and interacting with the RNA interference 
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pathway. Based on fluorescence co-localization and post-transfection low lysate 
concentrations compared to Lipofectamine-mediated 3WJ and 3WJ-EGFapt (Figure 4.3), it 
was inferred that low internalization was the source of poor efficacy and that something 
was preventing particles from binding or activating the target receptor. 
One explanation for poor internalization of the RNA nanoparticles is that, after 
binding EGFR, 3WJ-EGFapt were incapable of dimerizing EGFR, a process required for 
EGFR internalization [279]. However, 3WJ-EGFapt uptake was not altered in the presence 
of free EGF (Figure 4.3). If 3WJ-EGFapt is incapable of triggering dimerization, then EGF 
presence should bind surrounding receptors and activate dimerization with receptors 
harboring 3WJ-EGFapt. The non-response to EGF indicated that dimerization with 
surrounding receptors was not boosting uptake or, alternatively, 3WJ-EGFapt particles were 
preventing dimerization altogether. Therefore, the CL4 aptamer affinity for EGFR was 
either poor or mechanistically incapable of interacting with EGFR. To evaluate the 
interaction of EGFR with EGF and 3WJ-EGFapt, siRNA against EGFR was used to 
knockdown EGFR. The use of siEGFR to knockdown surface expression of EGFR resulted 
in decreases in uptake of EGF and 3WJ-EGFapt but no change in uptake of non-targeted 
3WJ (Figure 4.4A), confirming that internalization of EGF and 3WJ-EGFapt depends on 
binding EGFR. EGFR knockdown resulted in a decrease in luciferase knockdown (increase 
in expression) mediated by 3WJ-EGFapt, but not 3WJ. This indicates that the efficacy of 
3WJ-EGFapt, but not 3WJ, is somewhat dependent on the presence of functional EGFR. 
Therefore, internalization of at least a portion of 3WJ-EGFapt was preceded by binding 
EGFR.  
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Since siRNA inhibition of EGFR validated that 3WJ-EGFapt was capable of 
interacting with EGFR, the next goal was to investigate the internalization pathway and 
subsequent intracellular trafficking. Endocytic inhibitors and confocal fluorescence 
microscopy were used to determine the degree of uptake through caveolin-mediated 
endocytosis, clathrin-mediated endocytosis, and macropinocytosis. Uptake of 3WJ, 3WJ-
EGFapt, or EGF was unaffected by inhibitors of caveolin-mediated endocytosis (Figure 
4.5C), indicating internalization is not likely occurring through this pathway and confirmed 
by poor fluorescence co-localization of 3WJ-EGFapt with caveosomes (Mander’s = 0.101) 
(Figure 4.6). Clathrin inhibitors, however, reduced EGF and 3WJ-EGFapt uptake to 40% 
and ~75%, respectively. This was a strong indicator that clathrin-mediated endocytosis was 
involved in the internalization of EGF and 3WJ-EGFapt. The clathrin-dependence of EGF 
internalization by EGFR has been reported previously [280]. Interestingly, the decrease in 
uptake of 3WJ-EGFapt in the presence of CPZ and AMN resulted in a corresponding 
increase in luciferase knockdown to approximately 60% and 40%, respectively (Figure 
4.5D). The discrepancy between 3WJ-EGFapt uptake and knockdown suggest the presence 
of a compensatory internalization mechanism. As such, inhibition of macropinocytosis 
resulted in a decrease in 3WJ-EGFapt uptake to 40% while not affecting luciferase 
expression, which is consistent with the ability of 3WJ-EGFapt to enter cells via alternative 
pathways. The dependence of 3WJ-EGFapt delivery on macropinocytosis was unexpected 
since these particles were shown to interact preferentially with EGFR. However, co-
localization coefficients indicated equal co-localization of 3WJ-EGFapt with clathrin-
coated vesicles and macropinosomes (Figure 4.6). Therefore, clathrin-mediated 
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endocytosis and non-specific macropinocytosis were key pathways in 3WJ-EGFapt 
internalization.  
Blocking the acidification of endosomal vesicles with bafilomycin A1 did not affect 
luciferase expression compared to controls upon transfection with 3WJ or 3WJ-EGFapt 
(Figure 4.7B), indicating that either the RNA nanoparticles are not trafficked through 
acidified vesicles or acidification is not important for delivery by RNA nanoparticles. Since 
endocytosis inhibitors and microscopy showed little internalization through non-acidified 
pathways such as caveolin-mediated endocytosis, it is likely that the RNA nanoparticles 
are resilient to acidification. This is a characteristic difference in RNA and DNA since 
naked DNA is easily digested by acidifying factors and endosomal DNase. 3WJ technology 
tends to be more resilient to this degradation due to –OH substitution with 2’-fluoro or 2’-
O-methyl. This substitution as well as its double stranded nature make it stable in serum 
and resilient to endosomal RNases targeted to single-stranded RNA [281]. In the presence 
of chloroquine, an endosomal buffering agent that localizes to acidic compartments and 
enhances endosomal escape, 3WJ-EGFapt-mediated knockdown decreased (Figure 4.7). 
Since only acidified compartments contain chloroquine, this response was evidence that 
3WJ-EGFapt was sorted, at least in part, to acidified late endosomes and lysosomes. This 
finding was in agreement with the hypothesis that 3WJ-EGFapt was primarily internalized 
through macropinocytosis and clathrin-mediated endocytosis, both resulting in acidified 
endosomes and the latter sorting to lysosomes. Further, the enhanced endosomal escape of 
chloroquine was not apparent when delivered with 3WJ-EGFapt. In fact, decreases in 
knockdown indicate that the presence of chloroquine was detrimental to knockdown. Due 
to the intercalating effect of chloroquine, it is possible that 3WJ-EGFapt localized to late 
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endosomes or lysosomes containing chloroquine and became intercalated, hindering 
interaction with the RNA interference machinery and preventing knockdown.  
Macropinocytosis is the non-specific process by which membrane ruffles engulf 
components in fluid-phase near the plasma membrane. The resulting macropinosome is 
large (up to 5 µm), is considered inherently leaky, and undergoes acidification but does not 
fuse with lysosomes [171, 172]. 3WJ and 3WJ-EGFapt particles are likely entrained by 
these membrane ruffles that engulf extracellular fluid near the cell. However, binding 
EGFR has been shown to activate the macropinocytic pathway in a number of cell types 
[282, 283]. Indeed, EGFR stimulation was shown to improve the uptake of exosomes by 
activation of the macropinocytic pathway [88]. Therefore, it is possible that the interaction 
of a portion of 3WJ-EGFapt bound to EGFR were not triggering uptake through EGFR-
mediated internalization but were activating macropinocytosis. While this is a viable 
explanation of the macropinocytic inhibitor effect on uptake, there are a few questions as 
to why the CL4 aptamer on 3WJ-EGFapt is undergoing different receptor interactions than 
EGF. One potential differentiation is the monovalency of the 3WJ-EGFapt. Literature shows 
that multivalency (particles possessing multiple copies of a ligand) have the ability to 
activate higher-order, multireceptor pathways through interaction with and stabilization of 
multiple local receptors simultaneously [284]. Therefore, the monovalent nature of the 
3WJ-EGFapt may not be triggering receptor dimerization, though this was explored here by 
delivery with free EGF to promote dimerization. Another potential cause could be the 
targeting of high vs. low affinity EGFR. Signaling cascades associated with interaction 
between high and low affinity EGFR with respective ligands have been shown to be 
dependent on receptor specificity. For example, non-canonical binding to low-affinity EGF 
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was observed to activate a host of signal transducers and activators of transcription and 
phospholipase C-gamma 1 [285]. Combination of discrete affinity receptors is an effective 
means to allow the cell to respond differently to varying concentrations of ligands. It is 
possible that the aptamer is an imperfect mimic that preferentially binds to non-canonical, 
low affinity receptors, promoting alternative interactions such as macropinocytosis 
activation. A further explanation is that CL4 binds to the receptor with such an avidity that 
it disallows release within the endosomal pathway. Reports show that structurally similar 
EGF and transforming growth factor-alpha (TGF-alpha) produce different effects on 
endocytic sorting despite having similar binding affinities [286]. TGF-Alpha is released 
much sooner than EGF due to higher required dissociation pH and subsequently allows 
EGFR recycle. 3WJ-EGFapt may bind with such an affinity that dissociation is difficult at 
early endosomal pH. If dissociation does not occur, the fate of the particle will be the same 
as the fate of the receptor, sorting to lysosomes for degradation or recycle back to the cell 
surface. If recycled to the surface, the likelihood of macropinocytosis activation is 
increased. 
Since clathrin inhibitors only affect internal endosome formation, they do not 
prevent surface EGFR interaction with 3WJ-EGFapt. Therefore, clathrin inhibition should 
result in a loss in uptake of nearly half the particles as indicated by equivalent confocal co-
localization to clathrin vesicles and macropinosomes (Figure 4.6). Here, however, there 
was only a mild decrease of ~25%. Therefore, a portion of 3WJ-EGFapt particles might 
involve non-canonical receptor interactions that trigger ruffle formations that eventually 
engulf the receptor-particle complex by macropinocytosis. Since the macropinosome is a 
notoriously leaky vesicle and 3WJ-EGFapt lacks endosomal buffering capacity, the 
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macropinosome may be a more efficient means of cellular entry due to ease of endosomal 
escape. However, macropinocytosis inhibition reduced uptake of 3WJ-EGFapt to 40% 
while leaving gene expression unchanged (Figure 4.5C-D). Upon macropinosome 
inhibition, non-canonically bound 3WJ-EGFapt particles cannot stimulate 
macropinocytosis and either internalize through clathrin-mediated mechanisms or become 
stripped from the cell surface during washing. Therefore, macropinocytosis inhibition 
should increase gene expression above that of the controls due to internalization 
mechanism shifting towards the less efficient clathrin-mediated uptake. Since this does not 
occur, there is little evidence that macropinocytosis is more efficient than clathrin-mediated 
endocytosis. Therefore, the sorting of 3WJ-EGFapt to late endosomes and lysosomes 
associated with clathrin-mediated internalization are not necessarily prohibitive of 
therapeutic effect. 
4.5 Conclusions 
Though EGFR interaction with the CL4 aptamer was verified by EGFR knockdown 
using RNA interference, it was shown in this report that the interaction of the aptamer 
produced different receptor response compared to EGF protein. The protein was 
demonstrated to induce receptor-mediated endocytosis through classic clathrin-mediated 
internalization while the aptamer produced a combination of uptake through clathrin-
dependent endocytosis and macropinocytosis. Though it is not abnormal to observe 
macropinocytic activation upon EGFR stimulation, it is uncertain as to why internalization 
of 3WJ-EGFapt is not restricted to EGFR-mediated internalization but proceeds through 
multiple pathways. The likely explanation is that the particles have affinities for traditional 
and non-canonical EGFR binding such that a portion of particles proceed through clathrin-
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mediated endocytosis while a portion remain receptor-bound until stimulatory signal is 
strong enough to activate macropinocytosis, upon which the particle-receptor pair becomes 
indirectly internalized through the natural formation of the macropinosome. Though this 
pathway is likely an easier means of entry due to ease of endosomal escape, there is no 
evidence that lysosomal sorting associated with clathrin-mediated endocytosis is 
detrimental to efficacy. While these findings are detrimental to the rapid internalization of 
3WJ-EGFapt through traditional receptor-mediated endocytosis, they do present the unique 
effect that RNA has on EGFR. Therefore, structural modifications of the aptamer for the 
specific use in MDA-MB-231 cells is a pre-requisite to efficient delivery. 
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CHAPTER 5. EVALUATION OF FOXC1 AS A THERAPEUTIC TARGET FOR BASAL-LIKE 
BREAST CANCER 
5.1 Introduction 
Basal-like breast cancer (BLBC) is an aggressive malignancy of 
basal/myoepithelial cells with poor prognosis. BLBC accounts for approximately 15% of 
all breast cancer diagnoses [287, 288] and exhibits a tendency to metastasize to the brain 
and lungs [289]. The cancer is often diagnosed in younger women, typically African-
American, and exhibits low patient survivability due to rapid growth rate [290] and 
aggressive mobility [291]. Ninety percent of basal-like carcinomas are associated with the 
triple-negative phenotype (TNP), characterized by an under expression of estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) 
[292]. Therefore, BLBC tumors cannot be treated by targeted therapies such as tamoxifen, 
aromatase inhibitors, or Herceptin. BLBC treatments are limited to doxorubicin and 
taxanes which exhibit poor success rates and dose-limiting side effects. Thus, there is an 
urgent need for the development of a more robust treatment option for the basal-like subset 
of breast cancers. 
Recent studies identified the forkhead-box transcription factor C1 (FOXC1) as a 
unique biomarker for BLBC [293]. Further studies solidified a link between FOXC1 
expression and the activation of Pin1 and the NF-kB signaling pathway [294], both of 
which are associated with the ER-negative phenotype exhibited by the majority of BLBC 
[295]. Further, overexpression of FOXC1 in BLBC tumors resulted in activation of the 
epithelial-to-mesenchymal transition [296] and accelerated cell proliferation accompanied 
by aggressive mobility [293]. Therefore, inhibition of these activated gene pathways and 
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the inhibition of FOXC1 itself are potential therapeutic approaches. Indeed, knockdown of 
FOXC1 was shown to reduce proliferation and mobility as well as reverse the epithelial-
to-mesenchymal transition in vitro [293]. 
Gene therapies involving transfer of nucleic acids for inducing expression of a 
therapeutic gene or inhibiting expression of a disease-associated gene product are a 
promising methodology for cancer treatments. In particular, RNA interference (RNAi) 
mediated by delivery of small interfering RNA (siRNA) is capable of knocking down 
expression of virtually any gene. For example, cellular proliferation was suppressed in 
pancreatic cancer by siRNA knockdown of NUF2 [297], cell survival was reduced by 
siRNA-mediated knockdown of eIF3c in colon cancer [298], and the malignant phenotype 
of prostate cancer was inhibited by siRNA-mediated knockdown of RPL19 [299]. 
Similarly, RNAi may be a promising approach for knockdown of FOXC1 expression in 
BLBC to decrease proliferation and metastasis, in analogy with the in vitro effects 
described above. Efficacy of RNAi therapies, however, is hindered by the lack of safe and 
efficient methods for in vivo siRNA delivery [300].  
To evaluate the potential of RNAi therapy for BLBC, we have investigated the 
effects of FOXC1 inhibition in a murine mammary carcinoma cell line, 4T1, commonly 
employed as a model of BLBC [301]. In particular, we have determined the effects of 
siRNA-mediated knockdown of FOXC1 on proliferation, migration and invasion of 4T1 
cells in vitro. In addition, a cell line lacking FOXC1 expression, 4T1-∆FOXC1, was 
generated by CRISPR/Cas9 technology as a “best-case scenario” to evaluate the potential 
of FOXC1 knockdown on the tumor biology, growth, and metastasis in an orthotopic model 
of BLBC in mice. 
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5.2 Materials and Methods 
5.2.1 Materials and Cell Lines 
The 4T1 murine cell line was obtained from ATCC (ATCC® CRL2539™). Cells 
were cultured according to ATCC protocols in DMEM (ATCC) supplemented with 10% 
premium grade fetal bovine serum (Seradigm) at 37ºC and 5% CO2. Phosphate buffered 
saline from GE Life Sciences (6.7 mM PO4, 137 mM NaCl, pH 7.2) was used to wash cells 
and trypsin containing 0.53 mM EDTA (Corning) was used to dissociate cells. Cells were 
transfected with siRNA using a Lipofectamine RNAiMAX vehicle (Invitrogen). Cells were 
lysed using Triton lysis buffer (25mM HEPES, 100mM NaCl, 1mM EDTA, 10% glycerol, 
1% Triton X-100, 10mM DTT, 1mM sodium orthovanadate, 10ng/mL leupeptin, 1% 
protease inhibitor, pH 7.4) FOXC1 and negative control siRNA were purchased from Santa 
Cruz Biotech. Protein quantification kit (BCA assay) was obtained from GE Biosciences.  
5.2.2 In vitro siRNA Transfection 
Murine mammary carcinoma cells (4T1) were cultured to 80% confluence and then 
plated into 6-well plates at 300,000 cells per well. The plates were incubated for 24 h in 
media containing 10% fetal bovine serum. The culture media was removed and cells 
washed with PBS. An siRNA dilution was formed by mixing 10 μL siRNA from a 10 μM 
stock with 150 μL serum-free media. Also, a lipofectamine dilution was formed by mixing 
varying volumes (0-10 μL) of Lipofectamine RNAiMAX in serum-free media to a total 
volume of 150 μL. The siRNA dilution was then added to the lipofectamine dilution and 
allowed to complex for 20 min. Serum-free media was then added to a volume of 3 mL to 
produce the desired final siRNA concentration (8.3-50 nM). The lipoplexes were pipetted 
onto the cells and incubated for 4 h. After incubation, media was removed, wells washed 
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with PBS, and 3 mL of growth media added to wells. Lipoplexes were formed with either 
siRNA targeting FOXC1 (Santa Cruz Biotech, sc-145221) or a negative control siRNA 
(Santa Cruz Biotech, sc-37007). After a total of 48 h incubation, media was removed from 
cells and each well washed with PBS. The cells were lysed with 35μL Triton lysis buffer 
and total protein quantified via bicinchoninic acid assay. 
5.2.3 Western Blot 
FOXC1 expression was determined by Western blot. Cell lysates (diluted to 50 μg 
total protein in 50 μL) were electrophoresed on SDS PAGE (10% polyacrylimide) for 2 h 
at 100 V. The protein was transferred from the polyacrylamide gel to a nitrocellulose 
membrane (Amersham Bio) for 2 h at 200 mAh. The membrane was stained with rabbit 
anti-FOXC1 primary antibody overnight followed by 2 h of secondary HRP-linked anti-
rabbit antibody. The membrane was washed three times with Tween 20 supplemented 
(0.2%) Tris-buffered saline and then once with Tris-buffered saline (200 mM Tris-base, 
1.37 M NaCl, pH 7.6) for 5 min. Wash fluid was drained from the membrane and 1 mL 
SuperSignal West Pico Luminol Enhancer solution and 1 mL West Pico Stable Peroxide 
solution (Thermo Scientific) were added followed by incubated in light-shielded 
environment for 5 min. The membranes were then exposed in a dark room to produce 
protein bands on autoradiography film which was scanned to produce digital images. 
ImageJ software was used to adjust the band intensities based on a β Actin control and 
normalize by negative controls to produce a numerical representation of protein 
knockdown. 
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5.2.4 Silencing of FOXC1 Expression in 4T1 Cells by CRISPR/Cas9 
An all-in-one plasmid kit was purchased from GeneCopeia (MCP227640-CG01-3) 
to facilitate the cloning of FOXC1 knockout cells using CRISPR/Cas9 [302]. The kit 
included three different plasmids containing unique sgRNA targeting sequences for the 
FOXC1 gene, Cas9, a mCherry reporter gene, and neomycin resistance gene. The plasmids 
were amplified in E. coli DH5α and purified using Wizard Plus Midiprep DNA Purification 
System (Promega). The plasmids were complexed with Lipofectamine 2000 (Invitrogen) 
at 120 μL Lipofectamine 2000 / 24 μg plasmid and added to 4T1 cells in a 100-mm dish 
for 5 h. Media was then replaced with 10 mL DMEM supplemented with 10% FBS and 
incubated a total of 48 h. The cells were imaged by confocal microscopy to verify positive 
transfection and plasmid expression by visualization of mCherry fluorescence. The cells 
were cultured in the presence of 150 μg/mL neomycin in DMEM supplemented with 10% 
FBS to select for transfected cells. Clones were isolated using cloning rings, dissociated 
using 5 μL trypsin, and expanded. Multiple colonies were collected as potential clone lines 
for each CRISPR/Cas9 plasmid as well as a cocktail of all three plasmids. Knockout of 
FOXC1 was quantified in Western blots of 4T1-∆FOXC1 lysates compared to unmodified 
4T1 cells as described above. 
5.2.5 Cellular Proliferation 
4T1 cells were cultured to 80% confluency and plated at 30,000 cells per well in a 
24-well plate. The plates were incubated for 20 h, the media removed, and the cells were 
washed with PBS. Cell Titer Blue live cell counting assay (Promega) was added to each 
well at 1:5 (v:v) of media (100 μL in 500 μL media). Cells were incubated for 4 h at 37ºC 
and then 100 μL media samples from each well moved to an opaque assay plate for 
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fluorescent quantification (530ex/590em) in a BioTek Synergy 2 plate reader. This was 
considered the 0 h time point (starting cell count). Cells were then (24 h post seeding) 
transfected with 2 μL siFOXC1 (20 pmol, 33.3 nM) and 1.6 μL Lipofectamine RNAiMAX 
in 600 μL serum-free media and incubated for 4 h as described above. Media was replaced 
with growth media and cell count assessed at 0, 22, 44, 72, 96, and 124 h via Cell Titer 
Blue assay. After each assay, wells were washed, media replaced, and cells returned to the 
incubator. 
5.2.6 Migration and Invasion 
4T1 cells were plated in 6-well plates at 300,000 cells per well and incubated for 
12 h. Cells in each well were transfected with siFOXC1 or control siRNA at 33.3 nM 
siRNA as described above. Plates were incubated for 48 h, media was removed, and cells 
were washed with PBS. Cells for invasion assays were dissociated with trypsin containing 
0.53 mM EDTA and plated into Transwell inserts pre-coated with Cultrex basement 
membrane extract (Corning, 8 μm pore, 24-well) at 100,000 cells per insert. Cells for 
migration assays were dissociated and plated into Transwell inserts with no apical 
membrane coating (Corning, 8 μm pore, 24-well) at 100,000 cells per insert. After 1 h, Cell 
Titer Blue assay was used to determine the initial number of plated apical cells and the 
media was replaced with serum-free DMEM. Agonist (DMEM with 10% FBS) was added 
to the basal reservoir and the cells were incubated for 19 h for migration assays and 25 h 
for invasion assays. Non-mobile apical cells were swabbed off the apical side of the 
membrane. Basal cells were fixed with 4% formaldehyde and stained with Giemsa stain 
(Sigma Aldrich) for microscope imaging. Cells were counted in five fields (top, bottom, 
left, right, and center) and averaged. 
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Scratch assays were performed using ibidi μ-Dish culture inserts. 4T1 cells treated 
with siFOXC1 were plated in the insert chambers and allowed to grow to confluency. The 
insert was removed and the cells allowed to migrate into the 500 μm gap. Progress was 
imaged at 0, 21, and 29 h. The same procedure was performed for 4T1 cells treated with 
negative control siRNA. 
5.2.7 Orthotopic BLBC Model 
4T1 or 4T1-∆FOXC1 cells were implanted (0.5−1 x 106 cells in 20 μL volume) into 
the abdominal mammary fat pad of female BALB/c mice (n=12) to generate orthotopic 
breast cancer tumors. Body weight was determined and tumor size measured with calipers 
twice per week. Twenty-four days after the tumor implantation the mice were sacrificed 
and tumor weight as well as metastatic activity were evaluated. Tumor samples of 250 mg 
were excised, cleaned, and sonicated in 2 mL Tissue Cell Lysis Buffer (Golden Bio). 
Lysates were assessed for FOXC1 expression by Western blotting according to the 
methods above. 
5.3 Results 
5.3.1 Optimization of FOXC1 Knockdown 
RNA interference was used to knockdown FOXC1 expression in 4T1 cells. To 
optimize knockdown, varying volumes (0-10 μL) of Lipofectamine RNAiMAX were 
complexed with a fixed concentration of siFOXC1 (33.3 nM). Resulting knockdown for 
each lipid/siRNA ratio was determined via Western blot. FOXC1 knockdown increased 
with the lipid/siRNA ratio, as expected (Figure 5.1). Essentially complete knockdown was 
observed with a lipid/siRNA ratio of 8:10 (v:v). In addition, the siRNA dose was scaled to 
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determine the minimum amount that would produce 100% knockdown of FOXC1. 
Knockdown was 0% at 8.325 nM siFOXC1, 64% at 16.65 nM siFOXC1, and >95% at 
>33.3 nM siFOXC1 (Figure 5.2). Thus, all subsequent transfections were performed at 
lipid/siRNA ratio of 8:10 (v:v) and 33.3 nM siRNA. 
 
Figure 5.1: (A) Western blot of FOXC1 expression in 4T1 cells transfected with 0.1 nmol 
siFOX or siNEG and the indicated volume of Lipofectamine RNAiMAX. (B) 
Quantification of FOXC1 knockdown expressed as [1-(intensity of siFOX band)/(intensity 
of siNEG band)]x100%. 
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Figure 5.2: (A) Western blot of FOXC1 expression in 4T1 cells transfected with the 
indicated siRNA concentration at lipid:siRNA 8:10 (v:v). (B) Quantification of FOXC1 
knockdown expressed as [1-(intensity of siFOX band)/(intensity of siNEG band)]x100%. 
5.3.2 Generation of 4T1-∆FOXC1 by CRISPR/Cas9 
In order to assess in vitro and in vivo behavior of 4T1 cells lacking FOXC1, 4T1-
∆FOXC1 cells were generated using the CRISPR/Cas9 genome editing system. 4T1 cells 
were transfected with one of three plasmids encoding Cas9 nuclease and a sgRNA 
complementary to the FOXC1 gene sequence or a pool of all three plasmids. Successfully 
modified colonies were verified by Western blotting for FOXC1 expression compared to 
unmodified 4T1 controls. Plasmids A and C were unable to reliably knockout FOXC1 
expression (Figure 5.3). However, plasmid B and the pooled plasmids produced several 
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knockout clones. Clone 5 resulting from transfection of 4T1 cells with plasmid B (4T1-
∆FOXC1) was chosen for further studies. 
 
Figure 5.3: Western blot of FOXC1 expression in 4T1 cells transfected with the indicated 
CRISPR/Cas9 plasmid(s). (*, clones with successful FOXC1 knockout) 
5.3.3 Effect of FOXC1 Knockdown on 4T1 Proliferation 
To confirm the effects of FOXC1 expression on cellular growth rate, 4T1 cells were 
transfected with siFOXC1 at the optimal conditions described above (33.3 nM). A 35% 
reduction in cell count of siFOXC1-transfected cells compared to unmodified 4T1 cells 
(p=0.0125) was observed at 4 days post-transfection (Figure 5.4A). Similarly, a 33% 
reduction in cell count of siFOXC1-transfected cells compared to siNEG was observed. 
Beyond 4 days, the difference between siFOXC1-treated cells and negative controls 
decreased until confluency was achieved. The siNEG-treated control also exhibited a small 
but statistically insignificant (p=0.155) reduction in cell growth compared to unmodified 
4T1 cells perhaps due to cytotoxicity of the transfection reagent. A similar decrease in cell 
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count after four days was observed in 4T1-∆FOXC1 cells compared to 4T1 cells (Figure 
5.4B). 
 
Figure 5.4: (A) Proliferation of 4T1 non-transfected controls (NTC), 4T1 cells transfected 
with negative control siRNA (siNEG), and 4T1 cells transfected with FOXC1 siRNA 
(siFOXC1). Cell counts were normalized by the initial cell number (n=3, ± standard 
deviation). (B) Proliferation of 4T1 and 4T1-∆FOXC1 cell lines. 
5.3.4 Effect of FOXC1 Knockdown on 4T1 Mobility 
Migration and invasion of 4T1 cells treated with siFOXC1 as well as 4T1-∆FOXC1 
cells were investigated using Boyden chamber assays. Migrating and invading cells were 
counted at 19 and 25 h after seeding, respectively. Migration and invasion of siFOXC1-
transfected cells decreased by 39% and 33%, respectively, compared to siNEG-transfected 
cells. Similarly, migration and invasion of 4T1-∆FOXC1 decreased by 33% and 36%, 
respectively, compared to unmodified 4T1 cells (Figure 5.5). Thus, both transient 
knockdown and complete elimination of FOXC1 expression reduced the metastatic 
potential of 4T1 cells in vitro. 
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Figure 5.5: Migration and invasion of 4T1 cells transfected with siFOXC1 or siNEG, and 
4T1-∆FOXC1 cells in Boyden chamber assays. (n=3, ± standard deviation) 
In addition, migration of FOXC1-expressing and -deficient cells was compared 
using a 2D scratch assay. After 21 h, a larger gap was observed in 4T1 cells transfected 
with siFOXC1 compared to the negative control (Figure 5.6B and E). By 29 h, the 500 μm 
scratch in siNEG-transfected 4T1 cells had completely filled (Figure 5.6E) while a small 
gap in the siFOXC1-transfected cells remained (Figure 5.6C). 
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Figure 5.6: 2D migration of 4T1 cells transfected with FOXC1 siRNA (A-C) or negative 
control siRNA (D-F) before transfection (A, D) and at 21 (B, E) and 29 h (C, F) post-
transfection. 
5.3.5 Effect of FOXC1 on 4T1 Tumor Growth and Metastasis In Vivo 
4T1 or 4T1-∆FOXC1 cells were injected into the mammary fat pads of Balb/c mice 
as an orthotopic model of stage IV breast cancer. The total body mass of all three groups 
remained undifferentiated over all 24 days of the study (Figure 5.7A). Surprisingly, the 
volume of 4T1-∆FOXC1 tumors was equivalent to 4T1 tumors up to 17 days and increased 
compared to unmodified 4T1 tumors at 21 and 24 days (Figure 5.7B). Visual inspection 
and mass of excised tumors confirmed these observations with 4T1-∆FOXC1 weighing 
67% more than unmodified tumors, 1.45±0.25 g and 0.867±0.086 g (α=0.05) respectively 
(Figure 5.7C-D). 
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Figure 5.7: (A) Body weight of animals receiving 4T1 or 4T1-∆FOXC1 cells. (n=6, ± 
standard deviation) (B) Tumor volume (measured by calipers) after implantation with 4T1 
or 4T1-∆FOXC1 cells. (n=6, ± standard deviation) (C) Mass of 4T1 and 4T1-∆FOXC1 
excised after 24 days. (n=6, ± standard deviation) (D) Excised 4T1 and 4T1-∆FOXC1 
tumors after 24 days. (E) Excised organs 24 days after injection of 4T1-∆FOXC1 cells 
showing tumor colonies as indicated by arrows. 
After 24 days, major organs were excised and inspected for the presence of 
metastases. All mice injected with 4T1 (not shown) or 4T1-∆FOXC1 (Figure 5.7E) 
exhibited tumor colonies on the liver and lungs, suggesting that FOXC1 knockout did not 
significantly inhibit metastasis in this model. Since knockout of FOXC1 is unable to block 
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metastasis, it appears unlikely that an siRNA treatment capable of producing 80%-95% 
knockdown would be efficacious in reducing tumor growth or metastasis. 
To ensure that the lack of difference in 4T1 and 4T1-∆FOXC1 tumor growth was 
not due to reversion of 4T1-∆FOXC1 to the wild-type phenotype following implantation, 
FOXC1 expression was compared in two excised 4T1-∆FOXC1 tumors, a wild-type 4T1 
tumor, and 4T1 cells grown in vitro by Western blotting. 4T1-∆FOXC1 tumor lysates 
showed significantly less FOXC1 expression compared to the 4T1 cell culture control and 
wild-type tumor (Figure 5.8). Thus, it appears the 4T1-∆FOXC1 tumors maintained their 
FOXC1-negative phenotype throughout the duration of the experiment. 
 
Figure 5.8: Western blots of 4T1 cell culture lysates (4T1) and excised wild-type 4T1 (WT) 
and 4T1-∆FOXC1 (KO1 and KO2) tumor lysates for protein expression of FOXC1 and β-
Actin loading control. 
5.4 Discussion 
The results reported here align well with the trends observed by Ray et al. [293], 
confirming that downregulation of FOXC1 expression has a negative effect on 
proliferation, migration, and invasion in vitro. Ray found that knockdown of FOXC1 
expression produced a reduction in the proliferative efforts of 4T1 cells by approximately 
50% after 3 days. Similar reduction by approximately 35% was observed for MDA-MB-
231 cells (human BLBC). Ray et al. also found that the migration and invasion of 4T1 cells 
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were decreased ~65% with shRNA-mediated knockdown of FOXC1 protein. However, the 
reduction of 4T1 proliferation was less dramatic (33%) in this project than that of 
corresponding Ray studies (50%). The decrease in migration and invasion by RNAi (39% 
and 33%) reported here were also less severe than that found by Ray et al. (each 
approximately 65%). It is uncertain as to why the decrease in proliferation, migration, and 
invasion from this project by siRNA-mediated knockdown were not as successful as those 
found by Ray et al. by shRNA-mediated knockdown. Regardless, it is clear that the impact 
of FOXC1 down-regulation in 4T1 and other BLBC cell lines produces a decrease in the 
cellular growth rate and potential for aggressive metastasis as measured in vitro. These 
results suggested that RNAi-mediated knockdown of FOXC1 expression may have 
promise as a BLBC treatment strategy. 
Although translation of RNAi drugs from in vitro to in vivo models is difficult due 
to the many barriers faced by siRNA delivery in vivo [303, 304], successful cases have 
been reported recently. Preclinical trials of Atu027 targeting the protein kinase N3 mRNA 
transcript have shown significant inhibition of tumor growth and metastasis to the lymph 
nodes in prostate and pancreatic mouse models [305]. As a result, Atu027 has entered phase 
1 clinical trials. Similarly, CALAA-01, which targets ribonuleotide reductase, was granted 
a phase 1 clinical trial. The CALAA-01 siRNA was delivered intravenously to tumor 
bearing subjects using self-assembled PEGylated cyclodextrin nanoparticles tagged with 
transferrin ligand. Tumor biopsies showed successful tumor targeting, intracellular 
localization, and mRNA/protein knockdown [306]. These and similar trials suggest that 
siRNA drugs have potential as cancer therapies. 
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To initially evaluate the potential of FOXC1 knockdown while avoiding 
complications due to the commonly encountered difficulties with siRNA delivery in vivo, 
we constructed a 4T1 cell line deficient in FOXC1 expression using CRISPR/Cas9. Upon 
injection of 4T1 or 4T1-∆FOXC1 into the mammary fat pads of Balb/c mice, we observed 
no statistical difference in the growth rate of the resulting tumors or their final size after 24 
days. In addition, a similar number of metastatic lesions were found in the lungs and liver 
of animals with 4T1-∆FOXC1 and 4T1 tumors. The lack of effect of the absence of FOXC1 
on tumor growth or metastasis was surprising, given the significant effect of FOXC1 
knockdown on in vitro proliferation, migration and invasion of 4T1 cells. As the 4T1-
∆FOXC1 tumors, completely lacking detectable FOXC1 expression, represent a “best-case 
scenario,” the results reported here suggest that an RNAi-based therapy targeting FOXC1, 
and perhaps even a FOXC1 antagonist, may not show efficacy against BLBC. 
5.5 Conclusions 
The inhibition of FOXC1 using RNAi in vitro reduced proliferation, migration, and 
invasion of 4T1 cells, confirming previously reported data by Ray et al. In addition, 4T1-
∆FOXC1 cells performed similarly to 4T1 cells treated with siFOXC1 in vitro. These 
results, however, did not translate into an animal model. 4T1-∆FOXC1 tumors did not 
exhibit reduced growth rates compared to controls despite the absence of detectable 
FOXC1. FOXC1 knockout was also unable to inhibit metastasis to the lung and liver after 
24 days. These results suggest knockdown of FOXC1 may not be a promising candidate 
for BLBC therapy. 
 
Copyright © Landon Mott 2019
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